var title_f22_14_22752="Finkelstein test deQuervains";
var content_f22_14_22752=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F58422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F58422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Finkelstein test for de Quervain's tenosynovitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 284px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEcAaIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6ozSE00UtIBSabkZoam9+9JjQhI3UKQMUw/epyjpUjHkjA61Wu7qK3RjKwUDrk1Y6qp9q5fx1A8+lyJHIyMQRlTjFDF6FyfVrKRuJUODnOalSZJRlGGPY15nZ6Ci28bNdTM+OCXzXbaGPLgAL7h2rFVE3Y6J4StTjzSWhF40tluNLcYJ4FfOl0vlXEqdNrEdfevprWUEmnMD+tfOHieHyNXuFxj5ic+lbROKa1M1iOuaZuBPByPWmsxK47Z/H/PFMLZ6Dr0qyEPJHryaZuHOCee3+fpSBvUUzcOo59x3pAPLD196Qkc88U09O+PXGabzjkAUDHluMlqaz/wD66Z245Ge1IW9xQA8vk/QY6UzcCTg/lSZOSetNzz0oGPzx36elN3cDj8qYT0ozQA/dgc5xSqxIyOuKjJGD6UbhgkkdO9Kwx+7nnnqaFbnr3xTSAeSwJxx/hSY546e9FgH7+fXr/P8Az+VAYbvwqM9SG9KU4AznAoGSgjOO/T3puefQdabnHvTN3v8ArQBM7k4DEkLwAT0phYdCaZnnp3pCflGTnFAEqsCeOvp619OfDrTo9J8NWsYUKzIGY984ya+bdBg+1a5YQN915lB+mc19T6apmWKGPIRVGcU0NbmlEDO5AOFA65rVhiSIAKBnHWooY1jjwB2/pUrPtNXYokBpCy46iqrTEthfTtSqhbBY/lQBYLr60ocE8U0IB0p/egABpDg54pc0mQAaAGHgmmkikmbB98VXd+TjNUIe7AAY9qRJMnn1qtuJFSJkY470CG38ohtpW/2SefpWL4MG3TfMI5cls59yat+J5tmnSKpwdpH6U3w7GYdKt1xztosK+p0kTbkBp9VrN90ePSrA5FSykLRRRSGQZ2jk98U4nggYzUY5H4UpNSMczcfhTc9aGPBxTG6+1DEg/iFOzwKZmlHQe9QUPHIGKz9bh86xkA6jkVdU8D6U25+eCQHuDVbgeX3w8lpAx5B4qfwvfTTXRTaBGjYFR658t9OhHLZqfw3si3HAyW6gf59K4E+WZ9FXviMLFp+bOwuB5lowz6EV8/fEa2NvrAb+9kfrX0FGd0Jz0xXjPxdtwrxS46NjIrtTPmprQ80Le461GSOOcetBb3OajLH0rQyHk88nNJuJJJ+bPvUZbp/Km7z60ASFs+/HajdnoO1RFuvHHSnK/OWG5RyRu2kj0zg4+uDQMd1/Om5689KTPHOKaT78UXAf3Py5wOgOD9f6/wCHWoycDpzSFuetJuGeM9KLgHsc0A9McjHpTSfrSA9+lIY7IzgZNAPHXt600tkcnI64pN3BA5470APLYJ4pdwz16f5/z9aYW5Bozkii4WJN2R/WjOOD9aZkZHWjdwAcUDHKR603p3oBH4etBweSTnue1AC5B+gppPHOM/l60hPU5ppY7R0oGdJ4CAfxbYAgH5jj619W6TbC3hA7kc183/BfSBf+KlvJQTFZjcOerH/62a+jDcMSAvAqo9xovzTqgIzzUI3yvnoKrIQDliSasCY54FMdixEgUDHPFSHOODVVZXP1qRQ7Dk8ZpgSO7DvRuYnrQcAH60x5cHGaEIkDcnJpryhQfXFVWkJY4P5VExY5pgSyyl89ahdzu+tGM5poUlvamIVSSRx2q0iHHPQc1FBHggkVNeuI7fAPJNAHM+J5/wBzjP3mwK2rD5bOMcDCiuY8RNmW2jzndJ+NdXbLiFQOgGKZC3LNk+JCvatCsiIlJ1PPWtZDlQaiRaHUUUVJRnwSB4wwxyMjBzUpOc15VZazqejosMTLNbLwI5V5A9A3UfrXV6V4xsb4+XKr2s+cbJSADxng9K8+hj6VXS9md+IwFWjra68jq+1NbriolkDDIIIIzTt/zf1rsucNhc/NilB4H0qJm+fgdqAxwPpU3GiQdqJDww5qMHhRgCh2O1qsTPPPFpSHUAW6biDWGt49oAUXOGx61d+IchW83AgYkHXpWZp17bPGRI65DYPNcNV2nc9/A81TDumtND0bS5/OsgckHGMgDI49+PzGPUHpXm/xfjJsC4HQ88e9dzo11G8G2EjaK5j4nwebpUpx05rpi72PBqR5bo8JLcjNR7+h7+tI5IPIOc1GWxzWxzku7bwuRxjjjI9KYepAHtTN35Ypu45O2gdibnnNIrEDPII561HuPbAX+VJu689evNAExJwaQHJ/zxURJ9BShjzn06CgY4nB65+gpuT3oLE96ZntwcfjQAuenFBPPfGe/NNLYA7/AEpoPA7egoGPyeeOaOcY9qaCTwAPTFIGI6dcdqAJGY4HHQEZ9e9HPv0xTM+nHpmm5IP+AoAl4z6UFsZHT2AqPcfSkLe3PrQMlDADFG/8veog2DyCfoaQN6igCU85BOenag9PX/JqPdQWwM5wetAz3r4F2HkaBLdMvzTyk59hx/SvUoiA3OcYrjfhnb/YvB+mxlSHMYY/jz/WuttT5jFjwBTGkXUGRk9MVISN2B1qAybQcVPAmW3MKoZJGOeR2p7vgcZppPTA7UxgSB/KmIVmLA9/1ppBNLz6DGacMggdBQIYqc96CuAc+lSKQDwKawpgNwADx2NMRSH/AM+tPJIPT9cU1m54/wA80xE4ztGOKz7+UvNgE4WrazDyznhgKyi5ZmY+tAmYOqkSaxbJzkHP8q7G3B8sfSvPzN5/ipwMFYwPr2rv7YjYOOcUyYiScNzmtO1ffEp9qzZ85B/UmrOnyHbg0mUjQooorMs8tntgA244UdT2rPutPV43UoMNxnrn8K3XjBHTr6j+lQugORyWPHIxXxjifXxqdzCt7/U9HZTa3bG2XrDLyv0HcH6flXVaV4ut7qTyrtWs5/WU/u2+jf0ODWLNapKCrBXA4YNg5qCe1Ut5QUHOMccYrpo4yrR0vdGNbBUa2trM9CguEm5Xp296sIcheOa8oj+12Dj+zrh4dpzsI3L+R49OmK6DT/GDqwXVIDECv+sjBZVPuOv869SjmNOppLRnkVstq09Y6o7cnAH0pkhIRjzWdYarZ367rO5jmx12npVi4bMTrnkgjp7V6MZKUbo86SadmeaeNiZ78qFJ+cnHrXkskOqHULhIhOqGQ8DIB5r17Xbq3ttUY3DAMc8nrmsK71qxicEKTjnpXJ7Tlk9LntQwqr4aL51Gx1HgWOaKyVZslio5P0rQ8aWxn0xxjgiqfhjUEvIAVULu5Are1WPzbBh2x6VtGV1c8qrTVN8qd0fLl7GYbqVMYKuR0qs3TArZ8XxG31+5TGMnOMetYJYnqe3pW5yDiTmm9vU0c9v/ANVNJPXdnPXNMB5/zigH/wDVTDkDnP0BBNKCQOo6daBjie/em5GDnt60nvn3poyKAJM5HIyf8/8A1qQNmmluRkdu30puTjkn8aBjt2QOKQdutISw7n09KATxzwaQx2MjaMnsOKQnjueOv+fxpA2AMHmmk9s9qYCkn35pAc8evrTTxjB65OP0/pSLn1PrQBKCd3T86YSaaTgHpSEnd196BknSjOcegphPbNNBzn9KQE+R3z7d6t6Pbm81SztwD+9lVfwzWfnHAPtXS/DyI3HjHTF6gOWPtwaAPpLSovIsreJBgIgUDFbcCiKJSwzxWbarmRMnjrWjnzJF5+VeOnWqKJ4IiTvcdc4q70bp2qAMB1xjHT8KlDnOOKoAPXjHSmBjx9acGBxkDOO1RSDGdpx3ANMRYAyOB1PPFNIweR+lCM23nr3pjyfOR+dAMdkgmopJMA9elRvMVJxjniqrSEjk9qYrlky8kVE0hweuf6VBk8jJP1p8YLsOnrQK5HK7BM8jIqCR9sLHpgckf5/zmnXb/Pt7CsjxDeC00yeRmwcEAn1pks5zw7ObnxBeyY/jwDXqFnzEK8j8CljK7sf9Yd35/wCRXren58pcHtQhIlmB44JosztkU4+9UxBZeeffFVgdkinIHNDKNgfSimB1wMkUVBRwMnCkAkEr161CN2MSAAngc5GP51EsuxiS33uaGlDbW/hGec18fdM+tUGh7oSuF4JHJI6VVjhlSd2kfMRAK5xkHuPoP85qcsAcgZJHQf4VNlW+Xk56mp5UyuZxM2ZI8FjyV67ug78/SqVzbyRwiTy5JuRxEBnBxz1xitwgcjG4dcEcEen86jmQlFCjJGOGOAOPak4lqoc0dOaKbzoWeKTGAyMUP5jGfxqxF4g1ayiaORlu4wCcycMMj+8OP0rWaFmI2Iuzr16f/WqnPaguFbJUkkD+97fkaunVqUn7rsZ1KNKr8auUJrjSNXlWTVY3spE6+Zyo465HQfXHStuz8MaPNAk8Hkzxv8wdCHDe+c1kyaeUyucLjGSc/Q1VksSmXt2kglBzuhJU/p1r0KWZSivfVzzauVQb9xnYWen29mCsCgDpgVpyoGt2BrhYNY1axQLOkF6gIALFkfBPAJxgnr2rorHxTp09qTOZ7SQcMtxEyjP+ywyCPQ1208XSqbO3qcFTB1ae8fuPEvijaeTrZkAPzDv3riDnJx9a9P8Aiw1tc7JraaKTLcFHByM15gQOM8jIz24zz/8ArrtjK6OBxadgzjA6Ad/wpOR/+ugDGCfQUcY/pVCA8Uo45BIx6UnajHBxyKYCuxY5JGe54BNN5waX64pvcfyoAO+fwpv/AAIU4/XmmkEn2oGIT+FAPHvQeAKaDz1H50DHE9c8Z+lNJ4Jz1HNHTpz6CmnpgY6daAA9QBnPoR3oBJPqKTP40g7c0AO3Hvkmmk470H8h70dD1H+FAw7E/nRkgcmgZ6Dik+nSkA8Z5A+mOma6z4W5/wCE2sdvPytn8q5AGu5+D0Jl8YRuRny4ifYZoA+jrTl/5n0FX7fJfOPeqFgDs5PfFXYpFU/KQxx1HSqRRcye57Hipeeuaq+bj06Gn+ad/bpVXAlVjn2NMckuOTTFlB68D/8AXRuDEEHNO4ieRiqjBOM81DncST1z/WllOV6ioJD0APfNMQkgZ5So4Xp9aYyAZGfxq1JhYwQKgK4DHOflyBQIjI5OTnrxUiNtVnHPFV4wznJ96luPktjgjJ4piMuWTdJkHArlvGh+0wxWvmbNxPQ8/wCef510ZIGWJAHvXB6zcNdauzISVXgVMnYErmn4UtWtptpGUUDDY7V6bZYEK+mPQV5/4TZzJtdcqeevT6V6LZlCgTjPpTixJWLCHoD1Heop1+cYP9atrGCBjp2xTZ4t3Ip3GNSb5F6dPaimBeOn6f8A16KnUDz6dflYjJ79TVOaRstndnrwfarHmPIMKQBzk4qvclAcAAgj5iRmvjbH2q0CK5AG47sgdz2p4vVLhBhtpz3P1NU5XYBiitj1/wDrVVZzycMPXjNAWN0XKuwAz2PBqUMFxkfMcEk/oK50XZyBwDVmK9DAk5yB0zjNBPKbscgMSnIbtyfT/wDXTXjyhIySeMZ/z3/rWM18MKpYgZzwenFWIrsgMGIAGMcj/Pane4nG2qL8oGHAVNx6ggkH/PTHes8wXEiyoMW7Z/dsCH47HH5cfX60/wC3BmZW9PQ0jXAL/KTs5B/LH4dKVrjSaE+zbipHUDghe+KiezQjevDHGCT2/H/PrUyXPXLEZ5J981IkyHCYbk/eHGPb9f0p2FdmVc6dayqBcRxyZbGCA2fwrHvfBmi3Z3m0SMsBjyiUA/I45+ldg5Q8jJz3J+n+f/15qu0Tc4A9R+daQnKHwsmVKFRe8vvOBl+G+nNIfJu72MHsXVgPplc/rWTqHw1vEQNp1/DOf7syGP8AUbv5V6cAd65AAwOvB6U4nYO5Hfv3rqhjKq6nHUy+i9OU8L1rwtq+kQNPd2jG3X70sTiRVHqccge5ArFA3AFTkMMgjnNfR/nIAx5471h6r4W0bVz5txaIs3XzYT5bk++OG/4EDXZSzDpNfccNXLXvTf3nhhFNYYznPHbPWvQNb+HV3FIW0m5S4gP/ACzuPkkHtuUbT+O2uR1HR9R02V0vrKeHbzvKbkP/AAMZU/nXbCvCfws8+ph6lP4kZhGM4z9aae4GcVJ1GQVx6imnrWpkMOTyc8nNN/GnE+v8qaD/AJxQAh7dRxmm49c/nT+RyfrSAFlyADxzjpQMYR160DrgUpwcgU5RlwDjn14H40AM7YFN/E04800n2oGL37/nScYHUEe9HNJnv1PXpQA4fU/WvVPgXa7rvUrn+6EjB/M15UM/rXtnwfge08KiRVxJeTk5A/hUbT+ZBOO3A5xkoa3PT4pmcqqlgg4AyfzNakA2rlmCgDOScV5Z4r8cjSbz+zdJMUmoLjzZWwywZ7Y7tx06Dv781FPLeu0t7NcXbnlvOlLg/RTwB7AVw18dGi+VK7PTwuXTrrmbsj3+OaJ+EkQ8E8Nmnbst3H1rwWKBNhkSFSB2K4NX4NV1TSpfM0++mAb/AJZyZlTr6E9PoRWdPNE/iibVMolH4ZXPZ2b/ADmmM3y8Ejnsea5HQfGsF60NtqURs7x1HJH7pzjja3YnsDj8a6SSQhB6Z+uK9KnVjUV4s8mrSnSfLNDn1PySfPBZB1ZeSPwq3BKk6rLE+9DyCDWHdvlD0rDlubixkMtk4Sb+6fuP9R/WtL2Mjv5myuMnpTJGxHz6etc5oniq11GQW1yPs16ODG5GH/3T3rfds4Hb6VSd9gZZ8obUwcdScd6zdTkITbnp/wDXrVZgE6HgVh6nJmQDsKbEzE1u8Fpp0smTuxgc1wWmys8haTk966fxc5a1VBwpI4xiuf0u2z5h9KylfmKT0Oy8MsBIpBPvj3rs95Q7xn1xXB6CzIVJAxjriu4gYSwAnrjtWiEbGn3PmoO49QavgAisPTW8uQDnB68VsJIMAE/lQwF8n/PNFSB19RRUjPDItSIG1j09v85q3FeRlxtbaCeT/jXMrfQyKSSvX1pQ4OXjI496+U5D611DqndXX5XXbt6Y4FQuqBTk/Ljuc1gC9dTy3brk/lTxfj5vOGQfT+QFLlZammXZkJIxk57kds1GJGQfLnBGCSM4HH+A/KkW7ikcFQeRzk8/jTL24SCEMySTKWCkRKWIyQN2B1x3qbMd7kUjhsYGH4wT19D9OKnS4KsdzdOCfqKqMo3hkbgDIx2+tR5yCAy8dRilyoOZmok7yMXDsVA/iOeO3408SyCXaTuUfeHOc1ixTCJz19iT2zjirAl3jJHGznscn3pWK5kaEtwyujjO3dhie3PH481Il4pCgNkqQCB27Y/lWPPIAZAp5+VgTx+X+e9KspbaUB5GSBwelGo0kdPb3I3IGZvbOOeP8/nVmMIyvtYAjvnOD/kdq5tJD8qqeM5HPTj/APXVu1vI4twZQGd9z4AGWJ6n8qd+4NdjYmDFsY4BySM/d7fj0/WoNxYFGUcDPr6f5xUQnMkqtvBGzG3pz3NKoXAbg7sDn9P6VV+oWVtSKQfu8ggD1FTQM3JJ69Qe1JIueejAc8dPx+v+eapXiXgj3WrxoQD+7ZdwcYHB5GOh/TiqTsL2ak7XsaMmGLBuMnGfbNKqCM+ZE+HxwwbB/Os60uzPHKjxtHcx/LJETnB7YPcHqD/9erSsVYkZJ6VSeplUpuPuyM/WfC2las5kvNPt3mwP3yDy5Pb5lwf1rmNS+HVg0R+x3N1bzfw7sSp+WAf1rvFkKr8w4xxnqPrR8rjPHTsa6IYicdmcU8LTlq0eK3XgrVbVwsr2hXp5iMxX/wBB4qza+DUwPtF27H0jUKPzOa9XuolbGRyB6Vh3GnbQptiAAf8AVn7v4en61rLF1ZL3XYzpYTDxfvq5y9t4W02BtzxGYr/z1YuPy6GtbyBFEEQBQBhQBgCnx3IilZLlCjrj73epE2zpvQrtGRgdv8/1rinVqSfvM9ijh6UFemrehj3+lWt9uW4t4y3/AD0RdrD8RWDqPhAqQ1lOQCOVlGfyIxXbGLGQpHWh1XjAIPU81rSxdSGzMMRgaVTVxPMp/D2oRhiEjl29kbDfkcVmSWk8ed9vMmO5jP8APFesyQA7uPTHGeKh+z4YMCV4/hOOa7I4+S+JHmzyuD1i7HkuOcdKQjpXpl5Yw3X/AB+QxyntvUBv++hWXJ4c07jNrtHGSrOf61usdC12jmeW1L2i1/X3nDsQvLEDFen6V4qWy8DafZaWzNqHkbUAHyox5JY9up461Xh0C2t4cQW0ABbrjJI/nUjWSjO4LnpynNZVcbdWijejltnebMXTdOnimae5Mc0pJZnYklieSSRx1reW52jEWPMU5ZMe1Ubi2mUHy9mT6AnHbmobeORrkNMNpAwRk449a8ycebU9inJRVkdLBL5+6P7rAd+v5VoKyeThjkgYOeMfhWOsYT54z82MYPOR3xWvDtkVBKDnHBz+n/1qzUbGjlcz7oBHbzUyGUofcHrW74S8W+Rdx6Pq9wB5uBZzyuMuf+ebHu3oep57jnFvXUgwk5J5HavPPiA7iwgUH96JdysOMEYIPtzivQwsnCSaPLxkFUjZn0jcOef8KxtSPyg8cc8VgfDjxWPFfhaC5mZDqEX7q6ReMOO+OwIwfxrcvzuHXmvaTuj56UeV2ZymvAeU0mSH6A+/rWz4N8dNbEW2vSM0YIEc4QkgejY/n09ffC1iN5ZAq/dUenXpWM0W04wQMc1LbTuikk0fQ9te297bebaTxyxkcFGyKyrs7nJOMmvJfCV22mavE4leKGRsSBeh9z75716q4DNnqp5FaxlzESVjk/FjYkjTjA5/nVTT12QdMEk07xU+7U9vHyioLR/lCZ71D+ILaHXaNCDHHgEHABz3+noOn6/h1cMBSJtnpXH6PIAV6cY5Fdnp0u8EMeox6VqiRltIPMCsQDnFasGXIORWZJCNwYDBBxn3x6Vat5CqKjLyBgHNMZrbfpRVUTpjktn6n/CivNlW1+L+vuLseF3PgOFwW0+/ubYkH5Ww6/rzVCTwfrcAPlXlrcAHurRnHt1Fei2w+QdPerHlkuew9qHQg90axxVSOzPIpbLxBaE+dpVwwGfnhKyA/kc/pVJtaignKXK+RL/zzlXYf1xXtgjw3AApl3p9tep5d1bQTKcErJGGH5GspYSL2OiGYTW6PHhqEYfdG2OPX9Kmt9QYkEvkAdBXb3/gjQ3BCWf2c8827tHj3wDj9K5ub4e3Acf2fq5VOMJcRBu395SP5VhLBy6HVDMYddCkl8YyMA5HXkUHUIiMdGz1Pf8AWrF34G8T20ayWsdpfL1Kwz7W/Jwv86xrvT9Ws42bUdF1G3Ud/KLKDj+8uR+tc8sNJdDrhjKctmaE08bK4U4boMHpx/k5pguCuwBiVXg46kHufxxXPx3cEu8QXAZt2CMjK8dCKdNcSAgk7ipzn296xdNnQqiZv3NxvCBOuCfrginR3W1UbOBnjH5VzxvmUqXIGDnNPivAoIJ5DBgM47//AFqzcWaQmjpI73DODjBbjHpirE0wbYODnkZ9PQ/hXOR3ZEwGQQTxg9/84/KtGBw0ZVumSQDzSt0Zd76o2be6WOQbmHTOO/p2+taVrqcT5Ut1/u9cf5/l9a5slSoCgDg4zxu9v8+tLbxSK4MYduOmf5fXijUpNPc7SC4RgvGU6BSM/wD6+tSoEdmbBJIyFCjjp/n9K52ylkO1WzjOP89en9a1YmwGXJO7gZ47d6adxONhmoRpbahZ3cSoDKfIk7Bg5ypOM/xY/wC+jVyXaB/EF4I4/l+tVtXfOlSglfM82Ly2PGG8xSPxzjr61euYxjAJIPXJH9PrVdBVNYxb81+v6lNnwe/J6f5/nTUdXZQOBzTZAegBPHJxgf5yDUe1ju45zjP41SMVbZk7k7RnH+e1VWwG/u54HHTinMxXCk8dvmqtNKe/p7GqVyHFMivLWC9t9k6rJGeOB07VzFxpN9ptzJLZu93aMciIDMkXf6sM/j7HrXTRXDZJkyfep/MjZc4HTnIqviVmOE50XpsctHqMLokkTAMegz1IPb8qvrKkilmARuQO+R9adqWi214zSW7pbXJbcZOiue+4Af8Ajw5479K5a2vXR3gmLrJExRw3VT0wT3+orGUWjvpyjVWm50pkVW2dG9x37UNwgO3d9f8AP+cGqH2hfLLHcXAOScfNz0HvViKYFPLMgGeQPb/JpJkTp2G3UTSdMqTyOM4qGBdqjOD9BWhEmQMkHPTv+NI0eR8+0Aj+tUmyLJECE7jztHAJB5qvLuDDaSVBxjHXirhBI4wOeCeTVR165bgHPHfinFFNiY2rlTk+wxkVG8XmDci4PXae/wCNP2nADsSQep6VHE5CKCc4G09sGrUdDJj7ZkKspXGM4b0qeOV41wzHywRzjqBWdGx8whmOSM7V4FWzKApD4LAc89qrkIlOwy+nUAMoA7Yx61wvjOQytu6gfIv17muqllJBxz2HTNcV4mZri6itbf5iBzg/rXXTg9Ejz6tS+5J8GtaGlePDaNxb6ihiIH3d4yVz/wCPD8a9/uWLBgOvTpXzJoltJYeJ9PkIAaG5jYn23Afyr6YQ+e6Ed8H616dJW0PJxNm+ZDHtUlTBHbmsnUNJG0si84z0ro0Xt39qGj3oflHI5rZpHOnY4eKHBYYA6+9eo2GYrGBWYttjHJrip7XFwcDrmuuhlDaUZBjhMH2qYqzG9TitVm+0X0j8YyMfhUdtIQ+DnGe/1/z/AJ4pwiLlmb+Ik4p4hIYEdqlDtodTogLbTzz1+tdtp0QAU9K4fw4cgZxxxniu+08/IOByK2iZtF1IwTz9P6VG67WG0cdf0qzEM7cipDFuHTP61QGeQhJyD+lFTsAGIwevr/8AWor5+cYcz0NUzzxXeIjk8datwXLOeakexfcQ2OeOuP8A9VOgg2v0x7V6riZXJY5CW5zketWUHz4yfWmBQWwFGakVcNn+lQUJd2+9SQe1ZBBRvQjmugRiVII4xg1n3cHy5AHSgGibTrjKAbqsXKnaxBYepHFY9pL5Tc/pWwsokUjv0pXGjnNS0HSdSmMmo6bZ3Mg/5aSxKWH/AALGf1rgviF4astOtJLjS4ZLZlXO1ZGZT9Q2f0xXq88XJ6Vy3jiAS6TKMZ/dntUuMZbotTnD4XY8BbVXZSJUU89uv1qJ9RLAYVlx/FxxVaUKsrq5OASOBn+tV89ePXn+n8/z5yMYJYSnLoawx1aPW5r2+tBSomZhzzxx9fr1rpdK1OK6j+WZWYcgg/e/yK4InB9PxpFfaQyEq45yDg5rnqZen8LOqlmcl8SPTVuhHt28jAB+atexkXYjOWKkcE+xwTnv3/KvL4NZm3gSjIxjcO9dPp18flcZx91hnpj+tedVoSp6SR61HEwqq8Wd6vylcA8jJ5/KrcU5EbBiQff3P+P8qwLG6YrsYZ447mrguCP4CAeePp2rn2OxalHxH4mayuvsf2UtskilD+ZjO1lbgY/2cc10um6s2o2MNzIph8xchS2Tj0z6VyHiqwa/azlj+9vELH0U9/w5/OuitisarCuFRAoA9ABxWl1ZWOzEqg8PT5F72t9/T8TU3bsHLc56Y9qVQdoxnkZx7GmxMo2EAbsHAH9asiRTtPGCPr/nnvVxPJnoU51Pb8z2/wA8Vl3JMZAJBzwOnP09a2pmUqSGXJ4+nP8An/61Zc0CKruECs+CzEE54wBz0/CqaCC7mTLc7cfMc9CQen+f61YiuA0G5eRjoe4rnfEMk1ij3MBQopzJHJwCvQnI4Uj1PHuKi0XVIryCOSIkwyrlSxwV9RUanRZWOmuJlWMvG5AAJ2/SvL/GN+9rqou1U/vEJbb/ABYIGfrjaPwrrNXlkiJCE5bOeT681xHjIsulwypEZJ4p1AUDOUZWDD89taRXNoyY3pPmRbg1kzRL5bgkc7geneuv0XdNDG4JbjOTjg+mfSvMNGtZ7Fle7jRbVmIU7wSN3ABwfXivYdAw1qu3kYwAo4rGpDkejOly51qi6EZVyHz3JA6VUnkKHHTI7mtXIK7lAxjjJ71l3hxcHePpk9/84pJ9yFG7sRNN+6JVlGBz34OKpTSsqgqflzk4PTrQZQ0wCDIYY7HHT/8AV+P1rOM4e1C7twwwBJ/un/CtIoio7GhHLuRcNn0Hp61BPJiRhkkZ9O9Lp8ga3tyw+8pbP48VDeOCFHOeuK2jq7HNUk0rkYcLclSfl2ckcY/zzU802OQQeMGs+aTbITjn+dQG4Z32KRgnk1vGC6nJOo3oiW4m2xO7HBC8ex9Ky9LsX+e6uFw7gEZ9Oo/pWtGglQEj5Ae/rU06bnjjPAJzgd69DD07Lme55mIq3fKjmtQsfMv7WSPgtMo4+or3TTkxbx8/O6jI79K870LTjqOrRNsAhhIc8ccdK9MgwHAA6DAroitbnLOWlibZhhnHNPAG4KWGSKY7APkngfjTrDEk7Owz6VZncJrETMP72M5ptyxt9LlQnHQVr26ASFm5GMVzniS5xdR2w6Z3EClLRDRRijAQDvUoiyOlRg4x6VchKtgH17Cs0Nl3QEK3TY9Mfhnp/n1rvrDdsUDOa5DR0CuD0HXH4V2FoRgYzWsSTRiYgrnpVlGyB/ntVSNxgVPE4JUdv/rVQIl8gHnj8c0U/cnfGfpRXK40r7Iq7OemQMPwrNmUq2AMAH1HIx1/z+h4N+6lCAjnoazJHZ3Pc9u1UyADEHvgZp3mneMd6YAc5GPxFABDdPxqLDuWI2Yt2pswYr+FCvg8CnL86gbSRj0qWNGTIhRgevHpUtpOyuQTWl9k3AHB/Kq8tnsO4DvRYRZb5147+tc34uX/AIlsgbupHSujhIVCCTxxXCfEzV0s9OkwedpIGMfpUlt6HgF8CLucdMOearHuMj8f8+/86klfczMepbJ4zUeQOua6TEaeB/8AWph4pxI5ppNAx0GTNHgc7hwO/PSu68QWyWlw89vgMGOQPuuuf5j+tcLDL5M8UoALRsrgH1BzW3r2txSl5Fc+XJyoI/n715WZKV4tLufSZByS9pCb7fqdRpOoR3cIlgZSMlXXPKnuCPyx7VvWlz+55OQOpJz/AJP+NeQeG3v21pZbMmOLBM25cB1xxx9cc9q9Js7oScYdPUDsc5H1+orgqQs7Pc9GS5W+V3Xc6LzQPuyHAOTk5x3/AMgVbhILfLjJz/gf1rFimKg7QMYwR6nrmraXGFKg5PbjqPTNZbBuaySlcHrxwO340/znwBntnOfyrMa7RQWbgAZBORVZNSjVuHJznjsT/TtVpj5Gze84nZngH5cH/PuKZODsByST83J6/wCf8apW04kjUqT7g9Rx9KsK6ZAPU/5/z9K0WplKLi7GLqkJlDoD97qB6f59a8/09v7A8RNYOqRWszNLbAA4GcFlA/2Senpj3r1aeNXU5HHc+p61yviPS47iPayM3RgVOCpHTHv1/wA5pq1rDjLUg1JxNGSCTzzniuM8UZfTp8H7u1v/AB5T/LNbGl6l5nm210Cs0LMhLIRuwcBhnsf89KxtclDLPH3aFyPbAOKcfdZroaP2FJfD0kE/R4yCO/fke+a7PQ2MGmWsTD51jUMcd8DP65rFeFJ4IAufKk25AGSR1P6A81vRgBgT6dq5pycjvmo2ui09wwj57+vWsnUJHLII9vJAYvnOPT/P69Knv7hEQg8D3rEuLlwCFJO0g9aqCuct3B3G3dwsU0ZD5Z2I9Ocd/qP5Vhm8kVHWPl1Ezdep2KB+pqfVZwQkpbBVuvPBwevtWbp90HLSYzFuGAPvOckqo+p6+wFdMYHHOrzNnUWcrQWhTHFvEqn1Jxgf1/Kqb3YaUD0XBwPwqhcXZSJISf3hYvLtOcuewPcAYA9xUKOoQtIcD3/xrWlT6nLWqdCS9vCzlA3HfFUp9UW3G2MbmUZIwfXv7cgfjWXfXvmsVhysfTI4JqlwSc16EKHWR5VTFdIHWW/ixQqCWzHyn+BuKV/FoVi8FpliMfO3SuSGKcXLMSwHPoMfoOK6Tiuz1Tw38QdNgt1ivITbyjGSoyD+IrpbLxxoc0oVbwAnpkda8HYZ5xzntScHqKd2G59Fz+I9MERka7TGM1lR/ErQrWUx5mkA6siEgV4YpH+RUi84xxii7Ee1an8XdPjjP9l20s8p6b12gVX0vVLjVrkXt3t8yTsOg9hXj/UHPXsa9P8AC/8Ax5wHjkDp/WpndlRO4AzGCOgFSWw+bGT/APXptkC0Y3AGtGC3G9SQcZ9KEJmtpYxgY6CumgfABJrDsYwp6VrRHHH9a2RBoJJ0yeKsQuSRg5/z/wDWrLWTkc1ahbcy4IzTA1fMf2P40VCrttHAorOz7juUG095OWXrmg6YecgVttIOcUwynP8A9aoCxkfYDt6A8d6cNO56D8a05JVSNnOSFUk4Uk/gByfwpS/Pp3o0CxnCwVT90U4WyqF+XH61cLc8dajb7oHap0GiqYwAMDHHrUEqAhgelW5B0PFVJ32qxY1LGjOvmW3jdicAV8//ABU1kXd/9mjYFQckegr1bxvrIitpUQ5OOB3r568Qs76hI7kksSTWNOopVOU0qUZRp872MxiRkimE8Y6fjSnIUtxtBAOSM5+nXsecYH1IzGTwQTXWcwHg00/hQSc8E0mc0DQtKpx0P1pmemaXJxgmgZ1PgJY5dVuEmG4m2ZgM9wy/nXS6xbzSustiY43jBxvXIx6fSuJ8IXIt/EEDZwrq6nsB8pOf0r0KC4Ry2WHI/OvBzNONW67H1+ROM6DUu7X5FawmZmkJDLICA6P0XjHHscfp9a0ioZSflIPUiq1xZ+Y8VwoPmKDtZfQ9j7f4UkE5Rwy8p3H061xxlzHZWpeyldbFx8zJ5bsMYPbv+HbioI9N2twRsx0z0I9+tW0ZXjDKwXjcuR+mfX2pzMxVC+1m6f1H4VpFEe05UT2YKfISq/X+LPvVyP5guF4/KqMUiu67h8xyc4x/ntVqInJYcYPTGOO5qk7EyXNqXdvOSAePoM9+9Y2rwmUFAOG4z6f55rVWceUoY8kcYx9fr/8AqrPu3dsAY6fUf5/OnzEKNnc4TxLYoIC0AVblGd43bOASMc+xwM/n1Fecarqjo8vmjEgyCrcY/wA/561634ggjlikAJyevv8A/WrltP0JLrxJb3jqpWziyMjI3lvkP4fMfrj0pxqRj8Rt7N1F7pueHYboWlrNdFk2x4EWBkEgcn3GMfia3FlZEL5+bPqM47Yyf5CodgMQUyKNpPBwe9Mv5CiMkTAjAPHT/wDX/nmuW/M7nW0lZMpX9xllViQxPfjn8ayTKQ5THIHXP+f8mo5p5JHAxsVFOAx6cZ/+tWe05kZiTtfkngDafX2710U43ZzYiSgmUvGFz5MNqiMMTEuV45VcAfqT+X4VhWt95exjt81chSeiA9cZ5JP+fSqWuF9V1SW4Uv5YAjiBGMIOnHbJyfxqSys0gALc9+nNelGndJLVnjzmoJuTsb1lJ5hEh+UclpG4x9PyAqC/vDckInywjgD1qvJM8gC4wg6AVFz065rrpUuXV7nlYjEc/uw2JCQRz07f57UfQ/nUf40oGf8A9VdByDiM/wD68mgZ49jmm9xS9B+OKBDueKfuJ68/lUXfH4U4H16GgCVc5ycAetSqBjIHT39qrqeealj9u9Aiwg64HY9uvHSvTPC6A2EXUHA+leYAfK3H5V6n4dDLpsLZ7ClPYuJ3GlxlkQH6810MEWMYxWNoalolPpgc10US4APBPrinEUi1AMfTHNWVJwPy5qovAqxF83T0rREFlCCBwfw4qSMlCCOcURoQwBP05qwIu/HXnimBYW4O0cfpRSBSAOV/Sip5F2HcrSa7ZYKidD16GmDW7UhiJVP4188Sxa6LbeLiRsrnGeprFXxNrNs7rJI7MDjGa4vbGns2fUY1iBhw9S/2lCWGGHIFfMi/EK8tELXPmYA7/wD1vwq7YfFqJn+fcMAA545pqqHIz6SF4rY5pHvYlUFnX868Oh+KMLpmLJJ6YOeajbxlf38Z8oOpxxkjrUyrpDjTbPaLjVraMfNKuR+dcVr3jW0W5NrFIpkY4wDXhGt+MNZs9UEc8jrEw4574qn4f1eS710yzsSfvbievFZSquWxp7KyuzsvFmvgahtlc7mOF5rk9ZQXOJoee5461neO7syawm09t3B61Y0C8WeIROQT05Gcis6XuS5jWbc48rMtiMH0qMnp0NaerWbW8pZV/dsSR7Gs7qwznHt1x7V6afNqjz2mtBhIH4U0nknmnHn3IpMHPTpQAIVBJYMRtI+U4wccHp0zjj+XUN6ZHGelKf8AJNAGB0pALFM8MqSRnDqdwP8An/PWti01plYBnKDqAeg9s1iEdOtNIwDk/lWNbDwrfEduFxtTDP3Nmeq+EdSn1O3ciSGJEfYVcncCPcDgVr3Ecbxebjy2LYIPOffIryPSNTudMnE1u5KggSR7sBx7/wBCORXUf8JbHJpzx7mUjI2MACP6cc//AFq8XE4OdH3oK57+GzCGJXJJ2fmdbaloJiuTsPGPStCW0X73Y89KydOvItS0Sz1CHcPNjAcMu07ujfhkH6jBrQ027+0xNGzEvGMEcE4zwfx/z7Zu6OiGugsqlF3BtwGc855qOHUYUTZJIPLPAbjg025lJDBV6AAt69vWuQ1uSdAzROoH93BAPtQveNUuTc7aeaOPoFdScbQeT37+wrJu9QY5KoAMf1rz+LxvNaSeVc25dSQFZGB28jgHv04H6njD38XW0qlk3bsZxjvgVp7Oa6EucJLR6naeZ56MWBbrk1Z0mAJZ3E7jYkr4XP8AEq5G76Z3Y9hXIwa7GltI4O9lBauxtg91bQW8YdnVTkxn5tqLkgAc9ATkdlPqKwqRexrh5Xu+xmyRz3aSG1kUjcRznBwecHGD6fgayZtQdCY5x8ucBxkKT3HTrXTXMsYtljjIUKBtA4wB6fyrldZP2lnYFQ7AkqfUAnI/BTWkaSauty6tfW0tineXIQ9cKRmudvrtmUxj5WPD47j+6anvbs7ApIZgMqD2yfvH8jj3Htg5R4716eEw1vfkfP5jjb/uofMXPGMUmcevHbFIe5PGKD2J4xXoLTY8VtvVjtxBGQef15x/jRu9+PpTVxv6AHn/AApfQ+tO4hd2M4/zxRxnnH4ikJ4/rRnP0p3AcMZ96XI65po9MYHpRjODxRcQ7PA6Ypw/nTQPb8qco5HXFADlYgg9cflUqkA8d/bpUQGMHjGPTrUij2/OmInhILge/wDWvYNDQf2dCoAryPT4jNexpzndzXsuhR7YIUI6LUSZUTtNDi2265H6VtooGOx9az9LjCxDAH5Vs21uSc549P8AP+eKqImOij3c/iKvW8PTjn6VJBBjnBq5FFg9M1oiRscAJXIGR046cY/qatRxjC5605Uwo7ipohnbgYH6UDINqDgkZFFWDbgkn5eeeh/xorgdbF30pr7y+WPc8yj0uH+ywu0cx+ntXlWs6TFFqkwI+Vj1A+vavYkmjW0A77K8t8Rgvq7tHkgDnGeK5Wdhw/ifTgY+AAvcgdPrWJo/h6W8mBgt8oDhmOADx0BPU11XiMuYANpOR96sXw/rEthceWYdylywYsRjPbpSb0sXFb2OvsfD0cIXcpSQYBG3BBrYgso4zleQOeODVa3nlmAcltz5PXitCFCihnbGOSaylcIqx5b8RYSdTgCDK7ueKmjso7K1aeMgMFzS+MrtLvVoIIVDEvnp29adrMLxacwJO48ZHetI9EE/hZyeuXBuLsMTn5AcH6n/AOv+dO0+48idHU5IOSen+fr/AIc0LtWa4bCnA+XjmnQEZ6HI7dxW1tDK56JJEuo6f26A/Q1yc0bJIyOcYOM1ueFr1SDE5IB70/xNYbf36L7GtaFSz5WY1oacyOcOfpTW/DB5pSfY4poI6YNdZzAeCB0FAzigEfpTSffnFIBPTp0pRyewPvn+lKQOflwvsSfyprEY9+e3Xp/LHb1Oc8YYxOxz/KkHXqKU9e5pp6EjJNIZ1nhDW3iJsZ3byyCVJ/h49/T+Q9qk1PU7rTb77RazLHJGfmQ9HU9VYehH4j2rjo3McqvGSCpyCPWtGTUhcxFbhV8wrgFhke3XpXm4nDtS54q6PbwOLi4ezqOzWx09j40sri1iBfZNgl45WG7dnB5/iB65Hr2NZeta9HJFjMXTAIb2pui+FtPv7FLoyyCXJ3jsD0wRiqXibwlbWcSPEyEyAsu3PTJHTt933rkcYRZ7MeaqrX1OP1C9t3c+a6HB6L8xP+fwrMkuoySY45QfXOM/rWlLpQe3zEP3yEjH94dqzwAuQy4I4/GvSgopaHmazk1fYu2et+WBHKjbGBDMOv5dDXsWk61BcaRBd2U43lVcOh5ilA5H1BzkEcgehrxmwtWmcSQymJ0bKspIYH1B7GtbT3udMSTyJR5TMA6kEc9m/Qj8vw5cTTjJe7ozrwrlTk76o9NuNSUs1zGvlwMdrKDxEf7mev0PcEd81z+o6hGs8shkUoqlRHj77cZ+uOV9OD68YL3lwsxcTMsgGNy5BXj69qqO2TliT25Jq6GFaV5HFisyV3GGrJp7mac5mk38kgYAAz1wPwH5VDu4ODzRn0zzTd3Az1r0UrHhtt6sPXJ46UH/APVTuOeOP50hIGM+v1oEIASQPWgdSe2O1O4z04o6DmmAgHI+tPXrwRSD19KXjPQ0AL+HFKM9etIuMjuMdakHTnHFMQnOOmadzz0o4wf8OaVcZ46e1MBVPOeDj3/SpByMgZI59z0/z+P0wxcdQc/jUi7ecj/61AjofBdp9o1IsRwg7V69pUYzgDoOlebfDoDz346n1r1DSsLJjnk571MionY6dH/o65FbVoDt5A61m6bj7MPpV6F8HGO9WhM14T9MVPGc9QM46VUt3457jirMZwcVaFctKSMZAzUi8jn/APXUKkYHNSRsBjrigCTzW9B+VFSAqRRUWHdnh9/qTRxEfMODzXJzb5pmkZvlH516PrOnx3EQSKPkjGap2XhhPLAdRk+9eRZs7r2PLNftppYjg/eHXNcNOr20xJPO705/Pr+FfRGr+F/NgdY1GTmvPtb8AXchZkUE1fJdWHGpysoeHNQR7dQ784z6/wCetdBcXIXTnZWJXHrzXn1z4b13Ty3lxsEHPBqPTL68kuFtL4OMcHJIzWXI2y20tUzR8O6E+q63LdvyoACitXxPoM0hEaMQor0XwrplnBpwNuRuI5zUh0xnnYSDIPvWiXKzGUuY8Kl0bYSsgIb8/wAazbzTfLYnHGeD0r3HxD4ZDxNJEg3YyDXmusWTQOySJgj3rZNMizRzemZhl4I612kDLe2ZRlOeM1i6LYrc7844ODUes3X9jzFC20MOAwrKStLQ0WqsY+o2/wBmunjyCM8VSJ55NTyXxvSH4z06YFRc8V3wldanDOPK7DT2Hpz9KM8Y6f1p2MYP1/D/AD/9akHtjFUSIeKQfoKUkkYppJPegBSRj3447U1icc0vOP65pDnnpQMb1PHp+VIByAc+/en4YngcYpOTTGWNP1G406YvbvwwwyNyrf8A1/eptS1Wa+tYkyUZSw5OeDg9e/OazznNIgJI9elYTw8KjvJHXQxtahpBiYAAXOcAVHJBDKP3kSscdSOfz61MwIBGP1pvJ9P5Vtyq1jn55X5r6lQWUKOWjMkZ/wBlsVOFUPu5zjHJ/pT/AP8AXSc96h04vdGv1mr/ADMY3vSEfn70/n2ppzjiqMRAMqxAyFKgt6Ft2B+O1vyoxxyQD1xT8Hjp07U3nFAAO5o7ilAPfp7UHdjGBQADrxz/AProHtj/ABoGdw44pec0wEPQ07HPtTRn8ee9O5z0oAVR/tcjtg8/0/z+T1B2lsHavJ9uQOfxIH4imDOfelxwOKYiUMMdKXOR2poz3xTlBHQc/nQAqDj9M/8A16kA6e9MXPUVIpIpiO5+HibWZz0JJ6V6XaZWRBk7QSQM8c4yfrwK4PwcrLbKz9SoGevQAD9K9EtELxAgDNRvdFbHYaU4a2UZAJ7VpxxZwcd+Kx9CkxDg84PpW5C4ZRjHWriJlqJNycHt2qZBnvg/Skts4wP51IuQ+DwK0ESpnjmrEQzio4x0GODVmNTx6UASBVxRTsUVPMM8+ihLP82R6Zq0sZAwOlMuRtXIx780W025M5HpXlnaPKuHJJG3aflxzn1zn68Y7/mvl7nGQOvHHf8AyKcXGOcdOtPRvmyP50MClc6XBKrBkHIrzfxj4Oh837TCNrAZ4r1nIz2/Oqd5ZpPbFMdvWmmS1c8z8JSmz2pvO0jkE5rtSAyb1xuHvXF6zatpl8G58tz1HY10WjXQmgAyM49aT1C1jVGJYirY/KuE8ceHxLFJNDncoyODzXa7/LkYDheozU0saXMDI4BB4+lTFjPn/wAOEw6m8UnGT0PGDV/4k6ALnTFmVhvX5hgVu+JNC+wawl1EMKWO7/GnaxIL3TzAOT0AFOT6oI6Hhmmb/O8nGTyAcYramt5YSBIhXcAQexH1/A8denYgnRHhu4s/EcTpGzQOfmGOld/rmgpLpSmNckKf5V0U6ltGY1o3d0eVEc9RTSv+cVoXVjNbE+bGQPWqu0c4/Suk5iAqehwPwpCvH4VPjrzTdo79cZzQBFt55J56465pMHNTYBBB5+tIVGOnPvQBEB15AGKaeCSP5VMFHTvjPWkIGaYyBlxn/Ckxke9TEDP9aTGeevqaQERBx2xSY/zipcZz7/55pMDp2PqaYEZHpjp+PuPpwPyHoKbg1LgEHGcdKQL/AJNA7kRHpSYqXA6UgX60h3GY+lJzUu33FNwPxoAaFJOF78dKTBIHT8sVJtB/lyaMdBQBHyTS4Ix0zTwOeM0YFMBmDkZoAOafj2pcL7UAMA5/CnAU4AZ6807A/wAmgVxFyMYp4H0oCjH+eKfjHQdu3b2oC4gBwfanopPAwM+gpcDqT+tT2q7p4we7CmB6foEPl6dGR3xXdaUcwqPauV0uLbpyAdcc11Okf6tahDZ0emjCepNaluzKw54yaoWK4jFaMSgj05rRIm5t2bbsY/Grfl5PvWZYna2K14mGecVYEkcYGKlA2jIpVxgU4jikMOaKjEqgUVNgucTcJuhcYzwc1RtHAdx6HrWpMuImzzwcD171zjSmO7kAwT1ArzDvNzaxHfpUqAjqOKoQ3qkYPX2qfz8HIIPuKRJcXOf605RgDscVQa6Ibn6Uq3nAGaEBV1/TEvbVhgE7SMV59pNw2mao9rOcLnC+mK9K+0FsDPGMdK8y+I8Zsp47yIKNr80xM7Kch03rzU1q2SO49awPD2opqGmxurgnGD6ite1fMhUkZU8/Ss3oykVvE8CSWrOQM4615zZnbfBSfuEmvR/Er7dOdsnPHNeWW0jSXkmBzvwPzoQM77TLW3utrMoJ7cVsTWUZQKVBH0rJ8PowjTOfxrZ1ORorfIPNUybGDqnh62ulwiLg5GMVyt98PEEbFFwe2OK7/SmklG5u3FaZUkYPAxVRquOxMqaZ876x4avNNLHaXQHsORWEUIGOQBwfb/P9K+k9T0mC8gdSi7iPSvHfGnh9tPu3ljULGeSMdTkf559Pz6aVXm0ZhOny7HG7OOnFG3r/AFqbaaaQQcVuZEQX0pGXk5qTb2xSYPYcUDItvSk2nFSYOB0x6460bemAKAIint+NJt6E+nU1MB0xt9OAB/Lr+Of5UmML26ZzQBCyD0waTaMd/wA+KmK8HIHfrSFTngUAQlB6AUmw9P6VKRyF4yckD27n9f1pSD7UDIgvoKRlyR9PWpcGgg89KAI9uD/OmleMH0qYAjsD+FNIIHb8qAGBOR7UmzPtUpXnHGKADnP60DItv+cU7GTk56Y5P4Cn4OeAD7UoBJFAhgXOOBx7Uu364p6g8cD8qcFIAHp3pgMC9BT1XJ6U4A9AKUDpz1/WgAC9zx71c0qLffwj3/pVYIduR93OMgcfT+Va3h2Iy6jH0AA9KGB6rp8f+iKPat7SFwoH4dKy7BMRgHpjFammkrLt4AqSjqbJf3YIHNW42Ixg9+tUbJ+BzzVpweoA61oZ2Ni2YEg85q/BKM4NYsDkbR/npV5CdwPHNUBtxP8Ad5qR3GMDvWZDIQVyRg96teYeGJz9fpRYdxxaIEgyID3GaKnA4HWio5pdh2RxMsvU+lc1flkvFI9cVtSNxWbqaD747e3evMudzK85dRlFI461HBqEsUo8z7uetasarJAG9qq3EC5PA+tOwrlyOWOWPK4zjtWZdagIZdnHSobZjFdbQeD2qnrcZEqyjOO9Swsa0F75gUDAI7ZrE8f2X27RZgV+YrVrTHBA9609RiFxZsvX2xQgPI/BmryabObWdmEZOOT+Ves6Y8NwiyRsCfUV5/f+F2uLtzCSpzwAK1dNjvtICqQXQd6ppMS0N/xMjSWDIp69DXnej6ZPFdOZ4WA3HBxXpNrew30eGJz3BFWBZxBcKBg9MYqOWw73M7TFCouPXFa0kayxAHpUD2wT5kwKkhmBQ5zkUASwRpBEBgDH6UyWUZIXtVP7QXchf0qVUJ60lqFyRZD1Y1heKdKXU4GTbww9K3hFjk9KkVV2nnPFUtNSWro8qt/AA537j+FZuu+DGtUZoNwP869jmcAYwMVQvtjxMJse1a+2adzP2S2R88TRNC5WRSrDtUW3kdc16rrmk20xcoi5x7Vwmo6Q8Uh8scemeB+NawxEJaXFLD1Iq9jEx0460AD86nkhaI4dSKYF7AE1ve5g13I2GD/Okx1x1NSEEjjk9sUrKvIABxkb1JOffrj/ACPemBCQPT1pCo7Cp3QIwGQQQG/MA4z3pm0ZzmgBmWCMgY7GZWZQTgkZwSPUbmx/vH1pmBU22m7aBjMDmk2j0xUwHfFNx60AREDr/KkwB2H1FTEd6Qr+dAXIsfQUADgY/Cpdoz079KQLkjufagZEQP8AGlwM807HHOacAM9/zoAYAPSnAYA7c44pyryKcBx1/AUxCALnnpThjinEYH+ApQOeOaBCKABz9M/1roPCEe6/LY44rDAwTkV1fgeLdcOf9r19qT2Gtz0e0UDGR2/StaCPDhhwCOlZ1qvzGt2zj3AZxQNl6xbkfyrUUAx9OQfyqlbw7dvatSOPKfr9K0RLFtxkYIPTvV2MDAHfqBUEEXPNXolHHQVQiaMAMMEH39atHARc9RUUYGR/hVhgAnsKAJgvHaikD4A5/SiuVzjcs4KUZXv0rO1PLWzcAke9STXD47ck9qrzSM0b5x0/wrhO0fYyn7Jk8EcfWqN3egy+WCc07zGWNlXABFQWluhk3ksWIzyaZJPbRMzKT3qzfW4ki2t1xUMU7hsDFWxIzxhjRcZzLb7OUKRx2rWt7wSx49apa4A0i59zx9M0unKGz7VNxGrbxbZi2AcmrkkKSj5lHpTbZRgipz2qkwsYl1pm0F7fg56UWN08b+XOPbOa1x0Yf56Vj6wgDKw4JobA0ZG29MkH8Kq3BURFgefTP1qS2Je1Qt6Vh61cSRKwQ4GM1m2WkLZXI+1EMcityNhtzXGaQzSy5djXbWsShByTxQhWEbJB7f0qN3IGM/rirMihQcemaqzDEbN3x/j/AIU7itcq3MwjUs3Wucv75pGIjzgHGSat6g7PIUJOM1RMS4PWuKrVb0R6mGw0UuZlJkZiCTk+5qtJbBx0GMVsrGDH7dce/T/P4014U3YxWKkzv5Fscxc6VHKeAKxbzQCcsld0IlJPHaoxChTJH+cVtDFThsznq4OnU3R5lPYXEB3DI2nIIOCPcH+tUipXAwBx0HavUrqzhbdle9YWoaZbY+4ehr0KON5tGjy6+XOGsWcTg8kAfhSYPFa95aRxt8u78ap+Wu3OK7lK6ueW1Z2KhBx7Um096ueUvvSeWufxxTuBU2kk0dM8Dp3q2I1wDikaNc4ouBVYYP0pGHrnr2NWxGpYA0jRrnHoKdwKgHIwKMH8DVtI1OPrj9absXPTtmi4WKu3Jx1owc+5q00a4/CjYu7p2NFwKwU+lOCnFWRGOuT+fsacIlCjr1ouBXA/P1pwB6YIPftVgRrtFOES5Xrzg0XAgUYJ6V2/w+iJLnH8Xf6VyKxrtzz0zXonw9hTyCcck/0ouC3OytoSCTjityxjIYcD65qC2hQkcds1s2MS4B71SBli3iOORir0aHHTvT7aNSmatIij88frVpkkaJ8wxVhPl5wKciLTig/TNMBYicgYzzU27Kf/AF6ZEoyB71OVA2/WmA9T8o5opM47CiuV1Hc0sf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The examiner gently rotates the patient's wrist ulnarly (arrow) while the patient's fingers are folded over the thumb.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Sheon, RP, Moskowitz, RW, Goldberg, VM, Soft Tissue Rheumatic Pain: Recognition, Management, Prevention. 3rd ed, Williams &amp; Wilkins, Baltimore 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_14_22752=[""].join("\n");
var outline_f22_14_22752=null;
var title_f22_14_22753="Oblique fracture great toe close up view";
var content_f22_14_22753=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oblique fracture of the great toe: AP and oblique views",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 568px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This fracture is subtle: there is no clear break in the cortex, and the fracture line is less apparent. However, in a patient with point tenderness and the appropriate history, the irregular lucent line seen on two views (arrows) confirms the presence of a fracture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_14_22753=[""].join("\n");
var outline_f22_14_22753=null;
var title_f22_14_22754="Sling and swathe";
var content_f22_14_22754=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63053&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63053&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sling and swathe with U slab for immobilization of a humeral fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 526px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sarwark JF, King EC, Luhmann SJ. Proximal humerus, scalpula, and clavicle. In: Rockwood and Wilkins' Fractures in Children, 6th edition, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_14_22754=[""].join("\n");
var outline_f22_14_22754=null;
var title_f22_14_22755="Fomepizole: Patient drug information";
var content_f22_14_22755=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fomepizole: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/3/2102?source=see_link\">",
"     see \"Fomepizole: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/39/28276?source=see_link\">",
"     see \"Fomepizole: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F173900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Antizol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F15125571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Antizol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10190855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2745242",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat methanol or ethylene glycol poisoning.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10190854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2745244",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fomepizole or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10190857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10190862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10190859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10190861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10190860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15553 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-8D13A6BE0D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_14_22755=[""].join("\n");
var outline_f22_14_22755=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173900\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125571\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10190855\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10190854\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10190857\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10190862\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10190859\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10190861\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10190860\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/3/2102?source=related_link\">",
"      Fomepizole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/39/28276?source=related_link\">",
"      Fomepizole: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_14_22756="Miglitol: Patient drug information";
var content_f22_14_22756=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Miglitol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/0/3077?source=see_link\">",
"     see \"Miglitol: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F196614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Glyset&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower blood sugar in patients with high blood sugar (diabetes).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to miglitol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703499",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Diabetic acid problem, problems with food break down, inflammatory bowel disease, bowel block, malabsorption syndrome, poor eating habits, or ulcers in the colon.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam and visit the foot doctor every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If taking with other high blood sugar (diabetes) drugs, use glucose (dextrose, D-glucose) or milk to treat low blood sugar. Table sugar may not work as fast.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698108",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gas.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be used alone or with other high blood sugar (diabetes) drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695894",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take right before a meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10869 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-AB43D6AFE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_14_22756=[""].join("\n");
var outline_f22_14_22756=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196614\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014095\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014094\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014099\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014100\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014102\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014097\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014098\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014103\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014104\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/0/3077?source=related_link\">",
"      Miglitol: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_14_22757="Peginesatide: Patient drug information";
var content_f22_14_22757=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Peginesatide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/31/26102?source=see_link\">",
"     see \"Peginesatide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14219619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Omontys&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F14190436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700784",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of heart attack, stroke, heart failure, blood clots, tumor growth, and death. People with higher red blood cell counts or having surgery have more chance of getting these problems. Your doctor will need to watch your blood cell counts and follow you closely to change the dose to match your body's needs. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F14190438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691725",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anemia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F14190437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3731890",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to peginesatide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703864",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have very high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3731896",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are not on dialysis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F14190442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697835",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a blood disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697192",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have cancer, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F14190443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High potassium level. Signs include feeling weak, lightheaded, dizzy, feel like passing out, or have numbness or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698081",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698247",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle or joint pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F14190444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F14190440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695245",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F14190441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696559",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F14190445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3731900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       May store at room temperature for up to 30 days before opening.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3654108",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any part not used after 28 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F14190446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83362 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7DB0BEB7E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_14_22757=[""].join("\n");
var outline_f22_14_22757=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14219619\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14190436\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14190438\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14190437\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14190442\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14190443\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14190444\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14190440\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14190441\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14190445\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14190446\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/31/26102?source=related_link\">",
"      Peginesatide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_14_22758="Suppurative parotitis in adults";
var content_f22_14_22758=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Suppurative parotitis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/14/22758/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/14/22758/contributors\">",
"     Anthony W Chow, MD, FRCPC, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/14/22758/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/14/22758/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/14/22758/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/14/22758/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/14/22758/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H973167060\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute infection of the parotid gland can be caused by a variety of bacteria and viruses. Acute bacterial suppurative parotitis is caused most commonly by Staphylococcus aureus and mixed oral aerobes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anaerobes. It often occurs in the setting of debilitation, dehydration, and poor oral hygiene, particularly among elderly postoperative patients.",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, microbiology, diagnosis, and treatment of suppurative parotitis will be reviewed here. Deep neck space infections and salivary duct stones are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=see_link\">",
"     \"Deep neck space infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22568?source=see_link\">",
"     \"Salivary gland stones\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H973167097\">",
"    <span class=\"h1\">",
"     ANATOMY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The parotid glands are located on the sides of the face anterior to the external auditory canal, superior to the angle of the mandible, and inferior to the zygomatic arch. Most of the parotid gland is superficial to the masseter muscle. The salivary gland consists of 20 to 30 intraparotid and periparotid lymph nodes with lymphatic drainage from the ipsilateral side of the face and forehead, including the auricular region and the external auditory canal [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22758/abstract/1\">",
"     1",
"    </a>",
"    ]. Stensen's duct arises from the anterior border of the parotid gland and is 4 to 7 cm long, narrows to 1.2 mm at an isthmus, and the os is 0.5 mm and is opposite the upper second molar (",
"    <a class=\"graphic graphic_figure graphicRef62744 \" href=\"UTD.htm?6/19/6449\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Acute bacterial suppurative parotitis may occur when salivary stasis permits retrograde seeding of the Stensen's duct by a mixed oral flora [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22758/abstract/2\">",
"     2",
"    </a>",
"    ]. Ductal obstruction by calculi or tumor may predispose to suppuration. Abscess formation may also arise by contiguous infection or hematogenous seeding to the intraparotid or periparotid lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22758/abstract/1\">",
"     1",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H973167104\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suppurative parotitis typically occurs in elderly postoperative patients who are dehydrated or intubated, although it may also be seen in outpatients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22758/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Other predisposing factors include recent intensive teeth cleaning, use of anticholinergic drugs and other drugs that reduce salivary flow, malnutrition, salivary calculi with obstruction, and neoplasm of the oral cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22758/abstract/4\">",
"     4",
"    </a>",
"    ]. Infection of embryogenic cysts, such as the first branchial cleft, may result in frequent suppuration of the parotid gland [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22758/abstract/5\">",
"     5",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H973167111\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suppurative parotitis is characterized by the sudden onset of firm, erythematous swelling of the pre- and postauricular areas that extends to the angle of the mandible. This is associated with exquisite local pain and tenderness with complaints of trismus and dysphagia. Systemic findings of high fevers, chills, and marked toxicity are generally present.",
"   </p>",
"   <p>",
"    On examination, a fluctuant quality is generally not appreciated because of the dense parotid fascia that overlies the gland. Purulent material may be expressed from the orifice of the Stensen's duct in over one-half of the cases.",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H973167143\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The microbiology of acute suppurative parotitis is quite variable and is often polymicrobial. Staphylococcus aureus is by far the most frequently isolated pathogen, but anaerobes are also common [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22758/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. Gram-negative organisms (Enterobacteriaceae, Eikenella corrodens, and other gram-negative bacilli) are often seen in hospitalized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22758/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]. For unexplained reasons, Klebsiella spp are particularly prevalent among patients with diabetes mellitus from Southeast Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22758/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38426?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The polymicrobial nature of parotid space infections was illustrated in a study of 32 patients with acute suppurative parotitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22758/abstract/4\">",
"     4",
"    </a>",
"    ]. Aerobic bacteria were isolated in 34 percent, anaerobic bacteria in 41 percent, and mixed aerobic and anaerobic bacteria in 25 percent. S. aureus was the predominant aerobe (in 10 patients), followed by viridans streptococci and Haemophilus influenzae (in four patients each). Pigmented Prevotella and Porphyromonas spp, Fusobacterium spp, and Peptostreptococcus spp were the predominant anaerobes.",
"   </p>",
"   <p>",
"    Rare causes of suppurative parotitis include Streptococcus pneumoniae, Streptococcus pyogenes, Moraxella catarrhalis, Enterobacteriaceae spp, Pseudomonas aeruginosa, Mycobacterium tuberculosis, and Actinomyces spp [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22758/abstract/9\">",
"     9",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H973167152\">",
"    <span class=\"h1\">",
"     IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies are useful to assess for inflammation or duct obstruction by a stone, and to differentiate between acute suppurative parotitis and frank abscess collection or a solid tumor. Imaging options include ultrasound, computed tomography (CT), and magnetic resonance sialography [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22758/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. On ultrasound, an abscess collection may be seen as a hypoechogenic lesion surrounded by an irregular echogenic rim within the gland parenchyma. Ultrasound is particularly useful for detecting stones in the duct or parenchyma, or for differentiating between obstructive and non-obstructive sialoadenitis. CT is the most sensitive tool for differentiating suppurative cellulitis from frank abscess with rim enhancement. X-ray sialography is also available, but cannot be used during acute infection and requires the injection of contrast material [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22758/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22568?source=see_link&amp;anchor=H18#H18\">",
"     \"Salivary gland stones\", section on 'Sialography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H973167159\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is usually made when the characteristic clinical findings are present, as discussed above. An elevated serum amylase in the absence of pancreatitis supports the clinical suspicion of parotid involvement. When purulent drainage is present at the opening of Stensen's duct, it should be collected for Gram stain and culture. Gram stain is particularly helpful in detecting staphylococci and Candida. Culture obtained intra-orally, however, should be interpreted with caution since the results may represent contamination by the oral flora. Needle aspiration of the swollen parotid gland by an extra-oral route is the best method to identify the causative organisms. Specimens should be cultured for both aerobes and anaerobes, as well as fungi and mycobacteria. The primary utility of the culture data is to obtain susceptibility testing of a dominant organism in order to ensure adequate antibacterial coverage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H973167167\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of suppurative parotitis includes hydration and intravenous antibiotics. Since suppurative parotitis may potentially spread to deep fascial spaces of the head and neck and is potentially life-threatening, outpatient management with oral antibiotics is not advised. Surgical incision and drainage should be implemented if there is no clinical response after 48 hours of treatment with empiric intravenous antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42625563\">",
"    <span class=\"h2\">",
"     Initial antibiotic regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial empiric antimicrobial regimens are based upon the expected microbiology and host factors and should be directed at Staphylococcus aureus (including methicillin-resistant Staphylococcus aureus [MRSA]) and mixed oral aerobes and anaerobes. Additional coverage for Enterobacteriaceae and Pseudomonas aeruginosa should be considered in patients with prior hospitalization or who are immunocompromised. The spectrum of the antimicrobial regimen should be narrowed once microbiologic data become available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181072748\">",
"    <span class=\"h3\">",
"     Immunocompetent hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the",
"    <strong>",
"    </strong>",
"    immunocompetent host, we suggest:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"       Nafcillin",
"      </a>",
"      (1.5 g IV every four hours) or another antistaphylococcal penicillin or a first-generation cephalosporin",
"      <strong>",
"       plus either",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       Metronidazole",
"      </a>",
"      (500 mg IV every six to eight hours)",
"      <strong>",
"       or",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (600 mg IV every six to eight hours)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    (15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    (600 mg orally or IV every 12 hours) should be substituted for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    in the immunocompetent host with risk factors for methicillin-resistant S. aureus (MRSA) infection. Risk factors for MRSA include a history of intravenous drug use, comorbid disease (eg, diabetes mellitus), or residing in a community or hospital where there is a substantial incidence of MRSA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181072755\">",
"    <span class=\"h3\">",
"     Immunocompromised hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the immunocompromised host, we suggest:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      (15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours)",
"      <strong>",
"       or",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      (600 mg orally or IV every 12 hours)",
"      <strong>",
"       plus",
"      </strong>",
"      one of the following regimens:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"       Cefepime",
"      </a>",
"      (2 g IV every 12 hours)",
"      <strong>",
"       plus",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (500 mg IV every six to eight hours)",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      Imipenem (500 mg IV every six hours)",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"       Meropenem",
"      </a>",
"      (1 g IV every eight hours)",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"       Piperacillin-tazobactam",
"      </a>",
"      (4.5 g IV every six hours)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42625570\">",
"    <span class=\"h2\">",
"     Oral step-down regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Step-down therapy to an oral regimen may be considered once the patient has improved and surgical management is deemed unnecessary (",
"    <a class=\"graphic graphic_table graphicRef60370 \" href=\"UTD.htm?15/46/16109\">",
"     table 1",
"    </a>",
"    ). The choice of an oral antimicrobial regimen for step-down therapy should ideally be guided by culture and susceptibility data. A combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    (450 mg orally three times daily) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (500 or 750 mg orally twice daily) may be used to cover oral aerobes (including Enterobacteriaceae spp), Pseudomonas aeruginosa, many strains of Staphylococcus aureus, and anaerobes; the higher dose of ciprofloxacin should be used when P. aeruginosa is suspected. An alternative regimen that does",
"    <strong>",
"     not",
"    </strong>",
"    have anti-Pseudomonas activity is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    (875 mg orally twice daily) with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    (600 mg orally twice daily); linezolid should be included if MRSA is suspected. Another possible regimen is linezolid plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    (400 mg orally once daily), which provides activity against oral aerobes (including Enterobacteriaceae spp), S. aureus, and anaerobes, but does not have good activity against Pseudomonas aeruginosa. The choice of regimen based upon the patient&rsquo;s immune status is outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef60370 \" href=\"UTD.htm?15/46/16109\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7811740\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of therapy depends upon the host immune status, severity and extent of infection, and response to therapy. For patients with uncomplicated suppurative parotitis, a total duration of 10 to 14 days is reasonable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H973167282\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progression of the infection may lead to massive swelling of the neck, respiratory obstruction, septicemia, and osteomyelitis of the adjacent facial bone. Since the parotid space abuts the parapharyngeal space, suppurative parotitis is an important source of parapharyngeal space infection with potential for septic jugular thrombophlebitis (Lemierre&rsquo;s syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22758/abstract/2\">",
"     2",
"    </a>",
"    ]. Another potential complication is facial nerve palsy, which is relatively rare [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22758/abstract/1\">",
"     1",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_figure graphicRef79036 \" href=\"UTD.htm?0/49/792\">",
"     figure 2",
"    </a>",
"    ). Rarely, a fistula may occur as a complication of acute suppurative parotitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22758/abstract/11\">",
"     11",
"    </a>",
"    ]. CT sialography and fistulography can be performed to evaluate the extent of the fistula and to exclude the possibility of an underlying malignancy. A fistulectomy may be required for definitive management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=see_link\">",
"     \"Overview of osteomyelitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=see_link&amp;anchor=H990947868#H990947868\">",
"     \"Deep neck space infections\", section on 'Parapharyngeal space infections'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical exploration and drainage may be required both for diagnosis and therapy. If an infectious process is not found, a search for noninfectious causes of parotid swelling (eg, malignancy or collagen vascular diseases) should be made. In rare instances, recurrent infection of the parotid gland may occur, particularly in patients with comorbid conditions, such as diabetes mellitus. In such patients, a parotidectomy may be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H973167211\">",
"    <span class=\"h1\">",
"     NON-SUPPURATIVE CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of organisms can cause parotitis. Mumps is the classic virus to cause parotitis, but other viruses that have been associated with parotitis include influenza virus, coxsackievirus, Epstein-Barr virus, lymphocytic choriomeningitis virus, parainfluenza viruses, herpes simplex virus, and cytomegalovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22758/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Viral parotitis may be distinguished from suppurative parotitis by a prodromal period, followed by acute swelling of the involved gland, which can last 5 to 10 days and is often bilateral. Viral parotitis does not cause a purulent discharge from Stensen's duct [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22758/abstract/9\">",
"     9",
"    </a>",
"    ]. Serologic evaluation can establish the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8154?source=see_link\">",
"     \"Epidemiology, clinical manifestations, diagnosis and management of mumps\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mycobacterium tuberculosis and non-tuberculous mycobacteria, such as M. avium intracellulare, have rarely been associated with parotitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22758/abstract/12\">",
"     12",
"    </a>",
"    ]. HIV infection can cause bilateral nonsuppurative parotitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22758/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Noninfectious causes of parotid swelling include collagen vascular diseases, cystic fibrosis, alcoholism, diabetes mellitus, gout, uremia, sarcoidosis, ectodermal dysplasia syndromes, familial dysautonomia, sialolithiasis, benign and malignant tumors, and drug-related disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22758/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/14/5346?source=see_link\">",
"       \"Patient information: Parotitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H973167204\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Suppurative parotitis is caused most commonly by Staphylococcus aureus, but can also be caused by oral aerobes",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anaerobes. It often occurs in the setting of dehydration, particularly among elderly postoperative patients. (See",
"      <a class=\"local\" href=\"#H973167060\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Suppurative parotitis is characterized by the sudden onset of firm, erythematous swelling of the pre- and postauricular areas that extends to the angle of the mandible. This is associated with exquisite local pain and tenderness with complaints of trismus and dysphagia. Systemic findings of high fevers, chills, and marked toxicity are generally present. (See",
"      <a class=\"local\" href=\"#H973167111\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      On examination, a fluctuant quality is generally not appreciated because of the dense parotid fascia that overlies the gland. Purulent material may be expressed from the orifice of Stensen's duct. (See",
"      <a class=\"local\" href=\"#H973167111\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The microbiologic etiology of parotid space infections is most commonly polymicrobial. The most common pathogens associated with acute bacterial parotitis are S. aureus, viridans streptococci, and oral anaerobic bacteria. (See",
"      <a class=\"local\" href=\"#H973167143\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is usually made when the characteristic clinical findings are present. When purulent drainage is present at the opening of the duct of Stensen, it should be collected for Gram stain and culture. However, the results should be interpreted with the knowledge that oral flora may be contaminating the culture. (See",
"      <a class=\"local\" href=\"#H973167159\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of suppurative parotitis includes hydration and intravenous antibiotics directed against staphylococci and oral flora.",
"      <strong>",
"      </strong>",
"      The appropriate regimen depends on the immune status of the patient and risk factors for methicillin-resistant S. aureus (MRSA) (",
"      <a class=\"graphic graphic_table graphicRef60370 \" href=\"UTD.htm?15/46/16109\">",
"       table 1",
"      </a>",
"      ). Risk factors for MRSA include a history of intravenous drug use, comorbid disease (eg, diabetes mellitus), or residing in a community or hospital where there is a substantial incidence of MRSA. (See",
"      <a class=\"local\" href=\"#H973167167\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For",
"      <strong>",
"       immunocompetent",
"      </strong>",
"      <strong>",
"       patients",
"      </strong>",
"      without risk factors for MRSA, one of the following regimens provides appropriate coverage:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"       Nafcillin",
"      </a>",
"      (1.5 g IV every four hours) or another antistaphylococcal penicillin or a first-generation cephalosporin",
"      <strong>",
"       plus either",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       Metronidazole",
"      </a>",
"      (500 mg IV every six to eight hours)",
"      <strong>",
"       or",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (600 mg IV every six to eight hours) (see",
"      <a class=\"local\" href=\"#H181072748\">",
"       'Immunocompetent hosts'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For",
"      <strong>",
"       immunocompetent",
"      </strong>",
"      <strong>",
"       patients with risk factors for MRSA",
"      </strong>",
"      , we suggest that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (15 to",
"      <strong>",
"      </strong>",
"      20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours)",
"      <strong>",
"       or",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      (600 mg orally or IV every 12 hours) be substituted for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"       nafcillin",
"      </a>",
"      in the above regimen (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For",
"      <strong>",
"       immunocompromised",
"      </strong>",
"      <strong>",
"       patients",
"      </strong>",
"      , we suggest using a regimen that includes MRSA coverage (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Appropriate regimens for",
"      <strong>",
"       immunocompromised patients",
"      </strong>",
"      include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      (15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      (600 mg orally or IV every 12 hours)",
"      <strong>",
"       plus",
"      </strong>",
"      one of the following regimens:",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"       Cefepime",
"      </a>",
"      (2 g IV every 12 hours)",
"      <strong>",
"       plus",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (500 mg IV every six to eight hours)",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      Imipenem (500 mg IV every six hours)",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"       Meropenem",
"      </a>",
"      (1 g IV every eight hours)",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"       Piperacillin-tazobactam",
"      </a>",
"      (4.5 g IV every six hours) (see",
"      <a class=\"local\" href=\"#H181072755\">",
"       'Immunocompromised hosts'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Step-down to an oral regimen may be considered once the patient has improved and surgical management is deemed unnecessary (",
"      <a class=\"graphic graphic_table graphicRef60370 \" href=\"UTD.htm?15/46/16109\">",
"       table 1",
"      </a>",
"      ). The choice of oral antimicrobial regimen for step-down therapy should ideally be guided by culture and susceptibility data. (See",
"      <a class=\"local\" href=\"#H42625570\">",
"       'Oral step-down regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The duration of therapy depends upon the host immune status, severity and extent of infection, and response to therapy. For patients with uncomplicated suppurative parotitis, a total duration of 10 to 14 days is reasonable. (See",
"      <a class=\"local\" href=\"#H7811740\">",
"       'Duration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22758/abstract/1\">",
"      Tan VE, Goh BS. Parotid abscess: a five-year review--clinical presentation, diagnosis and management. J Laryngol Otol 2007; 121:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22758/abstract/2\">",
"      Cohen MA, Docktor JW. Acute suppurative parotitis with spread to the deep neck spaces. Am J Emerg Med 1999; 17:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22758/abstract/3\">",
"      Brook I. The swollen neck. Cervical lymphadenitis, parotitis, thyroiditis, and infected cysts. Infect Dis Clin North Am 1988; 2:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22758/abstract/4\">",
"      Brook I. Acute bacterial suppurative parotitis: microbiology and management. J Craniofac Surg 2003; 14:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22758/abstract/5\">",
"      Triglia JM, Nicollas R, Ducroz V, et al. First branchial cleft anomalies: a study of 39 cases and a review of the literature. Arch Otolaryngol Head Neck Surg 1998; 124:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22758/abstract/6\">",
"      Raad II, Sabbagh MF, Caranasos GJ. Acute bacterial sialadenitis: a study of 29 cases and review. Rev Infect Dis 1990; 12:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22758/abstract/7\">",
"      Sherman JA. Pseudomonas parotid abscess. J Oral Maxillofac Surg 2001; 59:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22758/abstract/8\">",
"      Huang TT, Tseng FY, Yeh TH, et al. Factors affecting the bacteriology of deep neck infection: a retrospective study of 128 patients. Acta Otolaryngol 2006; 126:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22758/abstract/9\">",
"      Al-Dajani N, Wootton SH. Cervical lymphadenitis, suppurative parotitis, thyroiditis, and infected cysts. Infect Dis Clin North Am 2007; 21:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22758/abstract/10\">",
"      Varghese JC, Thornton F, Lucey BC, et al. A prospective comparative study of MR sialography and conventional sialography of salivary duct disease. AJR Am J Roentgenol 1999; 173:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22758/abstract/11\">",
"      Naragund AI, Halli VB, Mudhol RS, Sonoli SS. Parotid fistula secondary to suppurative parotitis in a 13-year-old girl: a case report. J Med Case Rep 2010; 4:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22758/abstract/12\">",
"      O'Connell JE, George MK, Speculand B, Pahor AL. Mycobacterial infection of the parotid gland: an unusual cause of parotid swelling. J Laryngol Otol 1993; 107:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22758/abstract/13\">",
"      Mandel L, Surattanont F. Bilateral parotid swelling: a review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 93:221.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13962 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-CA557B663F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_14_22758=[""].join("\n");
var outline_f22_14_22758=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H973167204\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H973167060\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H973167097\">",
"      ANATOMY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H973167104\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H973167111\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H973167143\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H973167152\">",
"      IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H973167159\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H973167167\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42625563\">",
"      Initial antibiotic regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H181072748\">",
"      - Immunocompetent hosts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H181072755\">",
"      - Immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42625570\">",
"      Oral step-down regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7811740\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H973167282\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H973167211\">",
"      NON-SUPPURATIVE CAUSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H973167204\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/13962\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/13962|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/19/6449\" title=\"figure 1\">",
"      Salivary gland anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/49/792\" title=\"figure 2\">",
"      Parapharyngeal space anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/13962|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/46/16109\" title=\"table 1\">",
"      Suppurative parotitis rx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38426?source=related_link\">",
"      Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=related_link\">",
"      Deep neck space infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8154?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis and management of mumps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=related_link\">",
"      Overview of osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/14/5346?source=related_link\">",
"      Patient information: Parotitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22568?source=related_link\">",
"      Salivary gland stones",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_14_22759="Estradiol and dienogest: Drug information";
var content_f22_14_22759=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Estradiol and dienogest: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/8/4230?source=see_link\">",
"    see \"Estradiol and dienogest: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F11451667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10192348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Natazia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10192927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Contraceptive;",
"     </li>",
"     <li>",
"      Estrogen and Progestin Combination",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F10237848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Contraception or treatment of heavy menstrual bleeding:",
"     </b>",
"     Females: Oral: Take 1 tablet daily in the order presented in the blister pack",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Initial dosing:",
"     </i>",
"     Start on day 1 of menstrual period (first day of bleeding). A nonhormonal contraceptive should be used for the first 9 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Switching from another combination oral contraceptive tablet:",
"     </i>",
"     Take the first dark yellow tablet on the first day of withdrawal bleeding; do not continue taking tablets from previous contraceptive pack. If withdrawal bleeding does not occur, rule-out pregnancy before starting therapy. A nonhormonal contraceptive should be used for the first 9 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Switching from a vaginal ring or patch:",
"     </i>",
"     Take the first dark yellow tablet on the day the ring or patch is removed. A nonhormonal contraceptive should be used for the first 9 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Switching from a progestin-only contraceptive:",
"     </i>",
"     Take the first dark yellow tablet on the day of the next progestin-only tablet would have been given, or the day the progestin implant or IUD is removed, or on the day the next injection would have been given. A nonhormonal contraceptive should be used for the first 9 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Missed doses:",
"     </b>",
"     If &le;12 hours late, take tablet as soon as remembering and take the next tablet at the usual time. If &gt;12 hours late, instructions vary by day of cycle and number of tablets missed:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      If missed ONE dose:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Days 1-17: Take missed tablet immediately; take next tablet at usual time; use back-up (nonhormonal) contraception for the next 9 days; continue taking 1 tablet each day for the rest of the cycle",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Days 18-24: Do not continue using current blister pack (throw away); take day 1 of new blister pack; use back-up (nonhormonal) contraception for the next 9 days; continue taking 1 tablet each day for the rest of the cycle",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Days 25-28: Take missed tablet immediately; take next tablet at usual time; continue taking 1 tablet each day for the rest of the cycle; no backup method of contraception is needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      If missed TWO doses in a row:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Days 1-17: Do not take missed tablets; start by taking the tablet for the day it was first noticed that the tablet was missed; use back-up (nonhormonal) contraception for the next 9 days; continue taking 1 tablet each day for the rest of the cycle. If tablets were missed on days 17 and 18, follow directions for missed tablets on days 17-25.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Days 17-25: Do not continue using current blister pack (throw away); take day 3 of new blister pack; use back-up (nonhormonal) contraception for the next 9 days; continue taking 1 tablet each day for the rest of the cycle.  If tablets were missed on days 25 and 26, follow directions for missed tablets on days 25-28.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Days 25-28: Do not continue using current blister pack (throw away); start a new pack on the same day, or start a new pack the day it would normally be started; continue taking 1 tablet each day for the rest of the cycle; no backup method of contraception is needed.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F10237855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Contraception:",
"     </b>",
"     Oral: Refer to adult dosing. Not to be used prior to menarche.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F10237852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Safety and efficacy have not been evaluated; dose adjustment not expected to be required.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F10237851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated with hepatic disease. Discontinue if hepatic dysfunction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F10240744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [four-phasic formulation]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Natazia&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Days 1-2: Estradiol valerate 3 mg [2 dark yellow tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Days 3-7: Estradiol valerate 2 mg and dienogest 2 mg [5 medium red tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Days 8-24: Estradiol valerate 2 mg and dienogest 3 mg [17 light yellow tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Days 25-26: Estradiol valerate 1 mg [2 dark red tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Days 27-28: 2 white inactive tablets (28s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F10237458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10237898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablets should be taken at the same time each day in the order presented in the blister pack. Do not delay administration by &gt;12 hours. In case of vomiting or diarrhea within 3-4 hours of taking a colored tablet, treat as if the dose was missed (or can take another tablet of the same color from an extra blister pack). Patients should be instructed not to take more than 2 tablets in any one day. A nonhormonal contraceptive (eg, condom or spermicide) should be used for the first 9 days of therapy. If patient is unsure of number of tablets missed, they should continue taking one tablet each day and use a back-up form of contraception.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10192929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of pregnancy; treatment of heavy menstrual bleeding",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F10237459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pain associated with endometriosis; dysmenorrhea",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F10237744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Central nervous system: Headache (13%, including migraine)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Mood changes (3%, including depression)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Acne (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Metrorrhagia and irregular menstruation (7% to 8%), breast pain/discomfort/tenderness (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea or vomiting (7%), weight gain (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     The following reactions have been associated with oral contraceptive use; frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cardiovascular: Arterial thromboembolism, cerebral hemorrhage, cerebral thrombosis, DVT, edema, hypertension, mesenteric thrombosis, MI, varicose vein aggravation, venous thrombosis (with or without embolism)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Dermatologic: Chloasma, melasma, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Endocrine &amp; metabolic: Amenorrhea, breakthrough bleeding, breast changes (enlargement, pain, secretion, tenderness), fluid retention, infertility (temporary), lactation decreased (with use immediately postpartum), menstrual flow changes, ruptured ovarian cyst, spotting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Gastrointestinal: Abdominal bloating, abdominal cramps, abdominal pain, appetite changes, gallbladder disease, nausea, weight changes, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Genitourinary: Cervical ectropion, cervical secretion, uterine leiomyoma, vaginal candidiasis, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Hematologic: Folate decreased, porphyria exacerbation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Hepatic: Cholestatic jaundice, focal nodular hyperplasia of the liver, hepatic adenomas, liver tumors (benign)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Neuromuscular &amp; skeletal: Chorea exacerbation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Ocular: Contact lens intolerance, corneal curvature changes (steepening), retinal thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Respiratory: Pulmonary embolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Miscellaneous: Anaphylactic/anaphylactoid reactions (including angioedema, circulatory collapse, respiratory collapse, urticaria), SLE exacerbation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports (Limited to important or life-threatening): Erythema (multiforme, nodosum), hepatitis, hypersensitivity, hypertriglyceridemia, stroke",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10237464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Breast cancer or other estrogen- or progestin-dependent neoplasms (current or a history of), hepatic tumors or disease, pregnancy, undiagnosed abnormal uterine bleeding",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use is also contraindicated in women at high risk of arterial or venous thrombotic diseases including: Cerebrovascular disease, coronary artery disease, diabetes mellitus with vascular disease, DVT or PE (current or history of), hypercoagulopathies (inherited or acquired), headaches with focal neurological symptoms, hypertension (uncontrolled), migraine headaches if &gt;35 years of age, thrombogenic valvular or rhythm diseases of the heart (eg, subacute bacterial endocarditis with valvular disease or atrial fibrillation), women &gt;35 years of age who smoke.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10237465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Breast cancer: The use of combination hormonal contraceptives has been associated with a slight increase in frequency of breast cancer; however, studies are not consistent. Use is contraindicated in women with (or history of) breast cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in women with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Chloasma: Risk of occurrence may be increased with history of chloasma gravidarum. Women with history of chloasma should avoid exposure to sun or ultraviolet radiation during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cholestasis: Risk of cholestasis may be increased with previous cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Lipid effects: Combination hormonal contraceptives may affect serum triglyceride and lipoprotein levels. Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Triglycerides may also be increased; use with caution in patients with familial defects of lipoprotein metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Retinal vascular thrombosis: Estrogens may cause retinal vascular thrombosis; discontinue if migraine, loss of vision, proptosis, diplopia or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thromboembolism: May increase the risk of thromboembolism; discontinue use of combination hormonal contraceptives if an arterial or venous thrombotic event occurs. Women with inherited thrombophilias (eg, protein C or S deficiency) may have increased risk of venous thromboembolism (DeSancho, 2010; van Vlijmen, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Vaginal bleeding: Presentation of irregular, unresolving vaginal bleeding warrants further evaluation including endometrial sampling, if indicated, to rule out malignancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with risk factors for coronary artery disease (eg, hypertension, hypercholesterolemia, morbid obesity, diabetes, or women who smoke); may lead to increased risk of myocardial infarction. May have a dose-related risk of vascular disease and hypertension; women with hypertension should be encouraged to use a nonhormonal form of contraception.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Depression: Use with caution in patients with depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Diseases exacerbated by fluid retention: Combination hormonal contraceptives should be used with caution in patients with diseases which may be exacerbated by fluid retention, including asthma, epilepsy, migraine, diabetes, or renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Gallbladder disease: May have a dose-related risk of gallbladder disease; may worsen existing gallbladder disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic adenomas: Extremely rare adenomas and focal nodular hyperplasia resulting in fatal intra-abdominal hemorrhage have been reported in association with long-term oral contraceptive use. Presentation of an abdominal mass, acute abdominal pain, or intra-abdominal bleeding warrants further evaluation to rule out source.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Combination hormonal contraceptives may be poorly metabolized in women with hepatic impairment. Discontinue if jaundice develops during therapy. This product has not been studied in women with hepatic impairment; discontinue if liver function becomes abnormal. Use is contraindicated with hepatic disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hereditary angioedema: May induce or exacerbate symptoms of hereditary angioedema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Migraine: Use with caution in patients with a history of migraine. Evaluate new, recurrent, severe or persistent headaches. Use with migraine headaches with or without aura if &gt;35 years of age is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: This product has not been studied in women with renal impairment; however a dose adjustment is not likely to be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; High potential for interactions: Use with caution in patients taking CYP3A4 inducers or inhibitors. Alternate forms of contraception may be preferred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thyroid replacement therapy: Estrogens may increase thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels. Women on thyroid replacement therapy may require higher doses of thyroid hormone while receiving estrogens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Obese: This product has not been studied in women with a BMI &gt;30 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: Not for use prior to menarche.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Smokers:",
"     <b>",
"      [U.S. Boxed Warning]: The risk of cardiovascular side effects is increased in women who smoke cigarettes; risk increases with age (especially women &gt;35 years of age) and the number of cigarettes smoked; women who use combination hormonal contraceptives should be strongly advised not to smoke. Use is contraindicated in patients &gt;35 years of age who smoke.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Surgical patients: Whenever possible, should be discontinued at least 4 weeks prior to and for 2 weeks following elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Heavy menstrual bleeding: For use only in females who have heavy bleeding without organic pathology and who also desire combination hormonal contraceptive therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; HIV infection protection: Combination hormonal contraceptives do not protect against HIV infection or other sexually-transmitted diseases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). The dose, route, and the specific estrogen/progestin influences these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F10327853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Estrogenic Properties): May enhance the adverse/toxic effect of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): May enhance the thrombogenic effect of Estrogen Derivatives. NSAID (COX-2 Inhibitor) may increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. Estrogen Derivatives may diminish the therapeutic effect of Ospemifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: Estrogen Derivatives may diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women.  Management: Monitor for reduced growth hormone efficacy. A larger somatropin dose may be required to reach treatment goal.  This interaction does not appear to apply to non-orally administered estrogens (e.g., transdermal, vaginal ring).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Estrogen Derivatives may enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives.  Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10237788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Food increases C",
"     <sub>",
"      max",
"     </sub>",
"     of estradiol by 23% and decreases C",
"     <sub>",
"      max",
"     </sub>",
"     of dienogest by 28%; AUC remains unchanged for both.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10237461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pregnancy should be ruled out prior to treatment and discontinued if pregnancy occurs. In general, the use of combination hormonal contraceptives when inadvertently taken early in pregnancy has not been associated with teratogenic effects.  Hormonal contraceptives may be less effective in obese patients. An increase in oral contraceptive failure was noted in women with a BMI &gt;27.3 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     . Similar findings were noted in patients weighing &ge;90 kg (198 lb) using the contraceptive patch. This product was not studied in women with a BMI &gt;30 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to increased risk of venous thromboembolism (VTE) postpartum, combination hormonal contraceptives should not be started in any woman &lt;21 days following delivery. Women without risk factors for VTE and who are not breast-feeding may start combination hormonal contraceptives during 21-42 days postpartum. After 42 days postpartum, restrictions for use are not related to postpartum status and should be based on other medical conditions (CDC, 2011). The manufacturer states that combination hormonal contraceptives should not be started until &ge;4 weeks after delivery in women who choose not to breastfeed, or &ge;4 weeks after a second trimester abortion or miscarriage",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F10237462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10237463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May decrease the quality and quantity of breast milk; an alternative form of contraception is recommended until child is weaned (per manufacturer). The theoretical concerns about decreased milk production are greatest early in the postpartum period when milk production is being established. Postpartum risk for VTE should be considered when initiating combination hormonal contraceptives after delivery. Combined hormonal contraceptives should not be started &lt;21 days postpartum due to increased risk of VTE. Risk of VTE is still elevated in breast-feeding women until ~42 days postpartum and is greater in women with additional risk factors. After 42 days postpartum, restrictions for use are not related to postpartum VTE risk and should be based on other medical conditions (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Natazia Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3/2-2/2-3/1 mg (28): $102.54",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10237900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Before starting therapy, a physical exam with reference to the breasts and pelvis are recommended, including a Papanicolaou smear. Exam may be deferred if appropriate; pregnancy should be ruled out prior to use. Monitor patient closely for loss of vision, sudden onset of proptosis, diplopia, migraine; blood pressure; signs and symptoms of thromboembolic disorders; signs or symptoms of depression; glycemic control in patients with diabetes; lipid profiles in patients being treated for hyperlipidemias. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12707707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bellaface (GT);",
"     </li>",
"     <li>",
"      Climodien (AT, BE, NO, PT);",
"     </li>",
"     <li>",
"      Climodiene (FR);",
"     </li>",
"     <li>",
"      Dienille (BG);",
"     </li>",
"     <li>",
"      Jeanine (BG, CZ, PL, RU);",
"     </li>",
"     <li>",
"      Qlair (IL);",
"     </li>",
"     <li>",
"      Qlaira (AR, AU, BE, BR, CH, CN, CO, CZ, DE, DK, EC, EE, FI, FR, GB, HK, IE, MY, NZ, PE, SE, SG);",
"     </li>",
"     <li>",
"      Valette (AT, AU, DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10237896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Combination hormonal contraceptives inhibit ovulation and may also cause changes in the cervical mucus, rendering it unfavorable for sperm penetration even if ovulation occurs. The four-phasic formulation provides the estrogen in decreasing concentrations and the progestin in increasing concentrations over the 28-day cycle.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10237791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Estradiol: V",
"     <sub>",
"      d",
"     </sub>",
"     : 1.2 L/kg; Dienogest: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 46 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: Estradiol: Albumin (60%) and sex hormone binding globulin (38%); Dienogest: Albumin (90%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via CYP3A4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Estradiol: Partially metabolized in the gastrointestinal mucosa, also undergoes significant first-pass metabolism; forms active metabolites (estrone, estrone sulfate, estrone glucuronide)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dienogest: Forms inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Dienogest ~91%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Estradiol: ~14 hours; Dienogest: ~11 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: Estradiol: ~6 hours; Dienogest: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine; feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, &ldquo;ACOG Practice Bulletin No. 110: Noncontraceptive Uses of Hormonal Contraceptives,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2010, 115(1):206-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/14/22759/abstract-text/20027071/pubmed\" id=\"20027071\" target=\"_blank\">",
"        20027071",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: Revised Recommendations for the Use of Contraceptive Methods During the Postpartum Period,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2011, 60(26):878-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/14/22759/abstract-text/21734635/pubmed\" id=\"21734635\" target=\"_blank\">",
"        21734635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeSancho MT, Dorff T, and Rand JH, \"Thrombophilia and the Risk of Thromboembolic Events In Women on Oral Contraceptives and Hormone Replacement Therapy,\"",
"      <i>",
"       Blood Coagul Fibrinolysis",
"      </i>",
"      , 2010, 21(6):534-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/14/22759/abstract-text/20581664/pubmed\" id=\"20581664\" target=\"_blank\">",
"        20581664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holt VL, Scholes D, Wicklund KG, et al, &ldquo;Body Mass Index, Weight, and Oral Contraceptive Failure Risk,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2005, 105(1):46-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/14/22759/abstract-text/15625141/pubmed\" id=\"15625141\" target=\"_blank\">",
"        15625141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Palacios S, Wildt L, Parke S, et al, &ldquo;Efficacy and Safety of a Novel Oral Contraceptive Based on Oestradiol (Oestradiol Valerate/Dienogest): A Phase III Trial,&rdquo;",
"      <i>",
"       Eur J Obstet Gynecol Reprod Biol",
"      </i>",
"      , 2010, 149(1):57-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/14/22759/abstract-text/19969409/pubmed\" id=\"19969409\" target=\"_blank\">",
"        19969409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sitruk-Ware R and Nath A, \"Metabolic Effects of Contraceptive Steroids,\"",
"      <i>",
"       Rev Endocr Metab Disord",
"      </i>",
"      , 2011, 12(2):63-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/14/22759/abstract-text/21538049/pubmed\" id=\"21538049\" target=\"_blank\">",
"        21538049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Vlijmen EF, Veeger NJ, Middeldorp S, et al, \"Thrombotic Risk During Oral Contraceptive Use and Pregnancy in Women With Factor V Leiden or Prothrombin Mutation: A Rational Approach to Contraception,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(8):2055-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/14/22759/abstract-text/21659542/pubmed\" id=\"21659542\" target=\"_blank\">",
"        21659542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15573 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-D8E5382BBA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_14_22759=[""].join("\n");
var outline_f22_14_22759=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11451667\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10192348\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10192927\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10237848\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10237855\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10237852\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10237851\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10240744\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10237458\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10237898\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10192929\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10237459\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10237744\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10237464\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10237465\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299285\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10327853\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10237788\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10237461\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10237462\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10237463\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322853\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10237900\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12707707\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10237896\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10237791\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15573\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15573|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/8/4230?source=related_link\">",
"      Estradiol and dienogest: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_14_22760="Pathologic gambling";
var content_f22_14_22760=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathologic gambling",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/14/22760/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/14/22760/contributors\">",
"     Brian K Unwin, MD, LTC, MC, USA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/14/22760/contributors\">",
"     Frank J Domino, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/14/22760/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/14/22760/contributors\">",
"     Susan McElroy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/14/22760/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/14/22760/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/14/22760/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathologic gambling and problem gambling affect up to 15 million Americans and are common in young people. The number of people with gambling problems is increasing. The societal impact of pathological gambling and problem gambling is therefore also increasing, with related issues involving employment, personal relationships, financial solvency, and criminal pursuits.",
"   </p>",
"   <p>",
"    No systematic process of educating, screening, and treating pathologic gamblers is currently in place. Provider and community education about the depth of this problem is crucial in identifying patients who are problem or pathologic gamblers and in helping treatment programs work. Primary prevention of this condition using educational programs that target at-risk youth and adults might help establish a decrease in problem gambling and a culture of controlled, responsible gambling behaviors among adults and their children.",
"   </p>",
"   <p>",
"    This topic will discuss the epidemiology, diagnosis, and treatment of pathologic gambling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gambling is defined as placing something of value at risk with the hope of gaining something of greater value. Less than 10 percent of adult gamblers develop a gambling problem [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Of those that do, pathologic gambling has been defined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) as persistent and recurrent maladaptive gambling behavior, as indicated by five or more of the following (",
"    <a class=\"graphic graphic_table graphicRef59506 \" href=\"UTD.htm?0/53/860\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preoccupation with gambling (eg, preoccupied with reliving past gambling experiences, handicapping or planning the next venture, or thinking of ways to get money with which to gamble)",
"     </li>",
"     <li>",
"      Needs to gamble with increasing amounts of money in order to achieve the desired excitement",
"     </li>",
"     <li>",
"      Has repeated unsuccessful efforts to control, cut back, or stop gambling",
"     </li>",
"     <li>",
"      Is restless or irritable when attempting to cut down or stop gambling",
"     </li>",
"     <li>",
"      Gambles as a way of escaping from problems or of relieving a dysphoric mood (eg, feelings of helplessness, guilt, anxiety, depression)",
"     </li>",
"     <li>",
"      After losing money gambling, often returns another day to get even (\"chasing\" after one's losses)",
"     </li>",
"     <li>",
"      Lies to family members, therapist, or others to conceal the extent of involvement with gambling",
"     </li>",
"     <li>",
"      Has committed illegal acts such as forgery, fraud, theft, or embezzlement to finance gambling",
"     </li>",
"     <li>",
"      Has jeopardized or lost a significant relationship, job, or educational or career opportunity because of gambling",
"     </li>",
"     <li>",
"      Relies on others to provide money to relieve a desperate financial situation caused by gambling",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the gambling behavior is not better accounted for by a manic episode.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Classification systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other terms have been used by gambling researchers and treatment professionals to describe patients who do not meet the psychiatric criteria for a gambling disorder, but who nevertheless appear to have substantial problems related to gambling. One large epidemiologic study, the Gambling Impact and Behavior Study, used the following definitions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A low-risk gambler was defined as someone who has gambled but never lost more than $100 in a single day or year, or lost more than $100 in a single day or year but reported no DSM-IV criteria.",
"     </li>",
"     <li>",
"      An at-risk gambler was defined as someone who has lost more than $100 in a single day or year and reported one or two DSM-IV criteria.",
"     </li>",
"     <li>",
"      A problem gambler was defined as someone who has lost more than $100 in a single day or year and reported three or four DSM-IV criteria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another approach, six classes of gamblers were identified, based on symptom profiles from a convenience sample study of lifetime gamblers and a computerized gambling assessment module. Gambling behaviors ranged from Class 1 non-problem gambling, affecting 57 percent of sample, to Class 6 with high problem-gambling symptoms, including withdrawal symptoms and help-seeking behaviors, affecting 6 percent of the sample [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continued growth in the gambling industry might be causing an increase in the prevalence of gambling problems. In 1991, 80 percent of the United States' population gambled compared with only 61 percent in the 1960s [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/5\">",
"     5",
"    </a>",
"    ]. In 1978 only two states had legalized gambling; in 1998, only two states had not legalized gambling [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of 119 prevalence studies conducted in the United States and Canada found that the lifetime prevalence of pathologic and problem gambling in adults is 1.6 and 3.85 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/1\">",
"     1",
"    </a>",
"    ]. Higher rates were reported in children and adolescents (3.88 and 9.45 percent, respectively).",
"   </p>",
"   <p>",
"    The Gambling Impact and Behavior Study was a large epidemiologic study conducted in 1999 that assembled and analyzed five data sets including national surveys (2,417 adults at home via telephone), 530 adults in gaming facilities, 534 adolescents (16 and 17 years of age at home via telephone), a 100 community statistical database, and 10 community case studies on the effects of casino openings [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/2\">",
"     2",
"    </a>",
"    ]. The following findings were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It was estimated that 2.5 million adults are pathologic gamblers and 3 million adults are problem gamblers.",
"     </li>",
"     <li>",
"      Men are more likely to be pathologic, problem, and at-risk gamblers than women.",
"     </li>",
"     <li>",
"      The availability of a casino within 50 miles (compared with 50 to 250 miles) is associated with approximately double the prevalence of problem and pathological gamblers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, patterns of adult gambling have changed substantially since the last national survey published in 1976 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lotteries and casinos are now the most common forms of gambling.",
"     </li>",
"     <li>",
"      Gambling patterns among women have grown more like the gambling patterns of men.",
"     </li>",
"     <li>",
"      Only 14 percent of people have never gambled compared with 33 percent in 1975.",
"     </li>",
"     <li>",
"      50 percent of people have played the lottery, and 25 percent have gambled in casinos (double the rates from 1975).",
"     </li>",
"     <li>",
"      The greatest increase in gamblers is in adults aged 65 and older. Nevertheless, the proportion of seniors who gamble is smaller than the proportion of younger gamblers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Furthermore, people ages 65 and older are much less likely to be at-risk, problem, or pathologic gamblers than younger individuals. A cohort study of geriatric patients seeking treatment for pathologic gambling found that, compared with younger pathologic gamblers, geriatric gamblers are more likely to gamble secondary to boredom [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Societal impact",
"    </span>",
"    &nbsp;&mdash;&nbsp;The economics of gambling are staggering. The amount of money wagered annually in the United States is estimated to be $0.5 trillion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/8\">",
"     8",
"    </a>",
"    ]. Americans spend approximately $31.5 billion annually on state lottery games alone, with many states becoming increasingly reliant on revenues from legalized gambling [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pathologic and problem gamblers are more likely than other gamblers or nongamblers to have been on welfare, declared bankruptcy, and to have been arrested or incarcerated [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/2\">",
"     2",
"    </a>",
"    ]. It is estimated that pathologic and problem gamblers in the United States cost society approximately $5 billion per year and an additional $40 billion in lifetime costs for productivity reductions, social services, and creditor losses [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    State supported assistance programs and insurance coverage for treatment and prevention of problem gambling seems limited in comparison to the problem. The state of Georgia spent only $31,000 in 1998 on programs to assist problem gamblers despite a quadrupling of Gamblers Anonymous chapters since the start of the state lottery in 1993 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/9\">",
"     9",
"    </a>",
"    ]. Conflicts of interest arise for state or federally-supported gambling programs, when revenue benefits are weighed against public health issues [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is also important to recognize that gambling (though not at a pathological level) may have positive attributes, such as a socialization activity among elders [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     High-risk groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;No consistent data are available about the role that demographic factors play in problem or pathologic gambling. Nevertheless, a number of demographic groups have been identified as having a higher rate of gambling problems than the general population.",
"   </p>",
"   <p>",
"    Such factors include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age. Gambling is common among children and adolescents [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. In one survey of 21,297 8th through 12th grade students in public and private schools in Vermont, 53 percent reported gambling in the past 12 months, and 7 percent reported problems attributable to gambling [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/13\">",
"       13",
"      </a>",
"      ]. Senior citizens may also have an increased risk. In one survey of attendees at a senior center in the US, approximately 10 percent were problem or pathological gamblers, with greater prevalence among males [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gender. The prevalence of pathologic and problem gambling in men is two to three times higher than in women [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/2,15\">",
"       2,15",
"      </a>",
"      ]. However, the progression of the disorder appears to be faster in women [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/16\">",
"       16",
"      </a>",
"      ]. Women who entered an outpatient treatment program for gambling were found more often to be single than their male counterparts, and started gambling significantly later than men.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other risk factors include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Adults in mental health treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/1\">",
"       1",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Nicotine or substance abuse: alcohol, marijuana, inhalants, illegal steroids [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/1\">",
"       1",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      African American [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/2,15\">",
"       2,15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Positive family history [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Childhood abuse and child neglect [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Lower socioeconomic status [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/2,15\">",
"       2,15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Witnessing trauma or being a victim of physical attack [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Carrying a weapon or being involved in a fight [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/1\">",
"       1",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Seatbelt nonuse [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/1\">",
"       1",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is considerable debate about whether pathologic gambling is an impulse control disorder or a nonsubstance abuse-related addictive disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. In addition, alterations in brain function have been observed in patients with pathologic gambling, but it is not clear whether these changes are etiologic and lead to disordered gambling, or whether they are the consequence of pathologic gambling.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Support for the hypothesis that the pathogenesis of pathologic gambling is related to impulse control disorders comes from studies that found changes in serotonin metabolites in both pathologic gamblers and patients with impulse control disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/22,24\">",
"       22,24",
"      </a>",
"      ]. Men who are pathologic gamblers also experience abnormal responses to challenges with serotonergic ligands.",
"     </li>",
"     <li>",
"      A relationship between pathologic gambling and substance abuse is suggested by similarities between the two disorders, including symptoms of tolerance, withdrawal, anticipatory craving, and a chronic relapsing course [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. Common genetic vulnerability for pathologic gambling and alcohol abuse also has been reported among twins [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/17\">",
"       17",
"      </a>",
"      ]. Finally, studies of decision making have found that compared with healthy controls, people with substance use disorders more frequently choose large immediate rewards when presented with gambling tasks despite larger intermittent punishments [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/22,25\">",
"       22,25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It may be that elements of both impulse and substance abuse disorders play a role in the pathogenesis of pathologic gambling.",
"   </p>",
"   <p>",
"    Emerging concepts about pathologic gambling view it as one of the \"natural addictions\" (eg, sexual addiction and some overeating disorders) which may involve the release of endogenous opioid peptides, such as enkephalin, in the ventral tegmental area of the brainstem [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/26\">",
"     26",
"    </a>",
"    ]. In addition, problem gamblers seem to exhibit more \"activation\" of the hypothalamic-pituitary-adrenal axis than non-problem gamblers, as well as changes in the brain-reward pathways and prefrontal cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dysregulation of dopaminergic tone may also play a role in the development of pathologic gambling. There have been case reports of patients with Parkinson disease developing pathologic gambling after being started on dopaminergic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. Pathologic gambling has also been reported in patients with restless leg syndrome taking dopaminergic agonists [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/33\">",
"     33",
"    </a>",
"    ]. Pramipexole is the dopamine agonist implicated most frequently, and accounted for 39 of the 67 reports to the United States Food and Drug Administration of possible drug-related pathological gambling [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18169335\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genes are important in the etiology of pathologic gambling. A twin study evaluated the concordance for lifetime pathologic gambling in a sample of 6744 males who served in the military, which included 1874 monozygotic twin pairs and 1498 dizygotic twin pairs. The lifetime history of pathologic gambling in the full sample was 1 percent. A lifetime history of pathologic gambling was found in 23 percent of the monozygotic and 10 percent of the dizygotic co-twins of men with pathologic gambling [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genes are as important in causing pathologic gambling in women as they are in men. A twin study that included 867 monozygotic twin pairs and 1008 dizygotic twin pairs found that genetic influences accounted for 49 percent of the variation in liability for pathologic gambling, and that there was no evidence of sex differences [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/35\">",
"     35",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of pathologic or problem gambling is made based upon fulfillment of the DSM-IV criteria outlined above (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Definitions'",
"    </a>",
"    above). The criteria have been validated for both Caucasian and African Americans [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pathologic gambling is often overlooked and undiagnosed. Gamblers may hide or deny gambling-related problems [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/15\">",
"     15",
"    </a>",
"    ]. Nevertheless, neither the efficacy of screening for problem gambling in the primary care setting, nor the optimal screening tool has been established.",
"   </p>",
"   <p>",
"    The South Oaks Gambling Screen (SOGS) is the only extensively used, validated screening tool for the identification of pathologic gamblers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/37\">",
"     37",
"    </a>",
"    ]. It is a 20 item scale that includes weighted items to determine if the patient is hiding evidence of gambling, spending more time or money gambling than intended, arguing with family members over gambling, and borrowing money from a variety of sources to gamble or to pay gambling debts. A national study in New Zealand concluded that SOGS was good at detecting pathologic gambling among those who would currently meet the diagnostic criteria, but was associated with a high false-positive rate [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. In addition, as the types of gambling changed in the 1980s and 1990s, a number of items on the SOGS appeared to be outdated, prompting a search for other screening tools.",
"   </p>",
"   <p>",
"    Although not validated, the Gamblers Anonymous Survey (",
"    <a class=\"graphic graphic_table graphicRef66405 \" href=\"UTD.htm?12/54/13164\">",
"     table 2",
"    </a>",
"    ), which includes 20 questions, may be helpful in gathering clinical information and can help lead the patient to the Gamblers Anonymous program. Seven positive responses to the survey questions suggest the diagnosis of pathologic gambling. A similar survey, \"Are you living with a compulsive gambler?\" [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/37\">",
"     37",
"    </a>",
"    ], can be used to assist family members in coping with a problem gambler.",
"   </p>",
"   <p>",
"    The easiest instrument for the primary care clinician to use is the",
"    <span class=\"nowrap\">",
"     LIE/BET",
"    </span>",
"    questionnaire [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/40\">",
"     40",
"    </a>",
"    ], which is similar to the CAGE questions asked as part of alcoholism screening. This tool has been validated in community-dwelling adult and adolescent populations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/41\">",
"     41",
"    </a>",
"    ]. It is composed of two questions that are sensitive to the core issues of pathologic gambling:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Have you ever had to lie to people important to you about how much you gambled?\"",
"     </li>",
"     <li>",
"      \"Have you ever felt a need to bet more money?\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A yes answer to either question suggests the need to investigate for the presence of additional criteria for problem or pathologic gambling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     COMORBID PSYCHIATRIC DISORDERS AND ALCOHOL ABUSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;High rates of mood, psychotic, anxiety, personality, and substance abuse disorders (including alcohol and tobacco), as well as attention deficit hyperactivity disorder, are seen in patients with pathologic and problem gambling [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/15,42-44\">",
"     15,42-44",
"    </a>",
"    ]. In one study, for example, people with pathologic or problem gambling were compared with nongamblers (people who had gambled fewer than two times in their life) and were 3.3 times as likely to report ever having experienced major depression, 3.5 times more likely to report schizophrenia, 2.3 times more likely to report phobias, 6.1 times more likely to report antisocial personality, 3.3 times more likely to report current or past alcohol abuse or dependence, and 2.1 times more likely to report current or past nicotine dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At some point during their lives, major depressive disorder is likely to occur in 76 percent of pathologic gamblers, with recurrent depressive episodes likely to occur in 28 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/45\">",
"     45",
"    </a>",
"    ]. This high correlation suggests that the coexistence of depression and gambling may help discriminate pathologic from nonpathologic gambling. Visitors to and residents of major gaming communities experience a significantly elevated suicide rate; in Atlantic City, abnormally high suicide levels for visitors and residents appeared only after gambling casinos were opened.",
"   </p>",
"   <p>",
"    The relationship between gambling and alcohol use was investigated in a study which found that 12.9 percent of heavy drinkers had one or more gambling related problem compared with 5 percent of nondrinkers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/42\">",
"     42",
"    </a>",
"    ]. Eighteen percent of persons with probable alcohol dependence had at least one gambling-related problem, and 10 percent of heavy drinkers were probable pathologic gamblers.",
"   </p>",
"   <p>",
"    Patterns of gambling are different for substance abusers compared to non-users. A nationally representative sample found that substance-abusing gamblers had a younger age of onset of gambling, and were more likely to engage in heavier gambling with greater risk [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to make evidence-based recommendations for the treatment of pathologic gambling because few outcome studies have been conducted, and most involved only small samples and have methodologic flaws [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Psychotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggregated data from randomized, controlled trials of psychological interventions in patients with pathologic gambling support a modest to moderate benefit for behavioral techniques (imaginal desensitization) and cognitive-behavioral interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/47-52\">",
"     47-52",
"    </a>",
"    ]. A meta-analysis of psychological treatment for pathological gambling demonstrated significant positive short- and long-term effects [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initiation of psychological treatment for pathological gambling begins with helping the patient overcome irrational thoughts. Pathologic gamblers are thought to believe they have the ability to control chance events by relying on superstitious behavior or methods [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Psychological therapies stress identification of reasons for gambling, confrontation of defenses, and cessation of chasing behaviors. Cognitive treatments focus on challenging and correcting the patient's errors in thinking; for example, exploring and understanding the illusion of control over chance events [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Behavioral therapy considers pathologic gambling a learned behavior and relies on techniques such as systematic exposure or desensitization and skill development (eg, relaxation techniques and improving social skills) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. Cognitive-behavioral therapy combines elements from both the behavioral and cognitive treatment approaches, using systematic exposure or desensitization, relaxation techniques, social skills training and covert sensitization, as well as relapse prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although these counseling and treatment techniques may be beyond the comfort level and experience of most physicians, awareness of treatment options and referral to qualified mental health providers are important in the successful treatment of pathologic and problem gamblers and their families.",
"   </p>",
"   <p>",
"    Unfortunately, patients are often reluctant to seek psychological help, and one-half of patients referred to mental health services fail to follow through on the referral [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/55\">",
"     55",
"    </a>",
"    ]. Thus, counseling and treatment for gambling-related problems may depend solely on a trusted relationship with a primary care clinician.",
"   </p>",
"   <p>",
"    Useful interventions that can assist the patient with gambling-related disorders include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enlisting family members to assist in encouraging the pathologic gambler to follow through on treatment recommendations.",
"     </li>",
"     <li>",
"      Treating the patient for comorbid conditions of major affective disorders and substance abuse, as well as intervening to reduce the risk of suicide.",
"     </li>",
"     <li>",
"      Providing the gambler and family members with support resources. The National Council on Problem Gambling can be reached by calling 800-522-4700 or accessing its Web site (",
"      <a class=\"external\" href=\"file://www.ncpgambling.org/\">",
"       www.ncpgambling.org",
"      </a>",
"      ). Their hotline will route the caller to an affiliate of the national organization within the caller's state and provide information on local Gamblers Anonymous chapters and Gam-Anon meetings (for family members and friends). They also provide information about counselors who are trained in treating patients with gambling addictions and other treatment programs and resources.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment goals for patients who are pathologic gamblers are similar to patients being treated for depression or alcoholism in that they focus on restoring a \"normal\" way of thinking and living to patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Gamblers Anonymous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modeled after Alcoholics Anonymous, Gamblers Anonymous is the primary self-help group for gamblers and uses a 12-step, abstinence-based treatment program [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. The effectiveness of Gamblers Anonymous has not been demonstrated in controlled studies and, unlike alcoholism, some researchers have discovered that complete abstinence from gambling may not be necessary for successful treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacotherapy for problem gambling is most effective when directed toward the patient's comorbid condition; a diagnosis of bipolar disorder, OCD, ADHD, and substance abuse should be considered in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Antidepressant medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial research demonstrated pharmacotherapy to have a role in the treatment of pathologic gambling's coexisting depression, rather than as a primary treatment for pathologic gambling [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/21\">",
"     21",
"    </a>",
"    ]. However, over the past decade selective serotonin reuptake inhibitors (SSRIs) have been found in small trials to be effective in reducing gambling behaviors independent of their effect on mood and anxiety disorders.",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    was studied in a randomized, placebo-controlled study of 10 men with pathologic gambling [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/59\">",
"     59",
"    </a>",
"    ]. The study used a crossover design, so that each patient received 8 weeks of fluvoxamine and 8 weeks of placebo. Treatment with fluvoxamine resulted in a significantly greater percent improvement in overall gambling severity on the Pathological Gambling Clinical Global Impression scale. This difference between the treatment and placebo groups was only significant in the second phase of the trial, suggesting that there was an initial placebo effect that diminished with time.",
"   </p>",
"   <p>",
"    A large placebo effect was also noted in a randomized controlled trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/60\">",
"     60",
"    </a>",
"    ]. The response rate was the same for sertraline and placebo (74 percent and 72 percent, respectively).",
"   </p>",
"   <p>",
"    Other SSRIs, including citalopram and fluoxetine, have been found effective for the treatment of non-depressed pathologic gamblers in open-label studies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. In one report, fluoxetine in combination with psychotherapy was associated with higher remission rates compared with psychotherapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/62\">",
"     62",
"    </a>",
"    ]. A small, open-label trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    also suggested possible benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These studies are limited by small size, short follow-up, and in some cases study design. Thus, confirmation in larger randomized, controlled trials with extended follow-up is required before definitive recommendations can be made.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Opioid antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;One open label [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/64\">",
"     64",
"    </a>",
"    ] and two small randomized, placebo-controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/65,66\">",
"     65,66",
"    </a>",
"    ] found that treatment with the opioid antagonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    results in improvement on gambling symptom assessment scales. Naltrexone may cause liver function abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized double-blind trial of nalmefene in 207 persons with pathologic gambling found that nalmefene 25 mg per day significantly reduced gambling assessment scores over a 16 week trial period compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/67\">",
"     67",
"    </a>",
"    ]. Higher doses of nalmefene were not more effective but caused more side effects. Overall, however, the dropout rate before week 16 was high in all groups: 47 percent of the placebo group and 31 percent of the nalmefene group completed the study. Nalmefene is not currently available in oral formulation in the United States outside of research settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial suggested that in patients with bipolar spectrum disorder (other than bipolar I disorder) and pathologic gambling,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    may be of benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/68\">",
"     68",
"    </a>",
"    ]. Topiramate appeared to have some efficacy in a randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/69\">",
"     69",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     Olanzapine",
"    </a>",
"    was not more effective than placebo in another randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PUBLIC HEALTH APPROACH",
"    </span>",
"   </p>",
"   <p>",
"    A public health approach to control problem gambling has been proposed, based on the lessons learned from addressing tobacco availability and addiction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22760/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Decrease available gambling locations and lottery venues",
"     </li>",
"     <li>",
"      Ban advertising for gambling activities",
"     </li>",
"     <li>",
"      Keep lottery tickets out-of-sight",
"     </li>",
"     <li>",
"      Plain package gambling products, and add warning label with risk of problem gambling",
"     </li>",
"     <li>",
"      Enforce the legal age for gambling",
"     </li>",
"     <li>",
"      Regulate or ban instant",
"      <span class=\"nowrap\">",
"       play/reward",
"      </span>",
"      games (immediate gratification may exacerbate gambling behavior)",
"     </li>",
"     <li>",
"      Decrease the number of video lottery terminals (VLT's)",
"     </li>",
"     <li>",
"      Consider a moratorium on building new casinos",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pathologic and problem gambling affect 5 to 15 million Americans and are a growing problem, particularly among older people. Pathologic gambling, as defined in DSM-IV, is persistent maladaptive gambling behavior, meeting a set of specified criteria (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Risk factors for gambling include young age, male, mental health or substance abuse conditions, exposure to violence, positive family history, lower socioeconomic status. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A positive answer to either of two questions suggests need for investigation of possible problem gambling: \"Have you ever had to lie to people important to you about how much you gambled?\" and \"Have you ever felt a need to bet more money?\" (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis and screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of behavioral and cognitive-behavioral therapies for patients with pathologic gambling is supported by randomized, controlled trials with some methodologic flaws. We suggest psychological treatment be included in a treatment plan for all patients with problem gambling. Unfortunately, patients are often reluctant to seek psychological help, and one-half of patients referred to mental health services fail to follow through on the referral. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Psychotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gamblers anonymous is a self-help program for pathologic and problem gamblers. The efficacy of this program has not been demonstrated in controlled studies, although it may be a reasonable option, particularly for patients resistant to psychiatric referral. The gambler and family members also should be provided with support resources such as the National Council on Problem Gambling (800-522-4700 or",
"      <a class=\"external\" href=\"file://www.ncpgambling.org/\">",
"       www.ncpgambling.org",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Gamblers Anonymous'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pharmacotherapy for problem gambling is most effective when directed toward the patient's comorbid condition; a diagnosis of bipolar disorder, OCD, ADHD, and substance abuse should be considered in all patients. Pharmacotherapy may have some benefit, independent of the underlying comorbid condition, but the data are only preliminary. SSRIs have shown mixed results with a substantial placebo effect. Opioid antagonists (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"       naltrexone",
"      </a>",
"      and nalmefene) have shown effectiveness in small randomized trials. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Pharmacotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/1\">",
"      Shaffer HJ, Hall MN, Vander Bilt J. Estimating the prevalence of disordered gambling behavior in the United States and Canada: a research synthesis. Am J Public Health 1999; 89:1369.",
"     </a>",
"    </li>",
"    <li>",
"     Gambling Impact and Behavior Study. National Opinion Research Center, University of Chicago. Available at: www.norc.uchicago.edu/new/gambling.htm (Accessed 3/7/05).",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC, American Psychiatric Association, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/4\">",
"      Cunningham-Williams RM, Hong SI. A Latent Class Analysis (LCA) of problem gambling among a sample of community-recruited gamblers. J Nerv Ment Dis 2007; 195:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/5\">",
"      L&oacute;pez Viets VC, Miller WR. Treatment approaches for pathological gamblers. Clin Psychol Rev 1997; 17:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/6\">",
"      Pasternak AV 4th. Pathologic gambling: America's newest addiction? Am Fam Physician 1997; 56:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/7\">",
"      Grant JE, Kim SW, Brown E. Characteristics of geriatric patients seeking medication treatment for pathologic gambling disorder. J Geriatr Psychiatry Neurol 2001; 14:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/8\">",
"      Feigelman W, Wallisch LS, Lesieur HR. Problem gamblers, problem substance users, and dual-problem individuals: an epidemiological study. Am J Public Health 1998; 88:467.",
"     </a>",
"    </li>",
"    <li>",
"     Viele, L. State lottery has cost some players plenty. Augusta, Ga.: Augusta Chronicle [Online], June 21, 1998. Available at: www.augustachronicle.com/stories/062198/met_lot2.shtml (Accessed 7/7/04).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/10\">",
"      Poulin C. Gambling. CMAJ 2006; 175:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/11\">",
"      Zaranek RR, Chapleski EE. Casino gambling among urban elders: just another social activity? J Gerontol B Psychol Sci Soc Sci 2005; 60:S74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/12\">",
"      Vander Bilt J, Dodge HH, Pandav R, et al. Gambling participation and social support among older adults: a longitudinal community study. J Gambl Stud 2004; 20:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/13\">",
"      Proimos J, DuRant RH, Pierce JD, Goodman E. Gambling and other risk behaviors among 8th- to 12th-grade students. Pediatrics 1998; 102:e23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/14\">",
"      Ladd GT, Molina CA, Kerins GJ, Petry NM. Gambling participation and problems among older adults. J Geriatr Psychiatry Neurol 2003; 16:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/15\">",
"      Cunningham-Williams RM, Cottler LB, Compton WM 3rd, Spitznagel EL. Taking chances: problem gamblers and mental health disorders--results from the St. Louis Epidemiologic Catchment Area Study. Am J Public Health 1998; 88:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/16\">",
"      Tavares H, Zilberman ML, Beites FJ, Gentil V. Gender differences in gambling progression. J Gambl Stud 2001; 17:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/17\">",
"      Slutske WS, Eisen S, True WR, et al. Common genetic vulnerability for pathological gambling and alcohol dependence in men. Arch Gen Psychiatry 2000; 57:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/18\">",
"      Eisen SA, Lin N, Lyons MJ, et al. Familial influences on gambling behavior: an analysis of 3359 twin pairs. Addiction 1998; 93:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/19\">",
"      Petry NM, Steinberg KL, Women's Problem Gambling Research Center. Childhood maltreatment in male and female treatment-seeking pathological gamblers. Psychol Addict Behav 2005; 19:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/20\">",
"      Scherrer JF, Xian H, Kapp JM, et al. Association between exposure to childhood and lifetime traumatic events and lifetime pathological gambling in a twin cohort. J Nerv Ment Dis 2007; 195:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/21\">",
"      Murray JB. Review of research on pathological gambling. Psychol Rep 1993; 72:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/22\">",
"      Potenza MN. The neurobiology of pathological gambling. Semin Clin Neuropsychiatry 2001; 6:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/23\">",
"      Blanco C, Moreyra P, Nunes EV, et al. Pathological gambling: addiction or compulsion? Semin Clin Neuropsychiatry 2001; 6:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/24\">",
"      DeCaria CM, Hollander E, Grossman R, et al. Diagnosis, neurobiology, and treatment of pathological gambling. J Clin Psychiatry 1996; 57 Suppl 8:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/25\">",
"      Bechara A. Neurobiology of decision-making: risk and reward. Semin Clin Neuropsychiatry 2001; 6:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/26\">",
"      Tamminga CA, Nestler EJ. Pathological gambling: focusing on the addiction, not the activity. Am J Psychiatry 2006; 163:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/27\">",
"      Meyer G, Schwertfeger J, Exton MS, et al. Neuroendocrine response to casino gambling in problem gamblers. Psychoneuroendocrinology 2004; 29:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/28\">",
"      Goudriaan AE, Oosterlaan J, de Beurs E, Van den Brink W. Pathological gambling: a comprehensive review of biobehavioral findings. Neurosci Biobehav Rev 2004; 28:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/29\">",
"      Molina JA, S&aacute;inz-Artiga MJ, Fraile A, et al. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment? Mov Disord 2000; 15:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/30\">",
"      Gschwandtner U, Aston J, Renaud S, Fuhr P. Pathologic gambling in patients with Parkinson's disease. Clin Neuropharmacol 2001; 24:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/31\">",
"      Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 2003; 61:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/32\">",
"      Dodd ML, Klos KJ, Bower JH, et al. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005; 62:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/33\">",
"      Tippmann-Peikert M, Park JG, Boeve BF, et al. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 2007; 68:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/34\">",
"      Szarfman A, Doraiswamy PM, Tonning JM, Levine JG. Association between pathologic gambling and parkinsonian therapy as detected in the Food and Drug Administration Adverse Event database. Arch Neurol 2006; 63:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/35\">",
"      Slutske WS, Zhu G, Meier MH, Martin NG. Genetic and environmental influences on disordered gambling in men and women. Arch Gen Psychiatry 2010; 67:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/36\">",
"      Cunningham-Williams RM, Ostmann EL, Spitznagel EL, Books SJ. Racial/ethnic variation in the reliability of DSM-IV pathological gambling disorder. J Nerv Ment Dis 2007; 195:551.",
"     </a>",
"    </li>",
"    <li>",
"     McGurrin, MC. Diagnosis and treatment of pathological gambling. In: Lewis, JA (ed), Addictions: concepts and strategies for treatment. Gaithersburg, Md, Aspen 1994, p. 123.",
"    </li>",
"    <li>",
"     Abbott, MW, Volberg, RA. Frequent gamblers and problem gamblers in New Zealand: Report on phase two of the national survey. Research Series No. 14. Wellington: New Zealand Department of Internal Affairs, 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/39\">",
"      Abbott, MW, Volberg, RA. The New Zealand national survey of problem and pathological gambling. J Gambling Studies 1996; 12:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/40\">",
"      Johnson EE, Hamer R, Nora RM, et al. The Lie/Bet Questionnaire for screening pathological gamblers. Psychol Rep 1997; 80:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/41\">",
"      G&ouml;testam KG, Johansson A, Wenzel HG, Simonsen IE. Validation of the lie/bet screen for pathological gambling on two normal population data sets. Psychol Rep 2004; 95:1009.",
"     </a>",
"    </li>",
"    <li>",
"     Bray, RM, Kroutil, LA, Luckey, JW, et al. 1992 Worldwide survey of substance abuse and health behaviors among military personnel. Research Triangle Park, N.C.: Research Triangle Institute, 1992.",
"    </li>",
"    <li>",
"     DeCaria, CM, Cartwright, C, Novotny, S, et al. The relationship between bipolar spectrum and impulse control disorders. 152nd Annual Meeting of the American Psychiatric Association 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/44\">",
"      Petry NM, Stinson FS, Grant BF. Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2005; 66:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/45\">",
"      Becona E, Del Carmen Lorenzo M, Fuentes MJ. Pathological gambling and depression. Psychol Rep 1996; 78:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/46\">",
"      Liu T, Maciejewski PK, Potenza MN. The relationship between recreational gambling and substance abuse/dependence: data from a nationally representative sample. Drug Alcohol Depend 2009; 100:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/47\">",
"      Oakley-Browne MA, Adams P, Mobberley PM. Interventions for pathological gambling. Cochrane Database Syst Rev 2000; :CD001521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/48\">",
"      Echeburua, E, Baez, C, Fernandez-Montalvo, J. Comparative effectiveness of three therapeutic modalities in the psychological treatment of pathological gambling: Long term outcome. Behav Cogn Psychother 1996; 24:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/49\">",
"      McConaghy N, Armstrong MS, Blaszczynski A, Allcock C. Behavior completion versus stimulus control in compulsive gambling. Implications for behavioral assessment. Behav Modif 1988; 12:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/50\">",
"      McConaghy N, Blaszczynski A, Frankova A. Comparison of imaginal desensitisation with other behavioural treatments of pathological gambling. A two- to nine-year follow-up. Br J Psychiatry 1991; 159:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/51\">",
"      Sylvain C, Ladouceur R, Boisvert JM. Cognitive and behavioral treatment of pathological gambling: a controlled study. J Consult Clin Psychol 1997; 65:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/52\">",
"      Cowlishaw S, Merkouris S, Dowling N, et al. Psychological therapies for pathological and problem gambling. Cochrane Database Syst Rev 2012; 11:CD008937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/53\">",
"      Pallesen S, Mitsem M, Kvale G, et al. Outcome of psychological treatments of pathological gambling: a review and meta-analysis. Addiction 2005; 100:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/54\">",
"      Ladouceur R, Sylvain C, Letarte H, et al. Cognitive treatment of pathological gamblers. Behav Res Ther 1998; 36:1111.",
"     </a>",
"    </li>",
"    <li>",
"     Spruill, J. Interprofessional health care services in primary care settings: implications for the education and training of psychologists. Washington, DC, American Psychological Association, 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/56\">",
"      Hodgins DC, Currie SR, el-Guebaly N. Motivational enhancement and self-help treatments for problem gambling. J Consult Clin Psychol 2001; 69:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/57\">",
"      Blaszczynski A, McConaghy N, Frankova A. Control versus abstinence in the treatment of pathological gambling: a two to nine year follow-up. Br J Addict 1991; 86:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/58\">",
"      Dell'Osso B, Allen A, Hollander E. Comorbidity issues in the pharmacological treatment of Pathological Gambling: a critical review. Clin Pract Epidemiol Ment Health 2005; 1:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/59\">",
"      Hollander E, DeCaria CM, Finkell JN, et al. A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. Biol Psychiatry 2000; 47:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/60\">",
"      Saiz-Ruiz J, Blanco C, Ib&aacute;&ntilde;ez A, et al. Sertraline treatment of pathological gambling: a pilot study. J Clin Psychiatry 2005; 66:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/61\">",
"      Zimmerman M, Breen RB, Posternak MA. An open-label study of citalopram in the treatment of pathological gambling. J Clin Psychiatry 2002; 63:44.",
"     </a>",
"    </li>",
"    <li>",
"     Gandara, JJ, Sanz, O, Gilaberte, I. Fluoxetine: open-trial in pathological gambling. 152nd Annual Meeting of the Am Psych Association 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/63\">",
"      Black DW. An open-label trial of bupropion in the treatment of pathologic gambling. J Clin Psychopharmacol 2004; 24:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/64\">",
"      Kim SW, Grant JE. An open naltrexone treatment study in pathological gambling disorder. Int Clin Psychopharmacol 2001; 16:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/65\">",
"      Kim SW, Grant JE, Adson DE, Shin YC. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 2001; 49:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/66\">",
"      Grant JE, Kim SW, Hartman BK. A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. J Clin Psychiatry 2008; 69:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/67\">",
"      Grant JE, Potenza MN, Hollander E, et al. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry 2006; 163:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/68\">",
"      Hollander E, Pallanti S, Allen A, et al. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry 2005; 162:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/69\">",
"      Dannon PN, Lowengrub K, Gonopolski Y, et al. Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. Clin Neuropharmacol 2005; 28:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22760/abstract/70\">",
"      McElroy SL, Nelson EB, Welge JA, et al. Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial. J Clin Psychiatry 2008; 69:433.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3988 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-817E36F31F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_14_22760=[""].join("\n");
var outline_f22_14_22760=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Classification systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Societal impact",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      High-risk groups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18169335\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS AND SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      COMORBID PSYCHIATRIC DISORDERS AND ALCOHOL ABUSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Gamblers Anonymous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Antidepressant medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Opioid antagonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PUBLIC HEALTH APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/3988\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/3988|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/53/860\" title=\"table 1\">",
"      DSM-IV criteria gambling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/54/13164\" title=\"table 2\">",
"      Gamblers anonymous survey",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_14_22761="Cataract in children";
var content_f22_14_22761=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cataract in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/14/22761/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/14/22761/contributors\">",
"     Kathryn M McCreery, FRCOphth, FRCSI, MRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/14/22761/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/14/22761/contributors\">",
"     Evelyn A Paysse, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/14/22761/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/14/22761/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/14/22761/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cataract is an opacity of the lens of the eye that causes partial or total blindness (",
"    <a class=\"graphic graphic_picture graphicRef76110 \" href=\"UTD.htm?28/29/29136\">",
"     picture 1",
"    </a>",
"    ). Cataracts are a common and frequently curable cause of blindness in children. Early detection and prompt intervention are critical for a good visual outcome, particularly in newborns.",
"   </p>",
"   <p>",
"    Cataracts in infants and children will be reviewed here. Lens dislocation in children and cataracts in adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41557?source=see_link\">",
"     \"Ectopia lentis (dislocated lens) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/19/2362?source=see_link\">",
"     \"Cataract in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported prevalence of childhood cataracts ranges from 1 to 15 per 10,000 children. The wide range reflects differences in populations, age groups, methods of ascertainment, and case definitions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/1\">",
"     1",
"    </a>",
"    ]. The prevalence of congenital cataract in developed countries is 1 to 3 per 10,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The crystalline lens consists of five major structures: embryonic nucleus, fetal nucleus, cortex, lens epithelium, and lens capsule [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/5\">",
"     5",
"    </a>",
"    ]. The crystalline lens focuses light rays onto the retina [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/6\">",
"     6",
"    </a>",
"    ]. Relaxation or contraction of the ciliary body changes the shape of the lens to permit focus of light rays from objects at distant and near fixation (",
"    <a class=\"graphic graphic_figure graphicRef59910 \" href=\"UTD.htm?2/6/2150\">",
"     figure 1",
"    </a>",
"    ). Contraction of the ciliary body to permit focus at near fixation is referred to as \"accommodation\".",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cataracts are usually classified according to their location in the lens (",
"    <a class=\"graphic graphic_figure graphicRef70532 \" href=\"UTD.htm?33/4/33859\">",
"     figure 2",
"    </a>",
"    ), morphologic appearance (",
"    <a class=\"graphic graphic_table graphicRef81218 \" href=\"UTD.htm?14/47/15100\">",
"     table 1",
"    </a>",
"    ),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    underlying pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital anterior polar cataracts &ndash; Congenital anterior polar cataracts are typically, though not always, bilateral, symmetrical, small opacities involving the anterior lens capsule that are usually nonprogressive (",
"      <a class=\"graphic graphic_picture graphicRef67779 \" href=\"UTD.htm?41/50/42784\">",
"       picture 2",
"      </a>",
"      ). They are frequently familial. Congenital anterior polar cataracts generally are associated with a good visual prognosis, but may be progressive and should be followed [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. If congenital anterior polar cataract is unilateral, it is frequently associated with anisometropia, which can be severe and cause amblyopia.",
"     </li>",
"     <li>",
"      Persistent fetal vasculature &ndash; Persistent fetal vasculature (PFV, formerly called persistent hyperplastic primary vitreous [PHPV]) is an arrest of embryonic development. The eye is mildly microphthalmic (",
"      <a class=\"graphic graphic_picture graphicRef75788 \" href=\"UTD.htm?21/26/21922\">",
"       picture 3",
"      </a>",
"      ), and a vascularized stalk extends from the optic nerve to the posterior aspect of the crystalline lens, causing a posterior lens plaque that can obstruct the visual axis. PFV may result in cataract formation, elongation of the ciliary processes, and glaucoma [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/10\">",
"       10",
"      </a>",
"      ]. Cataract surgery in children with PFV often is complicated. Visual prognosis may be limited by associated optic nerve or macular disease [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Congenital posterior polar cataract &ndash; Congenital posterior polar cataract may be unilateral or bilateral.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A unilateral posterior polar cataract (Mittendorf dot) is a remnant of the primary vitreous (mild form of PFV) and generally non-progressive.",
"     </li>",
"     <li>",
"      Bilateral posterior polar cataracts may be familial or sporadic and usually are progressive.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Posterior lenticonus or lentiglobus &ndash; Posterior lenticonus and posterior lentiglobus refer to congenital defects of the posterior lens capsule that respectively cause a conical (",
"      <a class=\"graphic graphic_picture graphicRef77495 \" href=\"UTD.htm?35/55/36721\">",
"       picture 4",
"      </a>",
"      ) or spherical bulge in the capsule and progressive cataract formation. The progression may take months to years; slow progression is usually associated with good visual prognosis.",
"     </li>",
"     <li>",
"      Posterior subcapsular cataracts &ndash; Posterior subcapsular cataracts involve the area immediately anterior to the posterior capsule (",
"      <a class=\"graphic graphic_figure graphicRef70532 \" href=\"UTD.htm?33/4/33859\">",
"       figure 2",
"      </a>",
"      ). They are acquired, in many cases, secondary to glucocorticoid therapy or ionizing radiation.",
"     </li>",
"     <li>",
"      Total cataracts &ndash; Total (complete or diffuse) cataracts involve the complete crystalline lens (",
"      <a class=\"graphic graphic_picture graphicRef76110 \" href=\"UTD.htm?28/29/29136\">",
"       picture 1",
"      </a>",
"      ) and preclude any view of the retina.",
"     </li>",
"     <li>",
"      Zonular cataracts &ndash; Zonular cataracts involve a particular zone of the developing lens (nuclear, lamellar, sutural, or cortical) and reflect an insult occurring at a particular time during lens development [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/5\">",
"       5",
"      </a>",
"      ]. Nuclear cataracts occur early in gestation, whereas lamellar cataracts occur in childhood.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Nuclear cataracts involve the embryonal or fetal nucleus and are highly amblyogenic. They usually are bilateral and can represent an intrauterine insult and often are associated with microphthalmos (",
"      <a class=\"graphic graphic_picture graphicRef80566 \" href=\"UTD.htm?18/38/19042\">",
"       picture 5",
"      </a>",
"      ). Bilateral cases may be associated with autosomal dominant inheritance [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lamellar cataracts involve the lamella peripheral to the Y sutures of the lens.",
"     </li>",
"     <li>",
"      Sutural cataracts involve the Y sutures of the lens; they can be unilateral or bilateral; inheritance is X-linked or autosomal recessive.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-third of congenital cataracts in children are inherited, one-third are associated with systemic diseases, and one-third are idiopathic or sporadic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hereditary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary cataracts are usually inherited in an autosomal dominant fashion with almost complete penetrance but variable expressivity. Autosomal recessive and X-linked forms are less frequent. Hereditary cataracts may be present at birth or develop over time; they may be sutural, anterior or posterior",
"    <span class=\"nowrap\">",
"     capsular/polar.",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Classification'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Infants and children with a family history of childhood-onset cataracts should be referred to an ophthalmologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Disease-associated",
"    </span>",
"    &nbsp;&mdash;&nbsp;The list of systemic and ocular disorders in which cataracts occur is extensive (",
"    <a class=\"graphic graphic_table graphicRef78696 \" href=\"UTD.htm?29/21/30045\">",
"     table 2",
"    </a>",
"    ). All children with such disorders warrant ophthalmic evaluation. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Ocular trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opacity of the lens may be an immediate, early, or late complication of ocular trauma (",
"    <a class=\"graphic graphic_picture graphicRef82023 \" href=\"UTD.htm?11/53/12112\">",
"     picture 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/13\">",
"     13",
"    </a>",
"    ]. Most of the injuries that result in traumatic cataract occur during play or sports-related activity and often involve projectiles [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Penetrating injuries are more commonly associated with cataracts than blunt injuries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8745?source=see_link\">",
"     \"Open globe injuries: Emergent evaluation and initial management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cataracts due to blunt trauma usually are stellate- or rosette-shaped and may be stable or progressive [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/13\">",
"     13",
"    </a>",
"    ]. Penetrating trauma with disruption of the lens capsule allows hydration of the lens cortex, which results in cataract; these cortical changes may remain focal (if small) or progress rapidly (within a period of hours) to total cortical opacification [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The possibility of non-accidental injury should be considered in cases of total or complete cataracts where the etiology is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cataractogenic effects of systemic glucocorticoids are well documented. We recommend ophthalmologic evaluation for children receiving long-term systemic glucocorticoids or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/33/14871?source=see_link\">",
"     adrenocorticotropic hormone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link&amp;anchor=H8#H8\">",
"     \"Major side effects of systemic glucocorticoids\", section on 'Eye'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of cataracts with inhaled glucocorticoids is not well established. We do not suggest ophthalmologic evaluation for children receiving only inhaled glucocorticoids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=see_link&amp;anchor=H14#H14\">",
"     \"Major side effects of inhaled glucocorticoids\", section on 'Ocular changes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Ionizing radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ionizing radiation is a well-documented cause of cataracts. The pediatric lens is particularly susceptible. The minimum dose considered to be cataractogenic is 500 rad [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/16\">",
"     16",
"    </a>",
"    ]. Children exposed to a lenticular dose of 1 Gy have a 50 percent increased incidence of cataract formation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/17\">",
"     17",
"    </a>",
"    ]. It is recommended that such children have a yearly eye examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of cataract is highly variable; there is no single characteristic presenting feature. Infants and children with cataracts may present with any or all of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parental complaint. Cataracts that involve the anterior portion of the lens can be seen by the unaided eye. Such cataracts often are first noted by a parent [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/6\">",
"       6",
"      </a>",
"      ]. This is the most common presentation for anterior polar cataracts.",
"     </li>",
"     <li>",
"      Poor vision. Poor vision in infants is manifest by visual behavior that deviates from normal (",
"      <a class=\"graphic graphic_table graphicRef73947 \" href=\"UTD.htm?6/12/6348\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Asymmetry of the red reflex identified on Bruckner testing (simultaneous red reflex test) (",
"      <a class=\"graphic graphic_figure graphicRef66431 \" href=\"UTD.htm?31/47/32506\">",
"       figure 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/18\">",
"       18",
"      </a>",
"      ]. Evaluation of the red reflex in old photographs of the child may help determine the age of onset of the cataract and aid in providing the family with a visual prognosis. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Prognosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Leukocoria (white pupillary reflex). Other causes of leukocoria include retinoblastoma, Coat's disease, toxocariasis, PFV, or retinal coloboma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5496?source=see_link&amp;anchor=H6#H6\">",
"       \"Approach to the child with leukocoria\", section on 'Cataract'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nystagmus. Nystagmus can result from visual deprivation in the first months of life; it is associated with poor visual prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/2,19\">",
"       2,19",
"      </a>",
"      ]. In children with congenital cataracts, nystagmus develops at two to three months of age. Children who develop cataracts after six months of age usually do not have nystagmus.",
"     </li>",
"     <li>",
"      Strabismus. Children with cataracts can present with strabismus [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/2\">",
"       2",
"      </a>",
"      ]. Strabismus may not develop until irreversible visual loss has occurred. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41800?source=see_link&amp;anchor=H14#H14\">",
"       \"Causes of horizontal strabismus in children\", section on 'Sensory esotropia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=see_link&amp;anchor=H7#H7\">",
"       \"Evaluation and management of strabismus in children\", section on 'Strabismus'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Photophobia. The glare caused by the scattering of light from some types of cataract may result in photophobia [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Delayed development. Infants with significant bilateral congenital cataracts may have delayed attainment of developmental milestones [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/2,20\">",
"       2,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Family history of hereditary cataracts.",
"     </li>",
"     <li>",
"      Genetic disorder associated with cataracts (eg, Down syndrome, galactosemia).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cataracts may be stationary or progressive. Although certain types of cataracts tend to be stationary, and others progressive, any type can progress. All cataracts should be followed for progression during the amblyogenic age range.",
"   </p>",
"   <p>",
"    Neonates and infants with cataracts that initially are visually insignificant should be followed closely during the first several years of life for progression that could lead to amblyopia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8153?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of amblyopia\", section on 'Deprivational amblyopia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cataracts are one of the leading causes of blindness in children. Cataracts cause blindness when they interfere with normal visual development [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Visual development occurs from birth to approximately eight years of age, with the majority occurring in the first three years of life. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=see_link&amp;anchor=H2#H2\">",
"     \"Visual development and vision assessment in infants and children\", section on 'Visual development'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During this critical period of visual development, any reduction of retinal stimulation results in amblyopia. In children with cataracts, the degree of amblyopia depends upon the density of the cataract and its age of onset. The earlier the onset of lens opacification and the denser the opacification, the deeper the resultant amblyopia. Visually significant cataracts that are present in the first six months of life are a true ophthalmic emergency. If left untreated, they will result in irreversible visual loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8153?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of amblyopia\", section on 'Deprivational amblyopia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of an infant or child with a cataract focuses on determining the etiology. Identification of associated disease (",
"    <a class=\"graphic graphic_table graphicRef78696 \" href=\"UTD.htm?29/21/30045\">",
"     table 2",
"    </a>",
"    ) may have implications for therapy and long-term monitoring (eg, galactosemia). Cataract is rarely the only manifestation of systemic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. A detailed history, physical examination, and ocular examination unveils an associated disease in the majority of cases. Laboratory evaluation is indicated for some types of bilateral cataract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important aspects of the history include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Family history of inherited cataracts",
"     </li>",
"     <li>",
"      Ocular trauma",
"     </li>",
"     <li>",
"      Metabolic disorder such as galactosemia or diabetes (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30886?source=see_link\">",
"       \"Clinical features and diagnosis of galactosemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40889?source=see_link\">",
"       \"Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      History of systemic glucocorticoid use (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Glucocorticoids'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Ionizing radiation (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Ionizing radiation'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Intrauterine infection (toxoplasmosis, rubella, cytomegalovirus, herpes simplex virus, varicella, syphilis) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/23,24\">",
"       23,24",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28041?source=see_link&amp;anchor=H650131395#H650131395\">",
"       \"Overview of TORCH infections\", section on 'Clinical features of TORCH infections'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Chromosomal defect (eg, trisomy 21, 13, and 18) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=see_link\">",
"       \"Clinical features and diagnosis of Down syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=see_link&amp;anchor=H14#H14\">",
"       \"Congenital cytogenetic abnormalities\", section on 'Trisomy 13 syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=see_link&amp;anchor=H11#H11\">",
"       \"Congenital cytogenetic abnormalities\", section on 'Trisomy 18 syndrome'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      General examination &ndash; The general examination should evaluate for physical findings of associated systemic diseases or syndromes associated with cataracts (",
"      <a class=\"graphic graphic_table graphicRef77226 \" href=\"UTD.htm?31/31/32254\">",
"       table 4",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Down syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical features and diagnosis of Down syndrome\", section on 'Dysmorphic features'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Turner syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)\", section on 'Clinical manifestations'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Trisomy 18 and trisomy 13 (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=see_link&amp;anchor=H11#H11\">",
"       \"Congenital cytogenetic abnormalities\", section on 'Trisomy 18 syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=see_link&amp;anchor=H14#H14\">",
"       \"Congenital cytogenetic abnormalities\", section on 'Trisomy 13 syndrome'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Craniofacial syndromes (eg, Stickler, Marshall, Robin, Apert, Crouzon) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/15/250?source=see_link\">",
"       \"Syndromes with craniofacial abnormalities\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8487?source=see_link\">",
"       \"Craniosynostosis syndromes\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Metabolic disease, including galactosemia, Lowe oculocerebral syndrome, peroxisomal disorders (Refsum disease, Zellweger disease, chondrodysplasia punctata) and lysosomal storage disorders (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30886?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical features and diagnosis of galactosemia\", section on 'Clinical features'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=see_link&amp;anchor=H13#H13\">",
"       \"Peroxisomal disorders\", section on 'Clinical presentation'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Intrauterine infections (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28041?source=see_link&amp;anchor=H650131395#H650131395\">",
"       \"Overview of TORCH infections\", section on 'Clinical features of TORCH infections'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eye examination &ndash; Eye examination by the primary care clinician should include assessment of the red reflex (simultaneous red reflex test [also known as Bruckner testing]), leukocoria, photophobia, extraocular movements, strabismus, nystagmus, and visual acuity. In patients with a history of ocular trauma, it is important to look for associated injuries. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Presentation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Ocular trauma'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Assessment of the red reflex is the most sensitive method of cataract detection. Simply evaluating the red reflex in both eyes simultaneously with a direct ophthalmoscope in a darkened room will reveal any significant lens opacity [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/6\">",
"       6",
"      </a>",
"      ]. This can be performed with both a dilated and undilated pupil.",
"      <br/>",
"      <br/>",
"      In the preverbal child, visual acuity is assessed by the ability to fix and follow. In the verbal child, visual acuity is assessed by optotype (Snellen) testing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=see_link&amp;anchor=H10#H10\">",
"       \"Visual development and vision assessment in infants and children\", section on 'Fixation reflex'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=see_link&amp;anchor=H13#H13\">",
"       \"Visual development and vision assessment in infants and children\", section on 'Optotype tests'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory evaluation may not be necessary if the history and examination reveal a definitive etiology for the cataract (eg, a family history of heritable cataracts, associated ocular disease or trauma, or obvious",
"    <span class=\"nowrap\">",
"     syndrome/chromosomal",
"    </span>",
"    defect).",
"   </p>",
"   <p>",
"    For other patients with unilateral or bilateral cataracts, laboratory evaluation may include (",
"    <a class=\"graphic graphic_table graphicRef78696 \" href=\"UTD.htm?29/21/30045\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urine for reducing substances after ingestion of galactose-containing milk (eg, human or cow's milk), and possibly urine amino acids and red cell galactokinase",
"     </li>",
"     <li>",
"      Toxoplasmosis, rubella, CMV, herpes simplex, and varicella titers and syphilis serology (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28041?source=see_link&amp;anchor=H609355024#H609355024\">",
"       \"Overview of TORCH infections\", section on 'Approach to the infant with suspected intrauterine infection'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Calcium, phosphate, and blood sugar (to exclude metabolic disorders, such as diabetes, hypoparathyroidism)",
"     </li>",
"     <li>",
"      Karyotype",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other genetic testing",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Referral indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Referral to an ophthalmologist is essential for children in whom a cataract is suspected. Newborns and infants younger than one year should be seen as soon as possible because the risk of amblyopia increases if diagnosis is delayed. Older children should be seen within weeks of the primary care visit.",
"   </p>",
"   <p>",
"    Referral to an ophthalmologist is also indicated for infants and children with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A family history of hereditary cataract",
"     </li>",
"     <li>",
"      Long-term systemic glucocorticoid use",
"     </li>",
"     <li>",
"      History of ionizing radiation exposure (eg, radiation therapy)",
"     </li>",
"     <li>",
"      Systemic disorder associated with cataracts (",
"      <a class=\"graphic graphic_table graphicRef78696 \" href=\"UTD.htm?29/21/30045\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of cataract includes other conditions that cause leukocoria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5496?source=see_link&amp;anchor=H2#H2\">",
"     \"Approach to the child with leukocoria\", section on 'Causes of leukocoria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of cataracts in children depends upon the child's age and the potential for interference with visual development. If the cataract is visually significant, management entails removal of the lens and",
"    <span class=\"nowrap\">",
"     optical/visual",
"    </span>",
"    rehabilitation, which is critical to preventing amblyopia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with good vision",
"    <span class=\"nowrap\">",
"     (20/50",
"    </span>",
"    or better), small opacities (&lt;3 mm), or extra-axial opacities can be managed conservatively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/2,26\">",
"     2,26",
"    </a>",
"    ]. Associated refractive error is treated with spectacle or contact lens correction. Occlusion therapy is often required for children with incomplete unilateral cataracts",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    amblyopia after cataract extraction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8153?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of amblyopia\", section on 'Occlusion therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Cataract extraction",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Indications &mdash; Cataract extraction is usually warranted for children with bilateral complete cataracts. For children with incomplete cataracts (unilateral or bilateral), indications for surgery include [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/28\">",
"       28",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Decreased visual response",
"     </li>",
"     <li>",
"      Reduced visual acuity",
"      <span class=\"nowrap\">",
"       (20/50",
"      </span>",
"      or worse)",
"     </li>",
"     <li>",
"      Opacity &gt;3 mm in diameter",
"     </li>",
"     <li>",
"      Onset of strabismus, which indicates a significant disruption in fusion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Timing &mdash; Infants with cataracts should undergo surgery as soon as possible, usually in the first four to six weeks to months of life [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/2,5,7\">",
"       2,5,7",
"      </a>",
"      ]. The visual axis must be cleared by 16 weeks of age to achieve visual acuity of",
"      <span class=\"nowrap\">",
"       20/40",
"      </span>",
"      or better [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/29,30\">",
"       29,30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To prevent anisometric amblyopia in infants with bilateral cataracts, the cataracts should be removed within one to two weeks of each other (if not removed simultaneously). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8153?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of amblyopia\", section on 'Anisometropic amblyopia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with unilateral cataracts are at increased risk of dense deprivation amblyopia. Adherence to the post-operative schedule of occlusion therapy is essential to achieving good visual outcome. Unilateral cataracts often are associated with other ocular pathology, which may further limit visual potential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Post-operative care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cataract surgery in children requires a firm commitment on the part of the child's parents to become involved in postoperative care [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/2,31\">",
"     2,31",
"    </a>",
"    ]. The post-operative regimen, which can place a significant burden of the family, may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The application of eye drops as often as every two hours in the early post-operative period; lack of adherence to this schedule may result in postoperative inflammation, which can have permanent adverse visual sequelae.",
"     </li>",
"     <li>",
"      Frequent office visits. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Follow-up'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Long-term occlusion therapy for amblyopia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Optical and visual rehabilitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The crystalline lens serves to focus light on the retina; it also has the ability to accommodate (ie, change focal point from distant to near). When the natural lens is removed (aphakia), it is usually replaced with an intraocular lens (IOL) in older children or an aphakic contact lens in young children or patients with small eyes. In addition, bifocal glasses are required for near work because the IOL or contact lens does not accommodate and is typically powered for distance. The Infant Aphakia Treatment Study is an ongoing multicenter randomized trial comparing IOL and contact lens correction for monocular aphakia in infants between one and six months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/32-34\">",
"     32-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After bilateral cataract extraction, aphakic spectacles may be used to restore focus. However, as techniques for IOL have improved, the use of aphakic spectacles instead of IOL has become less popular [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The age of the patient at the time of surgery is an important factor in determining the best form of optical rehabilitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Aphakic contact lens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many ophthalmologists prefer aphakic contact lenses to intraocular lens (IOL) implantation for optical rehabilitation in infants younger than six to nine months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/2\">",
"     2",
"    </a>",
"    ]. Some ophthalmologists would consider implanting an IOL in younger infants (ie, three months and older). However, the risk of post-operative complications, such as intraocular inflammation and secondary membrane formation, is increased in this age group. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Intraocular lens'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A major advantage of contact lenses over IOL in infants is the ability to change the power of the lens as the refractive power of the eye changes with ocular growth [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/7\">",
"     7",
"    </a>",
"    ]. A large proportion of ocular growth occurs during the first year of life [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. The total refractive power of the aphakic eye decreases from +30.75 at birth to +26.36 at one year, +23.00 at two years, and +21.20 at three years. The provision of a clear retinal image (ie, emmetropia) would require a +30 diopter IOL at birth and a +21 diopter lens at three years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/40\">",
"     40",
"    </a>",
"    ]. Infants who are initially rehabilitated with aphakic contact lenses may undergo secondary IOL implantation later in life if contact lenses become more difficult to manage (usually at &ge;2 to 3 years of age).",
"   </p>",
"   <p>",
"    Disadvantages to the use of aphakic contact lenses include the need for daily maintenance, risk of corneal infections in association with contact lens wear, and delayed amblyopia therapy with contact lens loss [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, there is a cost associated with frequent replacement of contact lenses due either to lens loss or the frequent need to change lens power that occurs with normal ocular growth. There may also be an increased incidence of strabismus in children with monocular cataract treated with aphakic contact lenses as opposed to IOLs [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Intraocular lens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advantages of an IOL include immediate and full time optical correction (in contrast to contact lenses which require regular insertion) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In children older than six to nine months, it is generally accepted that IOL implantation (pseudophakia) offers the best opportunity for visual rehabilitation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Nonetheless, ocular",
"    <span class=\"nowrap\">",
"     growth/IOL",
"    </span>",
"    power and posterior capsule opacification (secondary cataract) may to pose management problems. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Post-operative complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    IOL also may be beneficial in specific clinical situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiation cataracts, which may be associated ocular surface disease that precludes the use of contact lenses.",
"     </li>",
"     <li>",
"      Neurobehavioral disorders, in which there may be difficulty with contact lens insertion or wear.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most children require glasses with an IOL postoperatively to optimize optical focus and visual rehabilitation. In addition, older children require a bifocal to provide clear near vision. The use of multifocal intraocular lenses in children is investigational.",
"   </p>",
"   <p>",
"    Some ophthalmologists would consider implanting an IOL in infants three months and older. However, the risk of post-operative complications, such as intraocular inflammation and secondary membrane formation, is increased in young infants. In the Infant Aphakia Treatment Study, 114 infants with unilateral congenital cataract were randomly assigned to undergo cataract extraction with primary IOL implantation or aphakic contact lens between one and six months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/32\">",
"     32",
"    </a>",
"    ]. At one year of age, grating visual acuity was similar between the two groups. However, the rate of adverse events was increased in the IOL group (77 versus 25 percent), and more patients in the IOL group required additional intraocular procedures (63 versus 12 percent), predominantly to clear visual axis opacities [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/43\">",
"     43",
"    </a>",
"    ]. Additional follow-up (at 4.5 years of age) is scheduled to determine ultimate visual outcome and risk of long-term complications, such as glaucoma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     POST-OPERATIVE COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opacification of the posterior capsule of the lens (secondary cataract) occurs in virtually 100 percent of young children undergoing cataract surgery. Therefore, it is standard to remove the posterior capsule and perform a primary anterior vitrectomy at the time of cataract extraction in children younger than five to six years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. In older children, posterior opacification may occur, but most surgeons leave the capsule intact at the time of cataract extraction since these children will be able to cooperate with laser",
"    <span class=\"nowrap\">",
"     capsulectomy/anterior",
"    </span>",
"    vitrectomy",
"    <span class=\"nowrap\">",
"     when/if",
"    </span>",
"    needed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/42,48\">",
"     42,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Infant Aphakia Treatment Study (a randomized trial comparing intraocular lens [IOL] and contact lens correction for unilateral aphakia in infants between one and six months of age), 9 percent of 114 subjects developed glaucoma or suspected glaucoma during the first year of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/34\">",
"     34",
"    </a>",
"    ]. The risk of glaucoma was increased in younger infants and infants with persistent fetal vasculature. Ongoing follow-up is necessary because the mean interval between cataract surgery and diagnosis of glaucoma ranges from 4 to 5.2 years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/49-51\">",
"     49-51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retinal detachment is an occasional complication [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sudden vision loss, ocular pain, redness, or complaints of flashes of light or \"floaters\" in a child who has undergone cataract surgery deserves evaluation by the ophthalmologist [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41463?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of glaucoma in infants and children\", section on 'Aphakia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/41/36504?source=see_link\">",
"     \"Retinal detachment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endophthalmitis (infection within the eye) is a rare but severe complication, occurring in approximately 7 in 10,000 procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Risk factors for endophthalmitis include nasolacrimal duct obstruction, periorbital eczema, and upper respiratory infection at the time of surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/7\">",
"     7",
"    </a>",
"    ]. Endophthalmitis may occur several days to weeks after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/6\">",
"     6",
"    </a>",
"    ]. It is characterized by pain, redness, and haziness within the eye from inflammatory cells (",
"    <a class=\"graphic graphic_picture graphicRef59911 \" href=\"UTD.htm?1/45/1745\">",
"     picture 7",
"    </a>",
"    ). Acute endophthalmitis is a medical emergency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24873?source=see_link&amp;anchor=H2#H2\">",
"     \"Bacterial endophthalmitis\", section on 'Acute postcataract endophthalmitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The visual prognosis for pediatric cataracts has improved significantly over the years. Visual acuities of",
"    <span class=\"nowrap\">",
"     20/20",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    may be achieved if cataracts are diagnosed and treated early [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/48,53,54\">",
"     48,53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Visual outcome depends upon age of onset, whether the cataract is unilateral or bilateral, the type of cataract, pre- and coexisting ocular abnormalities, post-operative course and complications, and the adherence to amblyopia treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors associated with a poorer visual outcome include [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/2,5,19,55\">",
"     2,5,19,55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nystagmus at presentation",
"     </li>",
"     <li>",
"      Strabismus at presentation or in the follow-up period",
"     </li>",
"     <li>",
"      Unilateral congenital or infantile cataract",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular ophthalmology follow-up is crucial for successful outcome in children who have undergone cataract surgery (with or without IOL implantation) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22761/abstract/31\">",
"     31",
"    </a>",
"    ]. Most children will have frequent changes in refraction requiring spectacle prescription change and need ongoing amblyopia therapy to optimize visual outcome. Any ocular redness or reported changes in vision should be reported to the ophthalmologist immediately.",
"   </p>",
"   <p>",
"    Patients with poor visual outcome may benefit from local, state, or federal services for the visually handicapped",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    blind.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/62/6114?source=see_link\">",
"       \"Patient information: Cataracts (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Clinical features and evaluation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pediatric cataracts are usually classified according to their morphologic appearance (",
"      <a class=\"graphic graphic_table graphicRef81218 \" href=\"UTD.htm?14/47/15100\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately one-third of cataracts in children are inherited, one-third are associated with other disease (",
"      <a class=\"graphic graphic_table graphicRef78696 \" href=\"UTD.htm?29/21/30045\">",
"       table 2",
"      </a>",
"      ), and one-third are idiopathic or sporadic. Acquired cataracts may be caused by ocular trauma, glucocorticoids, and ionizing radiation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important aspects of the clinical presentation of cataract include red reflex, leukocoria, photophobia, extraocular movements, strabismus, nystagmus, and visual acuity. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Examination'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=see_link\">",
"       \"Visual development and vision assessment in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The evaluation of an infant or child with a cataract focuses on determining the etiology. Identification of associated disease (",
"      <a class=\"graphic graphic_table graphicRef78696 \" href=\"UTD.htm?29/21/30045\">",
"       table 2",
"      </a>",
"      ) may have implications for therapy and monitoring. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory evaluation for patients in whom the etiology of cataract is uncertain after history and physical examination may include evaluation for galactosemia and other metabolic diseases, intrauterine infection, and or genetic testing. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indications for referral to an ophthalmologist include suspicion of cataract, family history of hereditary cataract, long-term systemic glucocorticoid use, history of ionizing radiation exposure (eg, radiation therapy), and systemic disorders associated with cataracts (",
"      <a class=\"graphic graphic_table graphicRef78696 \" href=\"UTD.htm?29/21/30045\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Referral indications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Management and outcome",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of cataracts depends upon the age of the child and potential for interference with visual development. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend cataract extraction for newborns with bilateral complete cataracts (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Surgery should take place as soon as possible, ideally within the first four to six weeks of life. The two eyes should be operated on within one week of each other. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Cataract extraction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest surgery for children with incomplete cataracts (unilateral or bilateral) and one or more of the following (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Cataract extraction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Decreased visual response",
"     </li>",
"     <li>",
"      Reduced visual acuity",
"      <span class=\"nowrap\">",
"       (20/50",
"      </span>",
"      level or worse)",
"     </li>",
"     <li>",
"      Opacity &gt;3 mm in diameter",
"     </li>",
"     <li>",
"      Onset of strabismus, which indicates a significant disruption in fusion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When the natural lens is removed, it must be replaced with an intraocular lens (IOL) or an aphakic contact lens. In addition, bifocal glasses are required for near work. Aphakic contact lenses are usually used for children younger than six to nine months of age, an IOL for older children. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Optical and visual rehabilitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Post-operative complications may include opacification of the posterior capsule (if posterior",
"      <span class=\"nowrap\">",
"       capsulectomy/anterior",
"      </span>",
"      vitrectomy is not performed at the time of cataract extraction), glaucoma, retinal detachment, and endophthalmitis. Children who develop sudden vision loss, ocular pain, or ocular redness any time after cataract surgery should be evaluated by an ophthalmologist. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Post-operative complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regular ophthalmology follow-up is crucial for successful outcome in children who have undergone cataract surgery (with or without IOL implantation). (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/1\">",
"      Foster A, Gilbert C, Rahi J. Epidemiology of cataract in childhood: a global perspective. J Cataract Refract Surg 1997; 23 Suppl 1:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/2\">",
"      Zetterstr&ouml;m C, Lundvall A, Kugelberg M. Cataracts in children. J Cataract Refract Surg 2005; 31:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/3\">",
"      Abrahamsson M, Magnusson G, Sj&ouml;str&ouml;m A, et al. The occurrence of congenital cataract in western Sweden. Acta Ophthalmol Scand 1999; 77:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/4\">",
"      Rahi JS, Dezateux C, British Congenital Cataract Interest Group. Measuring and interpreting the incidence of congenital ocular anomalies: lessons from a national study of congenital cataract in the UK. Invest Ophthalmol Vis Sci 2001; 42:1444.",
"     </a>",
"    </li>",
"    <li>",
"     Tesser RA, Hess DB, Buckley EG. Pediatric cataracts and lens anomalies. In: Harley's Pediatric Ophthalmology, 5th ed, Nelson LB, Olitsky SE (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. p.255.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/6\">",
"      Calhoun JH. Cataracts in children. Pediatr Clin North Am 1983; 30:1061.",
"     </a>",
"    </li>",
"    <li>",
"     Lambert SR. Controversies in the management of infantile cataract. In: Pediatric Ophthalmology, Neuro-Ophthalmology, Genetics, Lorenz B, Moore AT (Eds), Springer, New York 2006. p.81.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/8\">",
"      Jaafar MS, Robb RM. Congenital anterior polar cataract: a review of 63 cases. Ophthalmology 1984; 91:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/9\">",
"      Nelson LB, Calhoun JH, Simon JH, Harley RD. Progression of congenital anterior polar cataracts in childhood. Arch Ophthalmol 1985; 103:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/10\">",
"      M&uuml;llner-Eidenb&ouml;ck A, Amon M, Moser E, Klebermass N. Persistent fetal vasculature and minimal fetal vascular remnants: a frequent cause of unilateral congenital cataracts. Ophthalmology 2004; 111:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/11\">",
"      Paysse EA, McCreery KM, Coats DK. Surgical management of the lens and retrolenticular fibrotic membranes associated with persistent fetal vasculature. J Cataract Refract Surg 2002; 28:816.",
"     </a>",
"    </li>",
"    <li>",
"     Wright KW, Kohn T, Matsumoto E. Lens abnormalities. In: Pediatric Ophthalmology, Wright KW (Ed), Mosby, St. Louis 1995. p.367.",
"    </li>",
"    <li>",
"     Wilson ME, Trivedi RH, Pandey SK. Miscellaneous issues and views. In: Pediatric Cataract Surgery, Wilson ME, Trivedi RH, Pandey SK (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. p.293.",
"    </li>",
"    <li>",
"     Wilson ME, Trivedi RH, Pandey SK. Etiology and morphology of pediatric cataracts. In: Pediatric Cataract Surgery, Wilson ME, Trivedi RH, Pandey SK (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/15\">",
"      Taylor JB, Young WO, Rutar T. Posterior subcapsular cataracts in children receiving adrenocorticotropic hormone (ACTH) for infantile spasms. J Child Neurol 2010; 25:1017.",
"     </a>",
"    </li>",
"    <li>",
"     Radiational injuries, Part 2: Non-mechanical injury. In: System of Ophthalmology, Duke-Elder S (Ed), CV Mosby, St. Louis 1972. Vol XIV, p.878.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/17\">",
"      Hall P, Granath F, Lundell M, et al. Lenticular opacities in individuals exposed to ionizing radiation in infancy. Radiat Res 1999; 152:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/18\">",
"      Tongue AC, Cibis GW. Br&uuml;ckner test. Ophthalmology 1981; 88:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/19\">",
"      Lambert SR, Lynn MJ, Reeves R, et al. Is there a latent period for the surgical treatment of children with dense bilateral congenital cataracts? J AAPOS 2006; 10:30.",
"     </a>",
"    </li>",
"    <li>",
"     Wilson ME, Trivedi RH, Pandey SK. Preoperative workup. In: Pediatric Cataract Surgery, Wilson ME, Trivedi RH, Pandey SK (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. p.23.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/21\">",
"      Wiesel TN, Hubel DH. Comparison of the effects of unilateral and bilateral eye closure on cortical unit responses in kittens. J Neurophysiol 1965; 28:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/22\">",
"      Wiesel TN, Hubel DH. Extent of recovery from the effects of visual deprivation in kittens. J Neurophysiol 1965; 28:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/23\">",
"      Lambert SR, Taylor D, Kriss A, et al. Ocular manifestations of the congenital varicella syndrome. Arch Ophthalmol 1989; 107:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/24\">",
"      Wolff SM. The ocular manifestations of congenital rubella. Trans Am Ophthalmol Soc 1972; 70:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/25\">",
"      Good WV. Cataract surgery in young children. Br J Ophthalmol 2001; 85:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/26\">",
"      Crawford JS. Conservative management of cataracts. Int Ophthalmol Clin 1977; 17:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/27\">",
"      Lambert SR, Plager DA, Lynn MJ, Wilson ME. Visual outcome following the reduction or cessation of patching therapy after early unilateral cataract surgery. Arch Ophthalmol 2008; 126:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/28\">",
"      Hiles DA, Biglan AW. Indications for infantile cataract surgery. Int Ophthalmol Clin 1977; 17:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/29\">",
"      Cheng KP, Hiles DA, Biglan AW, Pettapiece MC. Visual results after early surgical treatment of unilateral congenital cataracts. Ophthalmology 1991; 98:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/30\">",
"      Drummond GT, Scott WE, Keech RV. Management of monocular congenital cataracts. Arch Ophthalmol 1989; 107:45.",
"     </a>",
"    </li>",
"    <li>",
"     Ahmadieh H, Ja'farinasab MR. Postoperative medications and follow-up. In: Pediatric Cataract Surgery, Wilson ME, Trivedi RH, Pandey SK (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. p.105.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/32\">",
"      Infant Aphakia Treatment Study Group, Lambert SR, Buckley EG, et al. A randomized clinical trial comparing contact lens with intraocular lens correction of monocular aphakia during infancy: grating acuity and adverse events at age 1 year. Arch Ophthalmol 2010; 128:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/33\">",
"      Repka MX. Monocular infantile cataract: treatment is worth the effort. Arch Ophthalmol 2010; 128:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/34\">",
"      Beck AD, Freedman SF, Lynn MJ, et al. Glaucoma-related adverse events in the Infant Aphakia Treatment Study: 1-year results. Arch Ophthalmol 2012; 130:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/35\">",
"      Hiles DA. Visual rehabilitation of aphakic children. III. Intraocular lenses. Surv Ophthalmol 1990; 34:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/36\">",
"      Wilson ME, Bluestein EC, Wang XH. Current trends in the use of intraocular lenses in children. J Cataract Refract Surg 1994; 20:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/37\">",
"      Larsen JS. The sagittal growth of the eye. 3. Ultrasonic measurement of the posterior segment (axial length of the vitreous) from birth to puberty. Acta Ophthalmol (Copenh) 1971; 49:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/38\">",
"      SORSBY A, SHERIDAN M. The eye at birth: measurement of the principal diameters in forty-eight cadavers. J Anat 1960; 94:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/39\">",
"      Spierer A, Desatnik H, Blumenthal M. Refractive status in children after long-term follow up of cataract surgery with intraocular lens implantation. J Pediatr Ophthalmol Strabismus 1999; 36:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/40\">",
"      Gordon RA, Donzis PB. Refractive development of the human eye. Arch Ophthalmol 1985; 103:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/41\">",
"      Greenwald MJ, Glaser SR. Visual outcomes after surgery for unilateral cataract in children more than two years old: posterior chamber intraocular lens implantation versus contact lens correction of aphakia. J AAPOS 1998; 2:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/42\">",
"      BenEzra D, Cohen E, Rose L. Traumatic cataract in children: correction of aphakia by contact lens or intraocular lens. Am J Ophthalmol 1997; 123:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/43\">",
"      Plager DA, Lynn MJ, Buckley EG, et al. Complications, adverse events, and additional intraocular surgery 1 year after cataract surgery in the infant Aphakia Treatment Study. Ophthalmology 2011; 118:2330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/44\">",
"      Jensen AA, Basti S, Greenwald MJ, Mets MB. When may the posterior capsule be preserved in pediatric intraocular lens surgery? Ophthalmology 2002; 109:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/45\">",
"      Kohnen T. Visual axis opacification after pediatric intraocular lens implantation. J Cataract Refract Surg 2001; 27:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/46\">",
"      Apple DJ, Solomon KD, Tetz MR, et al. Posterior capsule opacification. Surv Ophthalmol 1992; 37:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/47\">",
"      Hosal BM, Biglan AW. Risk factors for secondary membrane formation after removal of pediatric cataract. J Cataract Refract Surg 2002; 28:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/48\">",
"      Brady KM, Atkinson CS, Kilty LA, Hiles DA. Cataract surgery and intraocular lens implantation in children. Am J Ophthalmol 1995; 120:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/49\">",
"      Rabiah PK. Frequency and predictors of glaucoma after pediatric cataract surgery. Am J Ophthalmol 2004; 137:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/50\">",
"      Swamy BN, Billson F, Martin F, et al. Secondary glaucoma after paediatric cataract surgery. Br J Ophthalmol 2007; 91:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/51\">",
"      Chen TC, Walton DS, Bhatia LS. Aphakic glaucoma after congenital cataract surgery. Arch Ophthalmol 2004; 122:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/52\">",
"      Chrousos GA, Parks MM, O'Neill JF. Incidence of chronic glaucoma, retinal detachment and secondary membrane surgery in pediatric aphakic patients. Ophthalmology 1984; 91:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/53\">",
"      Peterseim MW, Wilson ME. Bilateral intraocular lens implantation in the pediatric population. Ophthalmology 2000; 107:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/54\">",
"      Mistr SK, Trivedi RH, Wilson ME. Preoperative considerations and outcomes of primary intraocular lens implantation in children with posterior polar and posterior lentiglobus cataract. J AAPOS 2008; 12:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22761/abstract/55\">",
"      Spierer A, Desatnik H, Rosner M, Blumenthal M. Congenital cataract surgery in children with cataract as an isolated defect and in children with a systemic syndrome: a comparative study. J Pediatr Ophthalmol Strabismus 1998; 35:281.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6270 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-125.39.66.147-DB4EA05A22-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_14_22761=[""].join("\n");
var outline_f22_14_22761=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hereditary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Disease-associated",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Ocular trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Ionizing radiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Natural history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Referral indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Cataract extraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Post-operative care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Optical and visual rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Aphakic contact lens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Intraocular lens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      POST-OPERATIVE COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Clinical features and evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Management and outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6270\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6270|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/6/2150\" title=\"figure 1\">",
"      Cross section of the eye",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/4/33859\" title=\"figure 2\">",
"      Location of cataracts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/47/32506\" title=\"figure 3\">",
"      Red reflex interpretation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6270|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/29/29136\" title=\"picture 1\">",
"      Mature cataract 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/50/42784\" title=\"picture 2\">",
"      Anterior polar cataract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/26/21922\" title=\"picture 3\">",
"      Persist fetal vasculature",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/55/36721\" title=\"picture 4\">",
"      Posterior lenticonus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/38/19042\" title=\"picture 5\">",
"      Nuclear cataract 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/53/12112\" title=\"picture 6\">",
"      Traumatic cataract 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/45/1745\" title=\"picture 7\">",
"      Hypopyon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6270|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/47/15100\" title=\"table 1\">",
"      Cataract classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/21/30045\" title=\"table 2\">",
"      Disorders with cataracts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/12/6348\" title=\"table 3\">",
"      Visual behavior infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/31/32254\" title=\"table 4\">",
"      Exam childhood cataracts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5496?source=related_link\">",
"      Approach to the child with leukocoria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24873?source=related_link\">",
"      Bacterial endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/19/2362?source=related_link\">",
"      Cataract in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41800?source=related_link\">",
"      Causes of horizontal strabismus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=related_link\">",
"      Clinical features and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30886?source=related_link\">",
"      Clinical features and diagnosis of galactosemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=related_link\">",
"      Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=related_link\">",
"      Congenital cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8487?source=related_link\">",
"      Craniosynostosis syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41557?source=related_link\">",
"      Ectopia lentis (dislocated lens) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40889?source=related_link\">",
"      Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=related_link\">",
"      Evaluation and management of strabismus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=related_link\">",
"      Major side effects of inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8745?source=related_link\">",
"      Open globe injuries: Emergent evaluation and initial management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28041?source=related_link\">",
"      Overview of TORCH infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8153?source=related_link\">",
"      Overview of amblyopia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41463?source=related_link\">",
"      Overview of glaucoma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/62/6114?source=related_link\">",
"      Patient information: Cataracts (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=related_link\">",
"      Peroxisomal disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=related_link\">",
"      Physical abuse in children: Diagnostic evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=related_link\">",
"      Physical abuse in children: Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/41/36504?source=related_link\">",
"      Retinal detachment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/15/250?source=related_link\">",
"      Syndromes with craniofacial abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=related_link\">",
"      Visual development and vision assessment in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_14_22762="Fever without a source in children 3 to 36 months of age";
var content_f22_14_22762=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fever without a source in children 3 to 36 months of age",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/14/22762/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/14/22762/contributors\">",
"     Coburn H Allen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/14/22762/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/14/22762/contributors\">",
"     Gary R Fleisher, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/14/22762/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/14/22762/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/14/22762/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/14/22762/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever is a common symptom among children seeking medical care. Most children undergo evaluation for a febrile illness before their third birthday, and nearly one-third of pediatric outpatient visits are for fever [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the history and physical examination cannot identify a specific source of fever in an acutely ill, nontoxic-appearing child less than three years of age, the illness is often called fever without a source (FWS). Alternative terms are fever without localizing signs (FWLS) or fever without a focus.",
"   </p>",
"   <p>",
"    This topic will review the etiology, evaluation, and management of the child 3 to 36 months of age with fever of less than seven days duration. Fever in newborns, infants younger than three months, and fever of unknown origin (&ge;7 days) are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28074?source=see_link\">",
"     \"Evaluation and management of fever in the neonate and young infant (less than three months of age)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9706?source=see_link\">",
"     \"Approach to the child with fever of unknown origin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38905?source=see_link\">",
"     \"Etiologies of fever of unknown origin in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Fever of concern",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children 3 to 36 months of age, the diagnosis of fever is based upon core temperature, which is measured most accurately rectally. The history of an elevated temperature recorded at home should be considered equivalent to that taken in a medical facility. Fever 39&ordm;C (102.2&ordm;F) or higher is the threshold above which evaluation for a source of occult infection, including urinary tract infection (UTI), may be warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Occult sources of infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The majority of children with fever have either a self-limited viral infection or a recognizable source of bacterial infection. However, research in the 1970s identified a population of well-appearing febrile young children who had occult bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Subsequent studies demonstrated that some of these children went on to develop serious focal bacterial infections, such as pneumonia and meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Although laboratory testing identified a group of children at an increased risk for occult bacteremia, many who were not bacteremic received presumptive treatment with broad spectrum antibiotics while awaiting definitive blood culture results.",
"   </p>",
"   <p>",
"    The introduction of vaccines to prevent Haemophilus influenzae type b (Hib) and pneumococcal disease has dramatically lowered the incidence of occult bacteremia and, as a result, changed the issues facing the clinician who is evaluating a young child with fever. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Impact of vaccines'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Population of interest",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic will focus on the evaluation and management of well-appearing, immunocompetent children 3 to 36 months of age with fever &ge;39&ordm;C (102.2&ordm;F) of less than seven days duration and no focus of infection identified by a complete physical examination. The evaluation of the febrile infant younger than three months is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28074?source=see_link\">",
"     \"Evaluation and management of fever in the neonate and young infant (less than three months of age)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Immunization status",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the child who has fever without a source is greatly determined by immunization status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Complete immunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the discussion that follows, a completely immunized child has received the primary booster series of three immunizations with conjugate vaccines Streptococcus pneumoniae (PCV7 or PCV13), at least two doses of Haemophilus influenzae, type b (Hib), and remains on schedule. However, some experts consider two doses of PCV7 or PCV13 sufficient to prevent invasive Streptococcus pneumoniae infection. Patients who have not received the booster 12 to 15 months after the third Hib and either PCV7 or PCV13 are also considered to be at much lower risk of bacteremia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link&amp;anchor=H12#H12\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Alternative or abbreviated schedule'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Incomplete immunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the discussion that follows, an incompletely immunized child has not received the primary booster series of three vaccinations with both Hib and either PCV7 or PCV13. Based on these criteria, any child under six months of age is incompletely immunized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CAUSES OF FEVER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever can be caused by infectious and noninfectious processes. The vast majority of young children with fever have an infectious etiology. Noninfectious etiologies include drug fever, immunization reactions, central nervous system dysfunction, malignancy (eg, leukemia), and chronic inflammatory conditions (ie, inflammatory bowel disease and juvenile idiopathic arthritis).",
"   </p>",
"   <p>",
"    Although caretakers may sometimes attribute fever to teething, fever &gt;38.5&ordm;C is unlikely to be caused by teething [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39590?source=see_link&amp;anchor=H10#H10\">",
"     \"Anatomy and development of the teeth\", section on 'Primary teeth eruption'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The source of fever may be a recognizable bacterial or viral illness. In a study of a large cohort of children 3 to 36 months of age presenting to a primary care provider with a febrile illness, a readily identifiable presumed bacterial illness was diagnosed at the initial encounter in 56 percent of children, almost 90 percent of whom had otitis media [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/1\">",
"     1",
"    </a>",
"    ]. A specific viral infection (eg, croup, bronchiolitis, varicella, roseola) was identified in an additional 4 percent of children [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/1\">",
"     1",
"    </a>",
"    ]. Similarly, 6 percent of 21,216 children 3 to 36 months of age with fever &ge;39&ordm;C seen in the emergency department of an urban tertiary care children's hospital had a recognizable viral syndrome, 47 percent had FWS, and 47 percent had a specific bacterial infection requiring antibiotics or chronic illness (eg, immunocompromised state, central line) that affected the fever evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serious bacterial infectious syndromes that occur in children 3 to 36 months of age include meningitis, pneumonia, and cellulitis. In one series (prior to the introduction of Hib and pneumococcal conjugate vaccines) of 996 febrile children less than 36 months of age, &lt;1 percent had meningitis, 10 percent had focal soft tissue infections, and 30 percent had pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/11\">",
"     11",
"    </a>",
"    ]. These diagnoses are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=see_link\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link\">",
"     \"Cellulitis and erysipelas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OCCULT SOURCES OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of the evaluation of a young child with fever is to identify sources of infection that require further evaluation and definitive treatment. Such infections are usually bacterial, although the majority of children who are well-appearing and have no identifiable source of infection have a nonspecific self-limited viral illness [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/1,12\">",
"     1,12",
"    </a>",
"    ]. The remainder of this discussion will focus on occult bacterial infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children with fever and pneumonia have some abnormality on physical examination: usually tachypnea, abnormal auscultation, or nasal flaring, suggesting respiratory tract disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. However, a reliable physical examination in a young child can be a challenge. In an observational study, radiographic pneumonia was found in 20 to 30 percent of highly febrile young children (&lt;5 years) without clinical evidence of pneumonia, but with a white blood cell count (WBC)",
"    <span class=\"nowrap\">",
"     &ge;20,000/mm3",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/16\">",
"     16",
"    </a>",
"    ]. Similarly, another observational study demonstrated that 41 percent of children between 3 and 36 months of age with a WBC",
"    <span class=\"nowrap\">",
"     &gt;25,000/mm3",
"    </span>",
"    had lobar or segmental pneumonia on chest radiograph [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/17\">",
"     17",
"    </a>",
"    ]. This association between leukocytosis and pneumonia remains strong, even in the post-conjugate pneumococcal vaccine era [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Urinary tract infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urinary tract is the most common site of bacterial infection among febrile infants and young children. This finding was demonstrated in two large prospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The prevalence of UTI in these reports was significantly influenced by demographic factors, such as sex, age, race, and circumcision status (",
"    <a class=\"graphic graphic_table graphicRef76804 \" href=\"UTD.htm?0/16/269\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26360?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology and risk factors for urinary tract infections in children\", section on 'Host factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of UTI is highest among girls and warrants urinalysis and urine culture in all females age 3 to 24 months with fever &ge;39&ordm;C (102.2&ordm;F) and no source (",
"      <a class=\"graphic graphic_table graphicRef76804 \" href=\"UTD.htm?0/16/269\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Among boys, UTI is increased in uncircumcised compared with circumcised male infants with fever, with the greatest incidence in infants younger than three months of age (",
"      <a class=\"graphic graphic_table graphicRef76804 \" href=\"UTD.htm?0/16/269\">",
"       table 1",
"      </a>",
"      ). The low incidence of UTI among circumcised boys supports the practice of not routinely obtaining a catheterized urine specimen for culture in febrile, circumcised boys over six months of age.",
"     </li>",
"     <li>",
"      Among highly febrile boys (ie, temperature &ge;39&ordm;C or 102.2&ordm;F) who are 3 to 24 months with no source of infection, the probability of UTI is 10 to 25 percent in uncircumcised and 2 to 4 percent in circumcised [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/20\">",
"       20",
"      </a>",
"      ]. The highest prevalence is found in younger boys. Furthermore, bladder catheterization is a painful, invasive procedure that many parents might prefer to avoid if their child's probability of disease is less than 5 percent. Thus, our practice is to evaluate for UTI in uncircumcised males &le;12 months and circumcised males &le;6 months. Some investigators suggest that high fever (ie, &ge;39&ordm;C or 102.2&ordm;F) without a source is sufficient justification for urine studies on the first visit in all highly febrile boys between the age of 3 and 24 months [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/21\">",
"       21",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Initial approach'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26360?source=see_link\">",
"       \"Epidemiology and risk factors for urinary tract infections in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacteremia that occurs in a seriously ill patient with a focal infection, such as meningitis, septic arthritis, or cellulitis, is usually readily identified. The risk of sepsis in a child who is ill-appearing, febrile, and without an obvious source of infection is also apparent. This discussion will focus on the young febrile child who looks well and may have unsuspected, or occult, bacteremia.",
"   </p>",
"   <p>",
"    Before routine immunization with Hib and either PCV7 or PCV13, the prevalence of occult bacteremia was 5 percent in well-appearing febrile children [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The predominant pathogens were S. pneumoniae (80 percent) and Hib (20 percent). Neisseria meningitidis represented a small number of cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Predictors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors associated with an increased the risk of occult bacteremia in unimmunized children to over 10 percent included [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age 3 to 36 months",
"     </li>",
"     <li>",
"      Fever &ge;39&ordm;C",
"     </li>",
"     <li>",
"      WBC",
"      <span class=\"nowrap\">",
"       &ge;15,000/microL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neither response to antipyretics nor clinical appearance predicted bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/25-27\">",
"     25-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some children with bacteremia went on to have serious bacterial infections (SBI), including meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/7,28\">",
"     7,28",
"    </a>",
"    ]. When children at risk for bacteremia were treated empirically with antibiotics until the results of blood cultures were known, they were less likely to develop these complications [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/22,23,29\">",
"     22,23,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Impact of vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initiation of routine immunization of infants with the conjugate vaccines for Hib and S. pneumoniae has dramatically altered the prevalence of invasive disease due to these organisms. The incidence of occult bacteremia in well-appearing febrile children has fallen from 5 to below 1 percent, while the rate of isolation of a contaminant from blood cultures has remained constant at 1.8 to 3.0 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/15,30-37\">",
"     15,30-37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link&amp;anchor=H9#H9\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Invasive disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42489?source=see_link&amp;anchor=H7#H7\">",
"     \"Prevention of Haemophilus influenzae infection\", section on 'Efficacy/effectiveness'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since the routine immunization of children with PCV7 or PCV13 vaccine, pathogens other than S. pneumoniae are the cause of the majority of cases of unsuspected bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/32\">",
"     32",
"    </a>",
"    ]. E. coli and Staphylococcus aureus are frequently isolated organisms. Most reports of occult bacteremia also include cases caused by N. meningitidis, Group A streptococcus, and Salmonella species [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/32,38\">",
"     32,38",
"    </a>",
"    ]. Laboratory parameters (ie, WBC",
"    <span class=\"nowrap\">",
"     &gt;15,000/microL)",
"    </span>",
"    may be less reliable predictors of bacteremia with these pathogens. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'WBC and ANC counts'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition, the impact of PCV7 or PCV13 on variables, such as the role of nonvaccine serotypes in invasive pneumococcal disease and the duration and durability of protection after vaccination, continues to evolve. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link&amp;anchor=H9#H9\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Invasive disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/601?source=see_link&amp;anchor=H9889776#H9889776\">",
"     \"Impact of universal infant immunization with pneumococcal (Streptococcus pneumoniae) conjugate vaccines in the United States\", section on 'Invasive disease caused by non-vaccine serotypes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the decreased prevalence of occult bacteremia in the post-conjugate vaccine era, a less aggressive approach to the management of completely immunized, well-appearing, febrile (&ge;39&ordm;C) children 3 to 36 months of age who do not have a focal source of infection appears reasonable [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/34,39,40\">",
"     34,39,40",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Initial approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A cost-effectiveness decision analysis of evaluation and management strategies for FWS in the post-conjugate vaccine era considered negative aspects of diagnostic testing and treatment and used cases of meningitis and lives saved as outcome measures [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/41\">",
"     41",
"    </a>",
"    ]. The management strategies evaluated were no work-up, clinical judgment, blood culture, blood culture plus antibiotics, WBC plus blood culture and antibiotics, and WBC plus selective blood culture and antibiotics. The following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assuming a rate of pneumococcal bacteremia of &gt;1.5 percent, WBC plus selective blood culture and antibiotics was the most cost-effective approach.",
"     </li>",
"     <li>",
"      With a rate of pneumococcal bacteremia &lt;0.5 percent, strategies that utilized empiric testing and treatment were no longer cost-effective.",
"     </li>",
"     <li>",
"      At low rates of bacteremia, clinical judgment became more useful in selecting a high-risk population that might benefit from selective testing and treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of the evaluation of the young, well-appearing, febrile child without an apparent source of infection is to identify a subtle bacterial infection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the risk of a more serious occult bacterial infection, both of which require further investigation and antibiotic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historical features of a febrile illness that suggest an occult source of infection may be subtle and not immediately obvious to the caretakers. Therefore, a thorough history must include information about the child's functional status, including oral intake, presence of irritability or lethargy, and associated symptoms. The duration of fever appears to be a poor predictor of unsuspected bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific questions regarding cough, vomiting, or change in activity should be included. As an example, children with pneumonia may have cough or tachypnea noted by a caretaker. Signs or symptoms of UTI (eg, dysuria, frequency, abdominal pain, back pain, new onset incontinence), should be specifically sought. Likewise, vomiting, with or without diarrhea, can occur in young children with UTI, and caretakers occasionally note that the urine is foul-smelling, although these symptoms are nonspecific. Finally, a young child with a deep soft tissue or bone infection may protect the affected area.",
"   </p>",
"   <p>",
"    A careful history must identify any known underlying medical condition that increases the child's risk for serious infection, such as sickle cell disease or urinary tract reflux. In addition, the immunization history will greatly influence the subsequent evaluation, since the child who is incompletely immunized is at greater risk for occult bacteremia than the one who is completely immunized. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Immunization status'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H7\">",
"     'Incomplete immunization'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The child who is being evaluated for a subtle infection or fever without a source should be well-appearing. Febrile children who are acutely ill with symptoms, such as lethargy, poor perfusion, hypoventilation or hyperventilation, and cyanosis are said to appear toxic or septic. They are considered to have a significant bacterial infection until proven otherwise. Cultures of blood, urine, and CSF, when meningitis is suspected, should be obtained, intravenous fluid provided, antibiotic therapy initiated, and admission to the hospital arranged. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Ill-appearing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Attention to abnormal vital signs and a thorough physical examination may identify a source of infection. Specific features to note include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tachycardia, tachypnea, or pulse oximetry &le;95 percent",
"     </li>",
"     <li>",
"      Lesions in the oropharynx that may identify a recognizable viral illness, such as herpes gingivostomatitis (anterior ulcers) or Coxsackie virus (pharyngeal vesicles) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30216?source=see_link&amp;anchor=H21#H21\">",
"       \"Soft tissue lesions of the oral cavity in children\", section on 'Infections'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34585?source=see_link\">",
"       \"Clinical manifestations and diagnosis of enterovirus and parechovirus infections\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/27/31160?source=see_link&amp;anchor=H7#H7\">",
"       \"Herpetic gingivostomatitis in young children\", section on 'Clinical features'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Increased work of breathing indicated by nasal flaring, retractions or use of accessory muscle, or focal lung findings, such as rales or decreased breath sounds",
"     </li>",
"     <li>",
"      Abdominal tenderness",
"     </li>",
"     <li>",
"      Pain with bone palpation or passive joint range of motion",
"     </li>",
"     <li>",
"      Skin findings, such as petechiae, cellulitis, or viral exanthem",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing in febrile children 3 to 36 months of age has been used to screen for the risk of bacterial infection as well as to diagnose specific infections. The decision to perform laboratory tests depends upon a variety of factors including age, immunization status, and obvious findings of infection (eg, otitis media, bronchiolitis, croup).",
"   </p>",
"   <p>",
"    Recommendations regarding when to obtain specific tests are provided below. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Initial approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     WBC and ANC counts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have identified an increased risk of occult pneumococcal bacteremia among unimmunized children with WBC",
"    <span class=\"nowrap\">",
"     &ge;15,000/microL",
"    </span>",
"    and absolute neutrophil count (ANC)",
"    <span class=\"nowrap\">",
"     &ge;10,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/32,43-45\">",
"     32,43-45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single center, prospective observational study of 1911 children, 3 to 36 months of age, who had fever without a source &ge;39&ordm;C (102.2&ordm;F) and performed after introduction of Hib found that a WBC",
"      <span class=\"nowrap\">",
"       &ge;15,000/microL",
"      </span>",
"      had a sensitivity of 86 percent and a specificity of 77 percent for occult bacteremia [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/43\">",
"       43",
"      </a>",
"      ]. The frequency of bacteremia in these patients was 1.5 percent",
"      <span class=\"nowrap\">",
"       (149/1911).",
"      </span>",
"     </li>",
"     <li>",
"      A multicenter, prospective observational study of 6579 children, 3 to 36 months of age, who had fever without a source &ge;39&ordm;C (102.2&ordm;F) and performed after introduction of Hib found that a WBC",
"      <span class=\"nowrap\">",
"       &ge;15,000/microL",
"      </span>",
"      had a sensitivity of 80 percent and a specificity of 69 percent for occult bacteremia, and an ANC",
"      <span class=\"nowrap\">",
"       &ge;10,000/microL",
"      </span>",
"      had a sensitivity of 76 percent with a specificity of 78 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/44\">",
"       44",
"      </a>",
"      ]. In multivariate logistic regression analysis, ANC was an independent predictor of bacteremia with adjusted OR 1.15 (95% CI 1.06-1.25) for each 1000",
"      <span class=\"nowrap\">",
"       cells/mm3",
"      </span>",
"      increase in the ANC. The frequency of bacteremia in this sample was 2.5 percent.",
"     </li>",
"     <li>",
"      A multicenter retrospective observational study of 41,948 children, age 3 to 36 months, who had blood cultures performed after introduction of Hib and PCV7, found that a WBC",
"      <span class=\"nowrap\">",
"       &le;15,000/microL",
"      </span>",
"      had a negative predictive value of 99.5 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/32\">",
"       32",
"      </a>",
"      ]. In this study, the frequency of bacteremia (1.6 percent) was less than blood culture contamination (1.8 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these studies suggest that a WBC",
"    <span class=\"nowrap\">",
"     &gt;15,000/microL,",
"    </span>",
"    while not ideal in screening for occult bacteremia, is helpful in determining which incompletely immunized children deserve blood culture and treatment in the post-conjugate vaccine era. However, these reports and others also have demonstrated that an elevated WBC, by itself, has both limited sensitivity and specificity as an indicator of SBI, particularly as other pathogens, such as S. aureus become more prominent isolates in children with bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/32,46\">",
"     32,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Urine tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies and two meta-analyses have evaluated screening tests for UTI [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. In general, urine screening tests markedly improve the ability to detect UTI, but a urine culture should be sent in all young children in whom catheterized urine is obtained. The usefulness of various urine screening tests (dipstick, Gram stain, and microscopy) is summarized in the table and discussed elsewhere (",
"    <a class=\"graphic graphic_table graphicRef82157 \" href=\"UTD.htm?27/28/28109\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21129?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features and diagnosis of urinary tract infections in infants and children older than one month\", section on 'Rapidly available tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of a SBI is often made with cultures, although the inherent delay between the initial evaluation of the patient and the availability of culture results complicates decisions regarding empiric antibiotic therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood &ndash; Continuously monitored blood culture systems have decreased the length of time for a blood culture to turn positive. The mean time to positive blood cultures for pathogens is approximately 15 hours, compared with 31 hours for contaminants [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Urine &ndash; For the diapered child, urine for culture should be collected by catheterization, or in exceptional cases (eg, tight phimosis), suprapubic aspiration. Bag specimens should not be sent for culture because they are frequently contaminated. A clean catch is the preferred method of urine collection for culture in the child who is toilet-trained. The culture definition of UTI is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42886?source=see_link\">",
"       \"Urine collection techniques in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21129?source=see_link&amp;anchor=H17#H17\">",
"       \"Clinical features and diagnosis of urinary tract infections in infants and children older than one month\", section on 'Diagnosis of UTI'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      CSF &ndash; Children who are being evaluated for fever without a source should be well-appearing and therefore, not require lumbar puncture. That being said, CSF should be obtained from any patient with suspected meningitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'Course'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;A chest radiograph should be obtained in patients with tachypnea, respiratory distress, or oxygen saturation &le;95 percent. In addition, chest radiograph is suggested in children with WBC",
"    <span class=\"nowrap\">",
"     &gt;20,000/microL",
"    </span>",
"    even in the absence of these findings. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Pneumonia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Inflammatory mediators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary evidence suggests that elevations in levels of inflammatory mediators (ie, C-reactive protein and procalcitonin) may be better markers of SBI than WBC and ANC in children at significant risk for bacterial infection, although the usefulness of these tests in practice is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      C-reactive protein (CRP) is an acute phase reactant released by the liver following inflammation or tissue damage. Observational studies that have evaluated CRP as a screening tool for occult bacterial infection report a wide range of sensitivity and specificity that vary by cutoff levels used to identify infants and children with SBI [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/51-55\">",
"       51-55",
"      </a>",
"      ]. In addition, CRP concentrations generally do not increase until 12 hours after the onset of fever and can rise in both viral and bacterial infections [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Procalcitonin (PCT) levels rise in response to bacterial infections more rapidly than those of CRP. Limited preliminary data suggest that PCT levels may be more sensitive and specific markers for severe invasive bacterial infection in infants and children than WBC, ANC, and CRP [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/55-60\">",
"       55-60",
"      </a>",
"      ]. However, in most clinical settings, PCT has limited availability.",
"     </li>",
"     <li>",
"      A meta-analysis of five studies (1379 febrile children up to 36 months of age, including infants younger than three months) found that the diagnostic accuracy of C-reactive protein and procalcitonin were comparable for serious infection [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/61\">",
"       61",
"      </a>",
"      ]. The optimal values for identifying a high risk of serious infection were &ge;80",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      for C-reactive protein and &ge;2",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      for procalcitonin (sensitivity 40 to 50 percent, specificity 90 percent for each). Alternatively, the best values suggesting a low risk for serious infection were &lt;20",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      for C-reactive protein and &lt;0.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      for procalcitonin (sensitivity &gt;80 percent, specificity 70 percent for both).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, the evidence suggests that CRP and PCT are equivalent with respect to diagnostic accuracy. However, CRP is much more widely available than PCT and is thus more useful in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     INITIAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation and management of the febrile child 3 to 36 months of age without a source of infection must balance the consequences of not diagnosing a SBI with the decreasing prevalence of occult infection and the potential adverse effects of excessive testing and treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/40\">",
"     40",
"    </a>",
"    ]. Burdens of testing and expectant antibiotic therapy include false-positive results, adverse reactions to antibiotics, and, possibly, the effect of widespread antibiotic use on patterns of antibiotic resistance. The likelihood of SBI varies significantly by clinical appearance, age, and immunization status. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Occult sources of infection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Well-appearing children 3 to 36 months of age, with fever &ge;39&ordm;C (102.2&ordm;F), who have no underlying medical condition that would alter susceptibility to infection, and no focus of infection identified by a complete physical examination, are hereafter referred to as children with FWS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Ill-appearing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who are ill-appearing or have unstable vital signs should be fully evaluated for serious infection with cultures of blood, urine, and, when meningitis is suspected, CSF. Those with tachypnea or leukocytosis",
"    <span class=\"nowrap\">",
"     (&gt;20,000/microL)",
"    </span>",
"    should have a chest radiograph. These patients should receive parenteral antibiotic therapy targeting the likely pathogens in this age group (S. pneumoniae, S. aureus, N. meningitidis, H. influenzae type b) and be admitted to the hospital.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Well-appearing",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Immunization incomplete",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of occult bacteremia in incompletely immunized children is estimated to be as high as 5 percent (ie, what it was during the preconjugate vaccine era); the actual risk is probably somewhat lower because of \"herd immunity.\" (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Immunization status'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H14\">",
"     'Impact of vaccines'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Strategies for the evaluation and management of these children reflect the increased risk of bacteremia compared with completely immunized children and are drawn from experience and guidelines developed during the preconjugate vaccine era [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/4,29,30,32,43,49,62,63\">",
"     4,29,30,32,43,49,62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest the following approach to evaluation of these children:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CBC with differential.",
"     </li>",
"     <li>",
"      Blood culture should be obtained if the WBC is",
"      <span class=\"nowrap\">",
"       &ge;15,000/microL.",
"      </span>",
"      As a practical matter, the blood culture may be drawn with the CBC and sent if the WBC is",
"      <span class=\"nowrap\">",
"       &ge;15,000/microL.",
"      </span>",
"      Recognizing that WBC is not an ideal screening tool, some clinicians may prefer to always send a blood culture in these patients [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/32,38,41\">",
"       32,38,41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Urinalysis, and urine culture by bladder catheterization or in exceptional cases (eg, tight phimosis), suprapubic aspiration.",
"     </li>",
"     <li>",
"      Chest radiograph in children with WBC",
"      <span class=\"nowrap\">",
"       &ge;20,000/microL.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children with an abnormal urinalysis should be treated for a urinary tract infection, although in questionable cases awaiting results of urine culture represents a reasonable alternative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27674?source=see_link&amp;anchor=H2#H2\">",
"     \"Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend that children with FWS who are incompletely immunized who have a WBC",
"    <span class=\"nowrap\">",
"     &ge;15,000/microL",
"    </span>",
"    receive parenteral antibiotic therapy pending blood and urine cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/4,41\">",
"     4,41",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     Ceftriaxone",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    intramuscularly) is preferred because of its antimicrobial spectrum and prolonged duration of action.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"     Clindamycin",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    intravenously followed by oral clindamycin eight hours later) is one alternative for patients allergic to cephalosporins. Outpatient follow-up should occur within 24 hours. Patients in whom outpatient follow-up is uncertain should be admitted.",
"   </p>",
"   <p>",
"    This strategy of selective treatment of high-risk children with FWS and WBC",
"    <span class=\"nowrap\">",
"     &ge;15,000/microL",
"    </span>",
"    is in agreement with the practice guidelines of the American Academy of Pediatrics and the American College of Emergency Physicians for children with FWS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/4,64,65\">",
"     4,64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Support for treating patients 3 to 36 months of age with FWS and significant risk of bacteremia with empiric parenteral antibiotics is derived from meta-analyses and randomized trials performed before the routine availability of Hib, PCV7, and PCV13 conjugate vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/22,23,29\">",
"     22,23,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of four randomized controlled trials of 7899 children, age 3 to 36 months, who had a fever &ge;39&deg;C (102.2&ordm;F), found that treatment of occult bacteremia with IM",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      reduced the chance of serious bacterial infections by approximately 75 percent (Number needed to treat (NNT) 17; OR 0.25; 95% CI 0.07-0.89) and that oral antibiotics were not effective [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis of prospective and retrospective studies of children age 3 to 36 months with fever without a source and bacteremia found that the mean probability of subsequent meningitis was 8.2 percent (all H. influenzae, type b) in patients treated with oral antibiotics and 0.3 percent in patients treated with parenteral antibiotics versus 9.8 percent in untreated children. No child treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      developed culture-positive meningitis (0.3 percent; 95% CI 0.0-1.5 percent). The authors concluded that antibiotic therapy is effective in preventing meningitis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized, double blind, placebo controlled trial of 955 children between the ages of 3 to 36 months with fever &ge;39&ordm;C (102.2&ordm;F) demonstrated no difference in major infectious morbidity between bacteremic children receiving oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"       amoxicillin",
"      </a>",
"      (2 of 19) or placebo (1 of 8). The incidence of diarrhea was 15 percent in children receiving amoxicillin versus 11 percent in the placebo group (p = 0.10) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/23\">",
"       23",
"      </a>",
"      ]. The overall rate of bacteremia was 2.8 percent in this study.",
"     </li>",
"     <li>",
"      An unblinded, randomized controlled trial of 6733 children between the ages of 3 to 36 months with fever &ge;39&ordm;C (102.2&deg;F) also described an overall rate of bacteremia of 2.8 percent (195 of 6733) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/29\">",
"       29",
"      </a>",
"      ]. Five definitive focal infections (three meningitis, one pneumonia, and one sepsis) developed in the 3347 children receiving",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"       amoxicillin",
"      </a>",
"      versus none in those treated with IM",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (OR 0.0, 95% CI 0.0-0.5).",
"     </li>",
"     <li>",
"      An unblinded, randomized trial of 96 children, between 6 and 24 months of age with a temperature &gt;40&ordm;C (104&ordm;F), found that 4.3 percent of untreated patients (2 of 46) developed pneumococcal meningitis versus none of the 50 children treated with intramuscular aqueous",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/46/14054?source=see_link\">",
"       penicillin G",
"      </a>",
"      at the initial visit followed by oral penicillin for 10 days. Bacteremia was identified in 10.4 percent of all children [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Possible dermatologic adverse reactions were more commonly seen in the",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    group (8.7 versus 4.9 percent), but gastrointestinal complaints, such as diarrhea, were not different (14.5 versus 15.0 percent). No anaphylaxis was seen in either group.",
"   </p>",
"   <p>",
"    Taken together, these studies indicate that unimmunized children with FWS avoid progression of bacteremia to focal infections, especially meningitis, when treated with parenteral antibiotics. Given the increasing prevalence of penicillin resistant S. pneumoniae, intramuscular",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    remains a preferred parenteral agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Immunization complete",
"    </span>",
"    &nbsp;&mdash;&nbsp;A child with FWS who is completely immunized has a risk of bacteremia that is &lt;1 percent. Decision analysis suggests that at this low risk, laboratory evaluation and empiric antibiotic therapy do not significantly alter the likelihood of progression to focal bacterial infection and are not indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/41,67\">",
"     41,67",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Immunization status'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H14\">",
"     'Impact of vaccines'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, the risk of UTI as an occult source of infection remains substantial in fully immunized children, depending on age, gender, and circumcision status [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/40\">",
"     40",
"    </a>",
"    ]. This risk guides recommendations for evaluation and treatment in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For children over six months of age with FWS who are completely immunized, we suggest that girls less than 24 months of age and uncircumcised boys less than 12 months receive a urinalysis and urine culture. Urine for culture should be collected by catheterization or, in exceptional cases (eg, tight phimosis or severe labial adhesions), suprapubic aspiration. Bag specimens should not be sent for culture because they are frequently contaminated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42886?source=see_link\">",
"       \"Urine collection techniques in children\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H11\">",
"       'Urinary tract infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For girls &gt;24 months of age, uncircumcised boys &gt;12 months of age and circumcised boys &gt;6 months of age, all of whom have been completely immunized, we do not suggest routine laboratory evaluation or presumptive treatment with antibiotics. However, urinalysis and urine culture should be obtained in those with signs or symptoms of UTI, which must be specifically sought (eg, dysuria, frequency, abdominal pain, back pain, new onset incontinence). In addition, children with a prior history of UTI, urogenital anomalies, or prolonged fever (&gt;48 hours) warrant urinalysis and urine culture. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Urinary tract infection'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Some experts suggest that a high fever without a source (&gt;39&deg;C [102.2&deg;F]) is sufficient justification for urine culture on the first visit in uncircumcised boys 12 to 24 months of age (",
"      <a class=\"graphic graphic_algorithm graphicRef59396 \" href=\"UTD.htm?7/6/7268\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21129?source=see_link&amp;anchor=H10#H10\">",
"       \"Clinical features and diagnosis of urinary tract infections in infants and children older than one month\", section on 'Decision to obtain'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with FWS who are completely immunized against Hib and either PCV7 or PCV13, meet criteria for urine testing, and have an abnormal urinalysis should be treated for UTI. Appropriate follow-up should be arranged. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27674?source=see_link&amp;anchor=H2#H2\">",
"       \"Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month\", section on 'Overview'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the high risk for UTI and low risk for bacteremia among fully immunized children, evidence suggests that some emergency department (ED) clinicians may not utilize laboratory testing and antibiotic therapy appropriately when caring for these patients. As an example, between 2006 and 2008, estimates regarding laboratory testing and antibiotic treatment extrapolated from 1600 ED visits by fully immunized febrile children 6 to 36 months of age in the United States were as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/68\">",
"     68",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No testing was performed in 59 percent",
"     </li>",
"     <li>",
"      Complete blood counts were obtained in 21 percent",
"     </li>",
"     <li>",
"      Urine testing was",
"      <strong>",
"       not",
"      </strong>",
"      performed in an estimated 60 percent of girls with high fever",
"     </li>",
"     <li>",
"      Antibiotics were prescribed in an estimated 20 percent of patients in whom",
"      <strong>",
"       no",
"      </strong>",
"      testing was performed",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These estimates suggest that urine testing may be underutilized while measurement of complete blood count and antibiotic treatment may be overutilized in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up should be arranged within 24 hours for those children with FWS who have received parenteral antibiotics. Patients who are not treated with antibiotics should be instructed to seek medical attention within 48 hours if they have persistent fever.",
"   </p>",
"   <p>",
"    Careful instructions should be given to caretakers to return immediately if fever becomes higher, the patient looks sicker, or local symptoms or signs develop (eg, cough, diarrhea, cellulitis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Positive blood cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;An organism may not be identified definitively for 24 to 48 hours after the blood culture becomes positive, making management decisions difficult. The clinical appearance of the child and the Gram stain of the organism can be useful in deciding whether or not the child should be admitted to the hospital. Consultation with the microbiology laboratory personnel",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an infectious disease consultant may be helpful in narrowing the list of potential organisms and the likelihood that the findings represent a pathogen. Patients with a positive culture that is felt to be a pathogen should be reevaluated and managed according to appearance, persistence of fever, and specific isolate (",
"    <a class=\"graphic graphic_algorithm graphicRef81743 \" href=\"UTD.htm?13/59/14270\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The main goal is to identify and avoid progression to serious bacterial infection, especially meningitis:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     S. pneumoniae",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Febrile &ndash; In a retrospective observational study prior to PCV7 availability, 548 children with a blood culture positive for S. pneumoniae had outcomes examined. Children who were well, but persistently febrile at the revisit and did not receive antibiotics at the initial visit had a 33 to 42 percent chance of infection (primarily persistent bacteremia) and a 4.4 percent chance of meningitis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/63\">",
"       63",
"      </a>",
"      ]. Meningitis developed despite initial oral antibiotic therapy in 2 of 49 children (4 percent). Because of this high risk of SBI, patients with a blood culture positive for S. pneumoniae who are febrile on revisit should undergo a full sepsis evaluation (including lumbar puncture). They should also receive parenteral antibiotics tailored to the isolate's susceptibility or to the community susceptibility pattern for S. pneumoniae if the culture susceptibility is not yet available.",
"      <br/>",
"      <br/>",
"      These children may receive continued antibiotic therapy as an outpatient for 7 to 10 days with close follow-up if CSF findings show no evidence of meningitis. Antibiotic regimens should provide coverage for resistant S. pneumoniae. Possibilities include high dose oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"       amoxicillin",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose, three times daily; maximum dose: 3 grams daily), oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/26/34214?source=see_link\">",
"       amoxicillin-clavulanate",
"      </a>",
"      45",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose twice daily (maximum dose of amoxicillin: 3 grams daily), or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose three times daily in penicillin allergic patients.",
"     </li>",
"     <li>",
"      Afebrile &ndash; Well-appearing, afebrile children who did not receive antibiotics at the initial visit and who have a blood culture positive for S. pneumoniae have an approximately 9 percent risk of persistent bacteremia [",
"      <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/63\">",
"       63",
"      </a>",
"      ]. These patients can be managed with antibiotics as an outpatient with close follow-up. Another blood culture should be drawn before further antibiotic therapy is initiated. Antibiotic regimens should provide coverage for resistant S. pneumoniae. Possibilities include high dose oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"       amoxicillin",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose, three times daily; maximum dose: 2 to 3 grams daily), oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/26/34214?source=see_link\">",
"       amoxicillin-clavulanate",
"      </a>",
"      (45",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose, twice daily; maximum dose: 3 grams total daily dose of amoxicillin), or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose, three times daily) in penicillin allergic patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Other pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The limited data for bacteremia caused by organisms other than S. pneumoniae suggests that outpatient therapy with oral antibiotics does not prevent serious bacterial infection, even in well-appearing, afebrile children. In addition, the risk of meningitis is presumed to be high for patients with N. meningitidis bacteremia.",
"   </p>",
"   <p>",
"    For these reasons, hospital admission and parenteral antibiotic therapy is suggested for children with a blood culture that is positive for N. meningitidis, H. influenzae type b, S. aureus, gram negative rods, or other pathogens. A lumbar puncture should be performed if meningitis is clinically suspected. CSF evaluation is also recommended for patients with blood culture positive for N. meningitidis and for young infants (three to six months of age) with Group B Streptococcus bacteremia. Well children over three months of age with a blood culture positive for E. coli or S. aureus do not need a lumbar puncture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Probable blood culture contaminant",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the decline in the prevalence of occult bacteremia, it is now more likely that a blood culture will be positive for a contaminant than for a pathogen [",
"    <a class=\"abstract\" href=\"UTD.htm?22/14/22762/abstract/30-32,49\">",
"     30-32,49",
"    </a>",
"    ]. Microbiologic features, such as Gram stain, showing gram-positive rods, gram-positive cocci that are coagulase negative, and slow growth suggest a contaminant. Consultation with the microbiology laboratory",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an infectious disease specialist may be useful when preliminary results are unclear.",
"   </p>",
"   <p>",
"    The child who is well on follow-up, afebrile, and has an isolate from blood culture that is a likely contaminant can be followed without antibiotic treatment, pending the final identification of the organism.",
"   </p>",
"   <p>",
"    Children who are not well on follow-up or continue to have fever should be reevaluated and the assumption that the positive blood culture represents a contaminant should be reevaluated (",
"    <a class=\"graphic graphic_algorithm graphicRef81743 \" href=\"UTD.htm?13/59/14270\">",
"     algorithm 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Positive blood cultures'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Positive urine culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with a positive urine culture should be treated for UTI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27674?source=see_link&amp;anchor=H2#H2\">",
"     \"Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/40/40578?source=see_link\">",
"       \"Patient information: Fever in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/23/37235?source=see_link\">",
"       \"Patient information: Fever in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     General issues",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The following recommendations apply to well-appearing children 3 to 36 months of age, with fever &ge;39&ordm;C (102.2&ordm;F), who have no underlying medical condition that would alter susceptibility to infection, and no focus of infection identified by a complete physical examination, hereafter referred to as children with FWS. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of children with fever have either a self-limited viral infection or a recognizable source of bacterial infection. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Occult sources of infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Serious bacterial infections that occur in children 3 to 36 months of age include meningitis, pneumonia, and focal skin infections.",
"     </li>",
"     <li>",
"      Subtle sources of infection, such as pneumonia or osteomyelitis, can sometimes be identified with a careful history and physical examination.",
"     </li>",
"     <li>",
"      Relatively common occult sources of infection include pneumonia and urinary tract infections (UTIs), with occasional cases of bacteremia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A thorough history, including immunization status and complete physical examination, should be performed in all febrile children to identify obvious and subtle focuses of infection. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Ill-appearing child",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children who are ill-appearing or have unstable vital signs require full evaluation for serious infection with cultures of blood, urine, and when meningitis is suspected, CSF. A chest radiograph should be obtained in patients who have tachypnea or respiratory distress and is warranted for those with WBC",
"      <span class=\"nowrap\">",
"       &ge;20,000/microL,",
"      </span>",
"      even in the absence of physical findings of pneumonia. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Ill-appearing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children who are ill-appearing or have unstable vital signs should receive parenteral antibiotic therapy targeting the likely pathogens in this age group (S. pneumoniae, S. aureus, N. meningitidis, H. influenzae type b) and be admitted to the hospital. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Ill-appearing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Well-appearing child",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Incompletely immunized",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For children with FWS who have not been completely immunized, we suggest the following tests:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      CBC with differential: A blood culture should be sent for those with WBC",
"      <span class=\"nowrap\">",
"       &ge;15,000/microL.",
"      </span>",
"      Some clinicians may choose to send a blood culture for all patients. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Immunization incomplete'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urinalysis and urine culture by bladder catheterization or, in exceptional cases (eg, tight phimosis or severe labial adhesions), suprapubic aspiration. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Urine tests'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27\">",
"       'Immunization incomplete'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chest radiograph when WBC",
"      <span class=\"nowrap\">",
"       &ge;20,000/microL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Immunization incomplete'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that incompletely immunized children with FWS and WBC",
"      <span class=\"nowrap\">",
"       &ge;15,000/microL",
"      </span>",
"      receive parenteral antibiotic therapy pending culture results (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). A single dose of intramuscular",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (50",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      is preferred because of its antimicrobial spectrum and duration of action. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Immunization incomplete'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      These patients should be seen for follow-up by their primary care provider within 24 hours. An alternative is to follow-up in the emergency department if a regular source of primary care is unavailable. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Completely immunized",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For children &gt;6 months of age with FWS who are completely immunized, we suggest that girls &lt;24 months of age and uncircumcised boys &lt;12 months receive a urinalysis and urine culture. Urine for culture should be collected by catheterization or, in exceptional cases (eg, tight phimosis or severe labial adhesions), suprapubic aspiration. Bag specimens should not be sent for culture because they are frequently contaminated. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Urinary tract infection'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42886?source=see_link\">",
"       \"Urine collection techniques in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For girls &gt;24 months of age, uncircumcised boys &gt;12 months of age and circumcised boys &gt;6 months of age with FWS, all of whom have been completely immunized, we do",
"      <strong>",
"       not",
"      </strong>",
"      suggest routine laboratory evaluation. In addition, these children should not receive presumptive treatment with antibiotics (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). However, urinalysis and urine culture should be obtained in those at high risk for UTI. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Urine tests'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'Immunization complete'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Completely immunized children with fever &ge;39&deg;C (102.2&deg;F) and an abnormal urinalysis should be treated for a urinary tract infection. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Immunization complete'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27674?source=see_link&amp;anchor=H5#H5\">",
"       \"Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month\", section on 'Antibiotic therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Clinical follow-up",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that children with fever that persists for more than 48 hours or with a deterioration in clinical condition undergo repeat medical evaluation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Culture follow-up",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h3\">",
"     Urine cultures",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a positive urine culture require treatment tailored to the identified organism and their clinical status. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27674?source=see_link&amp;anchor=H2#H2\">",
"       \"Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month\", section on 'Overview'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h3\">",
"     Blood cultures",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children of 3 to 36 months of age with a positive blood culture for a presumed pathogen require reevaluation and management based on their appearance, persistence of fever, and specific isolate (",
"      <a class=\"graphic graphic_algorithm graphicRef81743 \" href=\"UTD.htm?13/59/14270\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Positive blood cultures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that the child who is well on follow-up, afebrile, and has an isolate from a preliminary report of a blood culture that is a likely contaminant, be followed on a daily basis as an outpatient without antibiotic treatment, pending the final identification of the organism (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Probable blood culture contaminant'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/1\">",
"      Finkelstein JA, Christiansen CL, Platt R. Fever in pediatric primary care: occurrence, management, and outcomes. Pediatrics 2000; 105:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/2\">",
"      Nelson DS, Walsh K, Fleisher GR. Spectrum and frequency of pediatric illness presenting to a general community hospital emergency department. Pediatrics 1992; 90:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/3\">",
"      Krauss BS, Harakal T, Fleisher GR. The spectrum and frequency of illness presenting to a pediatric emergency department. Pediatr Emerg Care 1991; 7:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/4\">",
"      Baraff LJ, Bass JW, Fleisher GR, et al. Practice guideline for the management of infants and children 0 to 36 months of age with fever without source. Agency for Health Care Policy and Research. Ann Emerg Med 1993; 22:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/5\">",
"      McGowan JE Jr, Bratton L, Klein JO, Finland M. Bacteremia in febrile children seen in a \"walk-in\" pediatric clinic. N Engl J Med 1973; 288:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/6\">",
"      Teele DW, Pelton SI, Grant MJ, et al. Bacteremia in febrile children under 2 years of age: results of cultures of blood of 600 consecutive febrile children seen in a \"walk-in\" clinic. J Pediatr 1975; 87:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/7\">",
"      Shapiro ED, Aaron NH, Wald ER, Chiponis D. Risk factors for development of bacterial meningitis among children with occult bacteremia. J Pediatr 1986; 109:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/8\">",
"      Baraff LJ, Oslund S, Prather M. Effect of antibiotic therapy and etiologic microorganism on the risk of bacterial meningitis in children with occult bacteremia. Pediatrics 1993; 92:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/9\">",
"      Tighe M, Roe MF. Does a teething child need serious illness excluding? Arch Dis Child 2007; 92:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/10\">",
"      Greenes DS, Harper MB. Low risk of bacteremia in febrile children with recognizable viral syndromes. Pediatr Infect Dis J 1999; 18:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/11\">",
"      McCarthy PL. Acute infectious illness in children. Compr Ther 1988; 14:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/12\">",
"      Wright PF, Thompson J, McKee KT Jr, et al. Patterns of illness in the highly febrile young child: epidemiologic, clinical, and laboratory correlates. Pediatrics 1981; 67:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/13\">",
"      Leventhal JM. Clinical predictors of pneumonia as a guide to ordering chest roentgenograms. Clin Pediatr (Phila) 1982; 21:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/14\">",
"      Zukin DD, Hoffman JR, Cleveland RH, et al. Correlation of pulmonary signs and symptoms with chest radiographs in the pediatric age group. Ann Emerg Med 1986; 15:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/15\">",
"      Craig JC, Williams GJ, Jones M, et al. The accuracy of clinical symptoms and signs for the diagnosis of serious bacterial infection in young febrile children: prospective cohort study of 15 781 febrile illnesses. BMJ 2010; 340:c1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/16\">",
"      Bachur R, Perry H, Harper MB. Occult pneumonias: empiric chest radiographs in febrile children with leukocytosis. Ann Emerg Med 1999; 33:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/17\">",
"      Brauner M, Goldman M, Kozer E. Extreme leucocytosis and the risk of serious bacterial infections in febrile children. Arch Dis Child 2010; 95:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/18\">",
"      Rutman MS, Bachur R, Harper MB. Radiographic pneumonia in young, highly febrile children with leukocytosis before and after universal conjugate pneumococcal vaccination. Pediatr Emerg Care 2009; 25:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/19\">",
"      Shaw KN, Gorelick M, McGowan KL, et al. Prevalence of urinary tract infection in febrile young children in the emergency department. Pediatrics 1998; 102:e16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/20\">",
"      Hoberman A, Chao HP, Keller DM, et al. Prevalence of urinary tract infection in febrile infants. J Pediatr 1993; 123:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/21\">",
"      Shaikh N, Morone NE, Lopez J, et al. Does this child have a urinary tract infection? JAMA 2007; 298:2895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/22\">",
"      Carroll WL, Farrell MK, Singer JI, et al. Treatment of occult bacteremia: a prospective randomized clinical trial. Pediatrics 1983; 72:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/23\">",
"      Jaffe DM, Tanz RR, Davis AT, et al. Antibiotic administration to treat possible occult bacteremia in febrile children. N Engl J Med 1987; 317:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/24\">",
"      Bass JW, Steele RW, Wittler RR, et al. Antimicrobial treatment of occult bacteremia: a multicenter cooperative study. Pediatr Infect Dis J 1993; 12:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/25\">",
"      Yamamoto LT, Wigder HN, Fligner DJ, et al. Relationship of bacteremia to antipyretic therapy in febrile children. Pediatr Emerg Care 1987; 3:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/26\">",
"      Baker RC, Tiller T, Bausher JC, et al. Severity of disease correlated with fever reduction in febrile infants. Pediatrics 1989; 83:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/27\">",
"      Teach SJ, Fleisher GR. Efficacy of an observation scale in detecting bacteremia in febrile children three to thirty-six months of age, treated as outpatients. Occult Bacteremia Study Group. J Pediatr 1995; 126:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/28\">",
"      Bratton L, Teele DW, Klein JO. Outcome of unsuspected pneumococcemia in children not initially admitted to the hospital. J Pediatr 1977; 90:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/29\">",
"      Fleisher GR, Rosenberg N, Vinci R, et al. Intramuscular versus oral antibiotic therapy for the prevention of meningitis and other bacterial sequelae in young, febrile children at risk for occult bacteremia. J Pediatr 1994; 124:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/30\">",
"      Stoll ML, Rubin LG. Incidence of occult bacteremia among highly febrile young children in the era of the pneumococcal conjugate vaccine: a study from a Children's Hospital Emergency Department and Urgent Care Center. Arch Pediatr Adolesc Med 2004; 158:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/31\">",
"      Sard B, Bailey MC, Vinci R. An analysis of pediatric blood cultures in the postpneumococcal conjugate vaccine era in a community hospital emergency department. Pediatr Emerg Care 2006; 22:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/32\">",
"      Herz AM, Greenhow TL, Alcantara J, et al. Changing epidemiology of outpatient bacteremia in 3- to 36-month-old children after the introduction of the heptavalent-conjugated pneumococcal vaccine. Pediatr Infect Dis J 2006; 25:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/33\">",
"      Carstairs KL, Tanen DA, Johnson AS, et al. Pneumococcal bacteremia in febrile infants presenting to the emergency department before and after the introduction of the heptavalent pneumococcal vaccine. Ann Emerg Med 2007; 49:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/34\">",
"      Waddle E, Jhaveri R. Outcomes of febrile children without localising signs after pneumococcal conjugate vaccine. Arch Dis Child 2009; 94:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/35\">",
"      Wilkinson M, Bulloch B, Smith M. Prevalence of occult bacteremia in children aged 3 to 36 months presenting to the emergency department with fever in the postpneumococcal conjugate vaccine era. Acad Emerg Med 2009; 16:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/36\">",
"      Benito-Fern&aacute;ndez J, Mintegi S, Pocheville-Gurutzeta I, et al. Pneumococcal bacteremia in febrile infants presenting to the emergency department 8 years after the introduction of pneumococcal conjugate vaccine in the Basque Country of Spain. Pediatr Infect Dis J 2010; 29:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/37\">",
"      Bressan S, Berlese P, Mion T, et al. Bacteremia in feverish children presenting to the emergency department: a retrospective study and literature review. Acta Paediatr 2012; 101:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/38\">",
"      Kuppermann N, Malley R, Inkelis SH, Fleisher GR. Clinical and hematologic features do not reliably identify children with unsuspected meningococcal disease. Pediatrics 1999; 103:E20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/39\">",
"      Nigrovic, LE, Malley, R. Evaluation of the febrile child 3 to 36 months old in the era of pneumococcal conjugate vaccine: focus on occult bacteremia. Clin Ped Emerg Med 2004; 5:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/40\">",
"      Jhaveri R, Byington CL, Klein JO, Shapiro ED. Management of the non-toxic-appearing acutely febrile child: a 21st century approach. J Pediatr 2011; 159:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/41\">",
"      Lee GM, Fleisher GR, Harper MB. Management of febrile children in the age of the conjugate pneumococcal vaccine: a cost-effectiveness analysis. Pediatrics 2001; 108:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/42\">",
"      Teach SJ, Fleisher GR. Duration of fever and its relationship to bacteremia in febrile outpatients three to 36 months old. The Occult Bacteremia Study Group. Pediatr Emerg Care 1997; 13:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/43\">",
"      Lee GM, Harper MB. Risk of bacteremia for febrile young children in the post-Haemophilus influenzae type b era. Arch Pediatr Adolesc Med 1998; 152:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/44\">",
"      Kuppermann N, Fleisher GR, Jaffe DM. Predictors of occult pneumococcal bacteremia in young febrile children. Ann Emerg Med 1998; 31:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/45\">",
"      Isaacman DJ, Shults J, Gross TK, et al. Predictors of bacteremia in febrile children 3 to 36 months of age. Pediatrics 2000; 106:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/46\">",
"      Peltola V, Mertsola J, Ruuskanen O. Comparison of total white blood cell count and serum C-reactive protein levels in confirmed bacterial and viral infections. J Pediatr 2006; 149:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/47\">",
"      Huicho L, Campos-Sanchez M, Alamo C. Metaanalysis of urine screening tests for determining the risk of urinary tract infection in children. Pediatr Infect Dis J 2002; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/48\">",
"      Gorelick MH, Shaw KN. Screening tests for urinary tract infection in children: A meta-analysis. Pediatrics 1999; 104:e54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/49\">",
"      Alpern ER, Alessandrini EA, Bell LM, et al. Occult bacteremia from a pediatric emergency department: current prevalence, time to detection, and outcome. Pediatrics 2000; 106:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/50\">",
"      Gilsdorf JR. C reactive protein and procalcitonin are helpful in diagnosis of serious bacterial infections in children. J Pediatr 2011; 160:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/51\">",
"      Pulliam PN, Attia MW, Cronan KM. C-reactive protein in febrile children 1 to 36 months of age with clinically undetectable serious bacterial infection. Pediatrics 2001; 108:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/52\">",
"      Isaacman DJ, Burke BL. Utility of the serum C-reactive protein for detection of occult bacterial infection in children. Arch Pediatr Adolesc Med 2002; 156:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/53\">",
"      Peltola H, Jaakkola M. C-reactive protein in early detection of bacteremic versus viral infections in immunocompetent and compromised children. J Pediatr 1988; 113:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/54\">",
"      Fern&aacute;ndez Lopez A, Luaces Cubells C, Garc&iacute;a Garc&iacute;a JJ, et al. Procalcitonin in pediatric emergency departments for the early diagnosis of invasive bacterial infections in febrile infants: results of a multicenter study and utility of a rapid qualitative test for this marker. Pediatr Infect Dis J 2003; 22:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/55\">",
"      Lacour AG, Zamora SA, Gervaix A. A score identifying serious bacterial infections in children with fever without source. Pediatr Infect Dis J 2008; 27:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/56\">",
"      van Rossum AM, Wulkan RW, Oudesluys-Murphy AM. Procalcitonin as an early marker of infection in neonates and children. Lancet Infect Dis 2004; 4:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/57\">",
"      Hsiao AL, Baker MD. Fever in the new millennium: a review of recent studies of markers of serious bacterial infection in febrile children. Curr Opin Pediatr 2005; 17:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/58\">",
"      Galetto-Lacour A, Zamora SA, Gervaix A. Bedside procalcitonin and C-reactive protein tests in children with fever without localizing signs of infection seen in a referral center. Pediatrics 2003; 112:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/59\">",
"      Andreola B, Bressan S, Callegaro S, et al. Procalcitonin and C-reactive protein as diagnostic markers of severe bacterial infections in febrile infants and children in the emergency department. Pediatr Infect Dis J 2007; 26:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/60\">",
"      Dubos F, Korczowski B, Aygun DA, et al. Serum procalcitonin level and other biological markers to distinguish between bacterial and aseptic meningitis in children: a European multicenter case cohort study. Arch Pediatr Adolesc Med 2008; 162:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/61\">",
"      Van den Bruel A, Thompson MJ, Haj-Hassan T, et al. Diagnostic value of laboratory tests in identifying serious infections in febrile children: systematic review. BMJ 2011; 342:d3082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/62\">",
"      Baraff LJ. Management of fever without source in infants and children. Ann Emerg Med 2000; 36:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/63\">",
"      Bachur R, Harper MB. Reevaluation of outpatients with Streptococcus pneumoniae bacteremia. Pediatrics 2000; 105:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/64\">",
"      Downs SM, McNutt RA, Margolis PA. Management of infants at risk for occult bacteremia: a decision analysis. J Pediatr 1991; 118:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/65\">",
"      Lieu TA, Schwartz JS, Jaffe DM, Fleisher GR. Strategies for diagnosis and treatment of children at risk for occult bacteremia: clinical effectiveness and cost-effectiveness. J Pediatr 1991; 118:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/66\">",
"      Bulloch B, Craig WR, Klassen TP. The use of antibiotics to prevent serious sequelae in children at risk for occult bacteremia: a meta-analysis. Acad Emerg Med 1997; 4:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/67\">",
"      Avner JR, Baker MD. Occult bacteremia in the post-pneumococcal conjugate vaccine era: does the blood culture stop here? Acad Emerg Med 2009; 16:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/14/22762/abstract/68\">",
"      Simon AE, Lukacs SL, Mendola P. Emergency department laboratory evaluations of fever without source in children aged 3 to 36 months. Pediatrics 2011; 128:e1368.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6075 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-3BFBD2B80D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_14_22762=[""].join("\n");
var outline_f22_14_22762=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Fever of concern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Population of interest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Immunization status",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Complete immunization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Incomplete immunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CAUSES OF FEVER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OCCULT SOURCES OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Urinary tract infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Bacteremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Predictors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Impact of vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - WBC and ANC counts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Urine tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Inflammatory mediators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      INITIAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Ill-appearing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Well-appearing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Immunization incomplete",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Immunization complete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Positive blood cultures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - S. pneumoniae",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Other pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Probable blood culture contaminant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Positive urine culture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      General issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Ill-appearing child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Well-appearing child",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Incompletely immunized",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Completely immunized",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Clinical follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Culture follow-up",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      - Urine cultures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      - Blood cultures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6075\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6075|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?7/6/7268\" title=\"algorithm 1\">",
"      Male infants UTI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?13/59/14270\" title=\"algorithm 2\">",
"      Blood culture followup in children 3 to 36 months of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6075|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/16/269\" title=\"table 1\">",
"      Prevalence of UTI in febrile infants and children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/28/28109\" title=\"table 2\">",
"      Tests to diagnose UTI in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27674?source=related_link\">",
"      Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39590?source=related_link\">",
"      Anatomy and development of the teeth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9706?source=related_link\">",
"      Approach to the child with fever of unknown origin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=related_link\">",
"      Clinical features and diagnosis of community-acquired pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21129?source=related_link\">",
"      Clinical features and diagnosis of urinary tract infections in infants and children older than one month",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34585?source=related_link\">",
"      Clinical manifestations and diagnosis of enterovirus and parechovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26360?source=related_link\">",
"      Epidemiology and risk factors for urinary tract infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38905?source=related_link\">",
"      Etiologies of fever of unknown origin in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28074?source=related_link\">",
"      Evaluation and management of fever in the neonate and young infant (less than three months of age)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/27/31160?source=related_link\">",
"      Herpetic gingivostomatitis in young children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/601?source=related_link\">",
"      Impact of universal infant immunization with pneumococcal (Streptococcus pneumoniae) conjugate vaccines in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/23/37235?source=related_link\">",
"      Patient information: Fever in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/40/40578?source=related_link\">",
"      Patient information: Fever in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42489?source=related_link\">",
"      Prevention of Haemophilus influenzae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30216?source=related_link\">",
"      Soft tissue lesions of the oral cavity in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42886?source=related_link\">",
"      Urine collection techniques in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_14_22763="Chemo escalate for desensitiz";
var content_f22_14_22763=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F61477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F61477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Desensitization protocols",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Platinum administration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mix calculated total dose in 100 cc D5W.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Administer 0.1 cc of this solution in 100 cc D5W over 1 h (1:1000 dilution).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       If tolerated, administer 1 cc of the solution in 100 cc D5W over 1 h (1:100 dilution).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       If tolerated, administer 10 cc of the solution in 100 cc D5W over 1 h (1:10 dilution).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       If tolerated, administer the remaining solution over 1 h (1:1 dilution)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       OR: Administer at 25 percent of usual rate for 1 h.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       If tolerated, administer at 50 percent of the usual rate for 1 h.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       If tolerated, administer at 75 percent of the usual rate for 1 h.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       If tolerated, administer the remaining at usual rate.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Robinson, JB, Singh, D, Bodurka-Bevers, DC, et al. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecologic Oncol 2001; 82:555. Copyright &copy;2001 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_14_22763=[""].join("\n");
var outline_f22_14_22763=null;
var title_f22_14_22764="Management of localized scleroderma in children";
var content_f22_14_22764=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F77267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F77267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Management of localized scleroderma in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Circumscribed (plaque) morphea",
"       </td>",
"       <td class=\"subtitle1\">",
"        Generalized morphea",
"       </td>",
"       <td class=\"subtitle1\">",
"        Linear morphea",
"       </td>",
"       <td class=\"subtitle1\">",
"        En coup de sabre",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Clinical features",
"        </strong>",
"       </td>",
"       <td>",
"        One or a few circumscribed sclerotic plaques with hypo-or hyperpigmentation and an inflamed violaceous border.",
"       </td>",
"       <td>",
"        Individual plaques (4 or more and larger than 3 cm) that become confluent and involve at least two anatomic sites.",
"       </td>",
"       <td>",
"        Linear induration involving dermis, subcutaneous tissue, and sometimes muscle and underlying bone, and affecting the limbs and/or the trunk.",
"       </td>",
"       <td>",
"        Linear morphea affecting the face or scalp, involving underlying subcutaneous tissues, muscles, and bone. Underlying cerebral abnormalities have been reported.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Treatment",
"        </strong>",
"       </td>",
"       <td>",
"        Often unnecessary. Topical corticosteroids for active lesions.",
"       </td>",
"       <td>",
"        Suppress inflammation with oral or IV glucocorticoids for three months&nbsp;in addition to methotrexate (15 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        /week) for&nbsp;24 months. Mycophenolate mofetil can be used in methotrexate-refractory cases.",
"       </td>",
"       <td>",
"        Suppress inflammation with oral or IV glucocorticoids for three&nbsp;months&nbsp;in addition to methotrexate (15 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        /week) for&nbsp;24 months.&nbsp;Mycophenolate mofetil can be used in methotrexate-refractory cases.",
"       </td>",
"       <td>",
"        Suppress inflammation with oral or IV glucocorticoids for three months&nbsp;in addition to methotrexate (15 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        /week) for&nbsp;24 months.&nbsp;Mycophenolate mofetil can be used in methotrexate-refractory cases.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Prognosis",
"        </strong>",
"       </td>",
"       <td>",
"        Good prognosis lesions less active within 3 years, but pigmentary changes often persist.",
"       </td>",
"       <td>",
"        Generally improves within 5 years of onset, although textural and pigmentary changes can remain.",
"       </td>",
"       <td>",
"        Long-term effects of childhood onset form minimized by effective suppression of inflammatory process. Ultimately the disease tends to resolve, but it can remain active for many years.",
"       </td>",
"       <td>",
"        Scarring, growth defects, and alopecia persist, but inflammatory component usually resolves.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IV: Intravenous.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_14_22764=[""].join("\n");
var outline_f22_14_22764=null;
var title_f22_14_22765="Common causes nausea and vomiting in palliative care pts";
var content_f22_14_22765=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PALC%2F87625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PALC%2F87625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common causes of nausea and vomiting in palliative care",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Toxic/metabolic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cytotoxic chemotherapy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Opioids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            NSAIDs, aspirin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Digitalis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Iron",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Antibiotics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Theophylline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            And many other drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Organ failure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Liver, renal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Metabolic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hypercalcemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hyponatremia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ketoacidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Poisoning",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Substance abuse",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Disorders of viscera",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Obstruction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Gastric outlet",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Small bowel",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Biliary/pancreatic duct",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Constipation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Gastroparesis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Inflammation/irritation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            NSAID",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Chemotherapy: (direct GI effects)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Radiation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Gastritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Gastroenteritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hepatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cholecystitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pancreatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Tumors of the gastrointestinal tract and thorax",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            CNS causes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Increased intracranial pressure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Malignancy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hemorrhage",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cranial irradiation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Abscess",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Vestibular",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Drug effects",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Labyrinthitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Anxiety",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Anticipatory nausea and vomiting",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_14_22765=[""].join("\n");
var outline_f22_14_22765=null;
var title_f22_14_22766="TNM stage larynx";
var content_f22_14_22766=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F66619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F66619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tumor node metastases (TNM) staging system for cancer of the larynx",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Primary tumor (T)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td colspan=\"3\">",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td colspan=\"3\">",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tis",
"      </td>",
"      <td colspan=\"3\">",
"       Carcinoma in situ",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Supraglottis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       T1",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor limited to one subsite of supraglottis with normal vocal cord mobility",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       T2",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor invades mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis (eg, mucosa of base of tongue, vallecula, medial wall of pyriform sinus) without fixation of the larynx",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       T3",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor limited to larynx with vocal cord fixation and/or invades any of the following: postcricoid area, preepiglottic space, paraglottic space, and/or inner cortex of thyroid cartilage",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"2\">",
"       T4a",
"      </td>",
"      <td colspan=\"3\">",
"       Moderately advanced local disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"3\">",
"       Tumor invades through the thyroid cartilage and/or invades tissues beyond the larynx (eg, trachea, soft tissues of neck including deep extrinsic muscle of the tongue, strap muscles, thyroid, or esophagus)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"2\">",
"       T4b",
"      </td>",
"      <td colspan=\"3\">",
"       Very advanced local disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"3\">",
"       Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Glottis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       T1",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"3\">",
"       Tumor limited to vocal cord(s) (may involve anterior or posterior commissure) with normal mobility",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       T1a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Tumor limited to one vocal cord",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       T1b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Tumor involves both vocal cords",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       T2",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor extends to supraglottis and/or subglottis, and/or with impaired vocal cord mobility",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       T3",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor limited to the larynx with vocal cord fixation and/or invasion of paraglottic space, and/or inner cortex of the thyroid cartilage",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"2\">",
"       T4a",
"      </td>",
"      <td colspan=\"3\">",
"       Moderately advanced local disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"3\">",
"       Tumor invades through the outer cortex of the thyroid cartilage and/or invades tissues beyond the larynx (eg, trachea, soft tissues of neck including deep extrinsic muscle of the tongue, strap muscles, thyroid, or esophagus)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"2\">",
"       T4b",
"      </td>",
"      <td colspan=\"3\">",
"       Very advanced local disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"3\">",
"       Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Subglottis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       T1",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor limited to the subglottis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       T2",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor extends to vocal cord(s) with normal or impaired mobility",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       T3",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor limited to larynx with vocal cord fixation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"2\">",
"       T4a",
"      </td>",
"      <td colspan=\"3\">",
"       Moderately advanced local disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"3\">",
"       Tumor invades cricoid or thyroid cartilage and/or invades tissues beyond the larynx (eg, trachea, soft tissues of neck including deep extrinsic muscles of the tongue, strap muscles, thyroid, or esophagus)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"2\">",
"       T4b",
"      </td>",
"      <td colspan=\"3\">",
"       Very advanced local disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"3\">",
"       Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Regional lymph nodes (N)*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NX",
"      </td>",
"      <td colspan=\"3\">",
"       Regional lymph nodes cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N0",
"      </td>",
"      <td colspan=\"3\">",
"       No regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N1",
"      </td>",
"      <td colspan=\"3\">",
"       Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       N2",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"3\">",
"       Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       N2a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       N2b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       N2c",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N3",
"      </td>",
"      <td colspan=\"3\">",
"       Metastasis in a lymph node, more than 6 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Distant metastases (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"3\">",
"       No distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M1",
"      </td>",
"      <td colspan=\"3\">",
"       Distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Anatomic stage/prognostic groups",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage 0",
"      </td>",
"      <td>",
"       Tis",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage I",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage II",
"      </td>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       Stage III",
"      </td>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"6\">",
"       Stage IVA",
"      </td>",
"      <td>",
"       T4a",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4a",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4a",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Stage IVB",
"      </td>",
"      <td>",
"       T4b",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       N3",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IVC",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"     * Metastases at level VII are considered regional lymph node metastases.",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_14_22766=[""].join("\n");
var outline_f22_14_22766=null;
var title_f22_14_22767="Septate uterus and cervix";
var content_f22_14_22767=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63396&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63396&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Septate uterus: complete (septum to external os)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 353px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_14_22767=[""].join("\n");
var outline_f22_14_22767=null;
